Medical practice pattern tool (2024)

This application claims priority from U.S. Provisional Patent Application Ser. No. 60/731,917, filed Oct. 31, 2005.

This invention relates to computer-implemented processes for the analysis of medical practice.

Conventional systems, such as the Episode Treatment Group (ETG) software by Symmetry Health Data System, Inc, various risk adjusters, and other measures of physician service use allow managed care organizations to find rates of utilization of given services, determine relative costs of physician care, and bucket costs into categories such as office visits, pharmacy, and facility use. The conventional systems thus might show that there are differences between medical providers, such as one might be more expensive than another; however, they do not take the necessary steps to address what a managed care organization should work on in order to decrease costs of medical care and improve quality. The conventional systems do not identify what the specific cost drivers are that cause differences between the medical providers. Further, the conventional systems do not present data in a way that is clinically relevant and easy to present in graphic form to facilitate the discussion of medical appropriateness and allow clinical judgment as to whether the service is under utilized, over utilized, or mis-used, based on medical evidence for or against the service in question. In other words, the conventional systems do not connect cost containment to quality improvement.

The conventional approaches therefore require a priori hypotheses about cost drivers and then extensive drilldowns and other data analysis to discover the cost drivers. The user must ask specific questions, hypothesizing which services might be cost drivers, for example: “Find out if lab testing is a factor in hypertension care, and then find which tests and who is using them.” Such analyses typically take a number of hundred person-hours of work, develop over a time frame of weeks to months, and may lead down dead ends. For example, an analysis of hypertension cost drivers took approximately four weeks in real time to complete, and found that pharmacy was the only factor differentiating costs of care among physicians. A comprehensive analysis investigating the cost drivers for a plurality of conditions in a number of different specialties would be quite cumbersome using the conventional methods and the results would likely be out of date when the analysis is completed.

Several references are related to the evaluation and comparison of healthcare providers according to costs, quality of care, and effectiveness. Some of the references are related to determining the proper treatment for a patient. For instance, PCT publication number WO 96/00423 A1 by MEDICODE, INC. compares individual medical practitioners or a group of medical practitioners against a statistical norm or trend. The comparison is made by converting medical providers billing data into a historical database. The application also discusses the determination of episodes of care and providing reports on the results. The application does not compare the services performed by the medical providers to determine what services stand out as the cause for the differences between the medical providers or the groups of medical providers.

U.S. Application publication No. 2002/0111826 A1 by Potter, et al. compares actual costs of episodes of care against budgeted costs to evaluate medical practitioners and to manage health care costs. Potter, et al. does not teach a timely and comprehensive analysis investigating the underlying cost drivers for a plurality of conditions in a number of different specialties.

U.S. Pat. No. 5,845,254, issued to Lockwood, et al., teaches a process of determining cost effectiveness of physicians in a group and the qualitative performance level of the group by adjusting the episodes of care by severity. Lockwood, et al. does not identify the cost drivers that cause differences between medical providers.

PCT Publication number WO 91/17510 A1 by HEALTHCHEX, INC. describes a means for processing health care services information relative to certain clinical variables, including age, gender, and diagnosis, and then ranking the data into orders of clinical complexity. The system then determines systematic relationships between medical services rendered to patients, clinical complexity, and cost. The system does not determine what the specific cost drivers are that cause differences between medical providers, nor does it address what an managed care organization should do to decrease costs of medical care and improve quality.

A family of U.S. applications and patents and a PCT application based on U.S. Pat. No. 5,835,897, issued to Dennis K. Dang teaches computer-implemented processes of determining the cost-efficiency and service quality of health care providers. The references in the family discuss episode treatment groups (ETGs) and the ETG grouper software. The application does not compare the services performed by the health care providers to determine what services stand out as the cause for the differences between the health care providers or the groups of health care providers.

U.S. application publication No. 2004/0111291 A1 by Dust, et al. teaches a process of identifying patients likely to generate high cost health care and sending patients to proper health care providers to meet certain requirements set by an employer that provides health care benefits. The method does not identify cost drivers for a plurality of conditions in a number of different specialties.

PCT publication number WO 95/19604 A3 by INFORMED ACCESS SYSTEMS, INC. teaches a process for selecting the appropriate treatment for a patient. The publication does not require a diagnosis; the process sorts potential patients into those that do not need professional medical care and those that do. The level and type of care is then determined for those that need treatment. The process does not compare the costs associated with treatments it recommends to determine the differences between groups of medical providers. Further, the publication does not teach a process for recommending particular services for treating a patient with a particular diagnosis.

PCT publication number WO 99/41653 A2 by IAMETER, INCORPORATED and associated U.S. Pat. No. 6,061,657 teach a process for treating a particular patient for a particular illness including the estimation of charges for the treatment and keeping the actual cost of the treatment close to the estimate. The publication does not teach the identification of specific cost drivers that cause differences between medical providers. The publication also does not provide a medical practice blueprint that includes a timely analysis of several conditions in several specialties that can be used to provide recommendations regarding certain practice patterns.

U.S. Pat. No. 6,223,164, issued to Seare, et al., teaches a system for analyzing historical medical provider billings to statistically establish a normative utilization profile wherein a medical provider's utilization profile is compared with a normative profile. Seare creates a model of the cost of a specific medical episode based on historical treatment patterns and a fee schedule and compares various treatment patterns for a particular diagnosis to the model to determine an allegedly cost-effective treatment approach. Seare also identifies medical providers who provide treatment that does not fall within the statistically established treatment patterns or profiles. Seare does not find the general practice patterns and does not describe the specific differences between the treatment patterns and the models.

Therefore, what is needed is a medical practice analysis tool that efficiently uncovers the true underlying cost drivers. Further what is needed is a tool that can provide a timely analysis of several conditions in several specialties to develop a medical practice blueprint, recommending certain practice patterns over others for the several conditions and specialties.

The invention comprises, in one form thereof, an algorithm that allows the discovery of the medical practice pattern of physicians or other practitioners stratified according to predefined criteria. For example, the practitioners are stratified according to those who are low, medium, and high users of resources for a given condition. Its input is episodes of care generated by episode grouping software, such as the Episode Treatment Grouper™ of Symmetry Health Data System, Inc. Its output is a series of tables and graphs showing the cost drivers for each stratum of practitioners (e.g. by low to high cost quintiles) and their variation from stratum to stratum.

The invention sifts through the costs at the service level and then shows which services are the significant factors for the condition of interest. The invention readily discovers those while conventional systems require testing of multiple hypotheses and potentially could miss the true cost drivers unless the appropriate questions were asked in the first place. Using conventional systems, a typical analysis of a single condition takes weeks, as noted above. A full analysis using the present invention could be produced in less than 30 minutes with automated formatting of the output data.

The inputs and outputs of the invention are clinically relevant and easy to present in graphic form. This facilitates the discussion of medical appropriateness and allows clinical judgment as to whether the service is under utilized, over utilized, or misused, based on medical evidence for or against the service in question. Therefore the invention allows the connection of cost containment to quality improvement.

The invention includes a method of practice pattern analysis for medical professionals. The method comprises the steps of defining a plurality of episodes of care from any database of medical services organized into episodes of care for a plurality of medical professionals, assigning the medical professionals into strata according to a given characteristic for the defined episodes, recording all medical services provided for each of the episodes of care, normalizing the number of medical services provided and costs by the number of episodes of care in the plurality of episodes, removing all the services having a particular value under a threshold to remove anomalous data, and generating a report of the actual medical services and costs versus a set of expected medical services and costs for each stratum of medical professionals, wherein the report is normalized to the number of episodes of care in the stratum.

More particularly, the invention includes a method of managing medical care performed by a group of medical practitioners. The method comprises the steps of compiling a plurality of episodes of care comprising a plurality of services provided by each practitioner in the group of practitioners; sorting the medical practitioners into strata according to a predefined criterion; and listing the services associated with the medical practitioners in each stratum with a selected service value being included with each of the services. An additional step comprises one of the following: assembling a list of services having a threshold parameter above a threshold defined such that only services that have a significant impact on the selected service value are preserved or comparing an actual selected service value to an expected selected service value for each of the services in each stratum. For the purposes of this description, the selected service value is defined as either the service cost total for all the episodes in each stratum or the service utilization total for all the episodes in each stratum. Other service values may be used in alternative embodiments. The threshold parameter is related to the selected service value. For example, the threshold parameter is equal to the selected service value or a normalized selected service value. The medical practitioners are associated with all the services in the episodes that the practitioner had a significant role for a total role analysis. The step of assembling services includes the steps of determining the threshold parameter for each service by dividing the selected service value in each stratum by the number of episodes in that stratum; setting the minimum threshold for the threshold parameter; and storing the services having a threshold parameter above the threshold in a potential cost drivers table. The step of assembling services may also include the steps of determining an expected selected service value for each of the services in each of the episodes of care; evaluating a threshold parameter by subtracting the selected service values in each stratum from the expected selected service value and dividing the difference by the number of episodes in that stratum; setting the minimum threshold for the threshold parameter; and storing the services having a per episode service value difference above the threshold in a potential cost drivers table.

The threshold parameter may also be evaluated by setting it equal to the selected service value for each service in each stratum, e.g.: the threshold parameter would equal the total cost of a service in each stratum or the total utilization of a service in each stratum. Alternatively, the threshold parameter is determined for each service in each stratum by dividing the service cost total for all the episodes in that stratum by the service utilization total for all the episodes in that stratum. In a further alternative, the threshold parameter is evaluated by subtracting the selected service values in each stratum from the expected selected service value.

The method may further comprise the steps of generating a report comparing among the strata the selected service values for the services in the potential cost drivers table; identifying the service that differentiates the strata; and providing the medical practitioners with a description of how to reduce the difference between the strata. The expected selected service value determination step may include the steps of totaling the selected service value for each service for all the episodes in the analysis to provide an analysis total of the selected service value; determining an analysis average for the selected service value of each service by dividing the analysis total of the selected service value by the sum of the episodes in the analysis; and multiplying the analysis average of the selected service value by the number of episodes in each stratum for each service to provide the expected selected service value. The step of compiling a plurality of episodes may include tracking each service by episodes of care performed by a group of medical practitioners; aggregating the medical services according to given characteristics; and sorting the episodes of care into predefined conditions. Particularly, the episodes of care may be formed using the Symmetry ETG grouper software. The condition analyzed in the method may be a complete ETG, a combination of ETGs, a subset of an ETG, or a combination of subsets of a plurality of ETGs.

The medical practitioners may be separated into strata according to several criteria including, but not limited to, cost, the number of services performed, performance in another condition, geographic region, specialty, type of practice, and size of practice. Medical practitioners having an anomalous selected service value may be removed from the analysis group. The practitioners may be attributed to the episodes according to a number of attribution rules. For example, the practitioner attributed to an episode may be the practitioner with the highest percentage of professional costs of the episode, the practitioner with the highest percentage of generated costs of the episode, all practitioners in the episode who contributed more than a preset percentage of the cost to the episode, a primary care physician associated with the episode, all practitioners with any involvement in the episode, the practitioner that performed a significant procedure in the episode, the practitioner that had the most face-to-face encounters with a patient associated with the episode, or combinations thereof.

An additional analysis includes the further step of analyzing the practice pattern of an individual practitioner in a total role drilldown analysis of a single medical condition. Similarly, the analysis may include the further step of analyzing the practice pattern of an individual practitioner in a total role MPPT meta-drilldown analysis including data from a plurality of medical conditions.

Further, the invention includes a method for providing a group of medical providers with guidelines for decreasing underuse, overuse, or misuse of medical services. The method comprises the steps of identifying a number of medical conditions performed by the group of medical providers; performing a medical practice pattern analysis; analyzing the results of the medical practice pattern analysis to identify a number of cost drivers that differentiate the strata in each condition; and providing the medical practitioners with a description of how to reduce the difference in the cost drivers between the strata in each condition. The step of performing a medical practice pattern analysis includes the further steps of identifying a plurality of episodes of care for the medical providers for a given condition and a plurality of medical services utilized in each episode of care; calculating a total episode cost for each episode of care; organizing the episodes of care into conditions with given characteristics; separating the medical providers for each conditions into strata by a given characteristic; executing a normalizing algorithm in each stratum for each condition with a threshold to identify and remove anomalous services in the episode of care; and producing a report showing a plurality of cost drivers and comparing the main cost drivers between the strata for each episode grouping.

Even further, the invention includes a medical practice pattern analysis report, comprising tables and graphs of a selected service value for a service for a plurality of strata, wherein the selected service value is greater than a threshold set to remove a plurality of other services having a less significant effect on a particular difference between the strata. The selected service value may include, but is not limited to, an absolute cost per episode of the service, an absolute service utilization per episode, a cost difference per episode, a service utilization difference per episode, and a service cost per utilization. A plurality of medical practitioners are attributed to a plurality of episodes including the services, and the strata are defined by a criterion that may include the average cost, average service utilization, performance in another condition, geographic region, specialty, type of practice, and size of practice of the medical practitioners responsible for the services. The graph may display a service that drives the difference between the strata as well as the selected service values for a plurality of services, wherein the selected service values are greater than the threshold.

Still further, the invention includes a medical method blueprint, comprising a plurality of cells, each describing a treatment recommendation for a particular type of episode of care, wherein the recommendation is based on a medical practice pattern analysis that revealed a service as a driver for a difference between a plurality of stratified medical practitioners. The cells may be grouped by specialty. The medical practitioners are stratified by a criterion that may include the average cost, average service utilization, geographic region, specialty, type of practice, and size of practice of the medical practitioners responsible for the services.

The advantages of the algorithm are therefore manifold: first, it uncovers the true underlying cost drivers, and second it does so quickly. Utilization of the algorithm would allow analysis of the top 20 conditions of the 20 largest specialties (400 analyses) in a few hundred person-hours. Conventional methods have been too cumbersome to allow such a systematic analysis. A similar analysis with current techniques could take years, by which time the results would be outdated. Lastly, because of its process of database set up at the front end, the algorithm is not limited to a single episode grouping. Rather, the analysis can be carried out across multiple episode groupings, and even across combinations of episode groupings and subsets of episode groupings.

The present invention is disclosed with reference to the accompanying drawings, wherein:

FIG. 1 is a flow diagram of the general process of the present invention;

FIGS. 2A and 2B include a more detailed flow diagram of the medical practice pattern tool of the present invention;

FIG. 3 is a blueprint cell according to the present invention;

FIG. 4 is a portion of the medical management blueprint of the present invention;

FIGS. 5, 6A, and 6B are bar graph outputs of the medical practice pattern tool according to Example A; and

FIGS. 7 and 8 are the bar graph outputs of the medical practice pattern tool according to Example B.

Corresponding reference characters indicate corresponding parts throughout the several views. The examples set out herein illustrate several embodiments of the invention but should not be construed as limiting the scope of the invention in any manner.

Referring to FIG. 1, there is shown a flow diagram of the medical practice pattern tool of the present invention. The medical practice pattern tool 100 includes the steps of inputting the services 102 performed by a plurality of medical practitioners into a grouping protocol 104, which identifies episodes of care comprised of the services and groups them into the episodes of care according to a medical services database. The grouping protocol 104 outputs several groups of episodes of care 106 and step 108 assigns medical practitioners into strata by cost or by the number of services performed. Step 110 lists the medical services performed in each episode of care within each stratum. Step 112 analyzes the services by generating an average cost and utilization per stratum, calculating the average cost and utilization per episode across all strata, generating expected cost and utilization for each service according to that average number and the total number of episodes in the service's stratum, generating total cost and utilization differences per episode for each service in each stratum, and removing all services where costs and/or utilization absolute values or differences from expected are below a threshold. In step 114, a report is generated showing the key cost drivers and differences from expected values, which are services having a total cost or utilization absolute value or difference per episode that is greater than or equal to a threshold value. In one embodiment, the reports are output in tables and bar graphs.

More particularly, the medical practice pattern tool 100 tracks services performed by medical practitioners in a given region, specialty, or combination thereof in steps 102 and 104. A medical practitioner is defined as any person that provides care to a patient, including but not limited to physicians, doctors, anesthesiologists, nurse practitioners, nurses, technicians such as radiology technicians, and therapists. In an alternative embodiment, medical practitioner is expanded to medical providers, which may include medical facilities such as clinics and hospitals. The services provided include any care provided to a patient, such as office visits, radiology, pharmaceuticals, and vaccinations. Step 104 assigns the services to episodes of care and determines the responsibility for each episode of care and sorts the episodes of care by predefined conditions. An episode of care is defined as all management, ancillary (including lab and radiology), pharmacy, inpatient facility, and surgical (i.e.: professional) services for one patient over a defined time period.

Step 104 may be carried out by any grouping protocol, such as, for example, the ETG grouper software by Symmetry Health Data System, Inc. This should not be construed to exclude other ETG groupers. The Symmetry ETG grouper is described in the family of patents based on U.S. Pat. No. 5,835,897 by Dennis K. Dang, which is herein incorporated by reference. According to Dang, an episode treatment group (ETG) is a clinically hom*ogenous and statistically stable group of similar illness etiology and therapeutic treatment. The ETG grouper method uses service or segment-level claim data as input data and assigns each service to an appropriate episode of care. The Episode Treatment Grouper™ collects these services into an episode and assigns the episode to one of approximately 900 clinically hom*ogeneous conditions or Episode Treatment Groups™ (ETGs™). Examples of ETGs include, for example, benign skin lesions (ETG 0682), allergic rhinitis (ETG 0332), benign hypertension without co-morbidity (ETG 0281), and joint derangement with surgery—knee and lower leg (ETG 0742.02).

ETGs gather all in-patient, ambulatory and ancillary claims into mutually exclusive treatment episodes (otherwise known as episodes of care), regardless of treatment duration, then use clinical algorithms to identify both concurrent and recurrent episodes. The ETG grouper continues to collect information until an absence of treatment is detected for a predetermined period of time commensurate with the episode. For example, a bronchitis episode will have a sixty day window, while a myocardial infarction may have a one year window. Subsequent records of the same nature within the window reset the window for an additional period of time until the patient is asymptomatic for the pre-determined time period.

ETGs can identify a change in the patient's condition and shift the patient's episode from the initially defined ETG to the ETG which includes the change in condition. ETGs identify all providers treating a single illness episode.

Medical claim data is input as data records by data entry into a computer storage device, such as a hard disk drive. The ETG grouper may reside in any of a number of computer system architectures, i.e., it may be run from a stand-alone computer or exist in a client-server system, for example a local area network (LAN) or wide area network (WAN). The ETG grouper and the medical practice pattern tool may be provided in a single software package and installed on a single workstation or server. Alternatively, the grouper and the medical practice pattern tool are separate modules. The grouper output, which is the medical practice pattern tool input, may even be provided by a third party.

Once relevant medical claim data is input, claims data is processed by loading the computer program into the computer system memory. During set-up of the program onto the computer system, the computer program will have previously set pointers to the physical location of the data files and look-up tables written to the computer storage device. Upon initialization of the computer program, the user is prompted to enter an identifier for a first patient. The program then checks for open episodes for the identified patient, sets flags to identify the open episodes and closes any episodes based upon a predetermined time duration from date of episode to current date. After all open episodes for a patient are identified, the new claims data records are read to memory and validated for type of provider, CPT code and ICD-9 (dx) code, then identified as a management, surgery, facility, ancillary, drug or other record. The CPT code is the American Medical Association's list of the Current Procedural Terminology; CPT-4 is the fourth version of this list. The ICD is the International Classification of Diseases published by the World Health Organization. ICD-9 is the ninth revision of this publication.

As used herein, “Management records” are defined as claims which represent a service by a provider engaging in the direct evaluation, management, or treatment of a patient. Examples of management records include office visits and therapeutic services. Management records serve as anchor records because they represent focal points in the patient treatment as well as for related ancillary services. “Ancillary records” are claims which represent services which are incidental to the direct evaluation, management and treatment of the patient. Examples of ancillary records include X-ray and laboratory tests. “Surgery records” are specific surgical professional fee claims. Surgery records also serve as anchor records. “Facility records” are claims for medical care facility usage. Examples of facility records include hospital room charges or outpatient surgical room charges. “Drug records” are specific for pharmaceutical prescription claims. “Other records” are those medical claim records that are not management, surgery, ancillary, facility or drug records.

Invalid records are flagged and logged to an error output file for the user. Valid records are then processed by an ETG Assignor Sub-routine and, based upon diagnosis code, are either matched to existing open episodes for the patient or serve to create new episodes.

Management and surgery records serve as “anchor records.” An “anchor record” is a record that originates a diagnosis or a definitive treatment for a given medical condition. Management and surgery records serve as base reference records for facility, ancillary, and drug claim records relating to the diagnosis or treatment that is the subject of the management or surgery record. Only management and surgery records can serve to start a given episode.

If the record is a management record or a surgery record, the diagnosis code in the claim record is compared with prior related open episodes in an existing look-up table for a possible ETG match. If more than one open episode exists, the program selects the most recent open episode. A positive match signifies that the current episode is related to an existing open episode. After the match is determined, the time window is reset for an additional period of time corresponding to the episode. A loop shifts the originally assigned ETG based on the additional or subsequent diagnoses. If any of the additional or subsequent diagnoses is a defined co-morbidity diagnosis, the patient's co-morbidity file is updated. If no match between the first diagnosis code and an open episode is found, a new episode is created.

Grouping prescription drug records requires two tables, a NDC (National Drug Code) by GDC (Generic Drug Code) table and a GDC by ETG table. Because the NDC table has approximately 200,000 entries, it has been found impracticable to directly construct an NDC by ETG table. For this reason the NDC by GDC table serves as a translation table to translate NDCs to GDCs and construct a smaller table based upon GDCs. Reading, then from these tables, the NDC code in the claim data record is read and translated to a GDC code. The program then identifies all valid ETGs for the GDC codes in the claim data record then matches those valid ETGs with active episodes.

The output of the ETG grouper is one or more episode treatment groups, each comprising a list of all the episodes of care in the group. The services that make up the episodes and the practitioners responsible for the services are included in a table. Although the medical practice pattern tool 100 is described using the ETGs defined by Symmetry's ETG grouper, any grouper protocol may be used, such as the Medstat Episode Grouper by Thomson Medstat and the Cave Grouper by the Cave Consulting Group.

Referring to FIGS. 2A and 2B, the user selects the episodes according to certain general characteristics such as completeness or outlier status in step 202. Complete episodes are episodes in which the predetermined time window described above has passed. Outlier episodes are episodes which exceed given criteria for cost or service level. In the current embodiment, only complete episodes are used. Alternatively a user could choose to examine incomplete episodes or both complete and incomplete episodes. Similarly, in the current embodiment only non-outlier episodes are used. However, a user of the invention could choose to analyze high-cost outlier episodes, for example, in order to find the cost drivers in those episodes (i.e. to determine what made them outliers).

In step 203, the user performs data cleansing as necessary. For example, anesthesia services that are measured in minutes in one institution and in occurrences in another institution could all be converted to occurrences. In another example, outpatient surgery facility fees, which might vary from institution to institution, could be converted into uniform fees to better allow comparison based on utilization rather than particular contracting arrangements.

In step 204, the user performs high level service groupings. For example, the episode grouper may already have grouped services into ancillary costs, management fees, inpatient facility costs, pharmacy, and surgical professional fees. In the current embodiment, the invention assigns services so as to create the additional high level categories of radiology services, physical therapy services, and allergy services (production and administration of vaccine, commonly known as “allergy shots”). The output of step 204 is the service group file 205.

In step 206 the system finds all managing practitioners in the specialty or specialties of interest and creates a list of practitioner IDs. Alternatively a list of practitioners can be provided or created by other means such as by user input. A provider ID list produced by other commercial data processes also may be used for this step. It should be noted that a number of different specialties or practitioners from different specialties may be combined at the user's discretion in order to capture all the practitioners of interest. For example, there may be practitioners in different specialties that perform similar services. The percentage of involvement for each practitioner is calculated for each episode by cycling through each episode, finding and storing all practitioners associated with the episode, calculating and storing each practitioner's percentage of the total of the episode, and outputting a practitioner episode percentage table reporting the roles of the practitioners in each episode. The percentage of involvement is calculated by the total cost that the practitioner contributed to the episode or by the number of services the practitioner ordered in the episode. Alternatively to percentages, other measures of involvement may be used. Any attribution rule may be used to assign episodes to practitioners; however, it should be noted that a practitioner that is deemed to have had a significant role in an episode is assigned all the services in that episode regardless of whether that practitioner was responsible for the service, according to the current embodiment.

A number of alternative attribution rules are described in a white paper from Bridges to Excellence and The Leapfrog Group, “Measuring Provider Efficiency, Version 1.0” [online], Dec. 31, 2004 [retrieved on Jan. 17, 2006]. Retrieved from the Internet: <http://bridgestoexcellence.org/bte/pdf/Measuring_Provider_Efficiency_Versionl12-31-20041.pdf> pages 38-41. The first method described in the white paper attributes an episode to the one practitioner with the highest percentage of the cost of the episode. This method will generally result in only one practitioner being attributed to an episode even when there are many treating practitioners. Further, the attributed practitioner may not have been responsible for the decisions that led to the costs of the episode. A second method in the white paper is similar to the first method with a minimum threshold for the percentage of the costs of the episode. Particularly, the episode is attributed to the practitioner with the highest percentage of the cost of the episode only if that percentage is over the threshold. This eliminates episodes with highly fragmented care. In a third method described in the white paper, the attribution rule assigns the episodes to the patient's primary care provider regardless of the primary care provider's role in the episode. This method is only applicable when the patients are required to select a primary care provider. The fourth method described in the white paper infers a primary care provider for patients that are not required to select one. The primary care provider is identified by review of the patient's visits to providers for a predefined period, such as 12 months, before the episode. The fifth attribution method described by the white paper assigns all the practitioners involved in an episode to the episode regardless of the percentage of the practitioner's involvement. The white paper's sixth method attributes an episode to the practitioner that performed a significant procedure in the episode. This method only applies to surgical episode types. The seventh method described by the white paper assigns the episode to the practitioner with the most face-to-face encounters with the patient. The attribution is thus not based on dollars. The white paper also describes a method that attributes an episode to the practitioners that had professional fees above a threshold percentage of the cost of the episode. The attribution rule is not to be limited to the above-described attribution methods.

The system then selects all services for all episodes attributed to each practitioner in step 207. A variety of rules may be used for assigning episodes to practitioners, such as, for example, those practitioners who have generated a certain percentage of services at least 25% of the total costs of the episode. The definition of a significant role may be varied to include more or less practitioners as needed for the particular analysis.

The medical practice pattern tool 100 now produces a file 208 comprising all services in all episodes attributed to each practitioner, for each practitioner of interest. The file includes all services with an additional field identifying the practitioner to whom was attributed the episode containing the service. Where an episode has been attributed to more than one practitioner, for example, where two practitioners shared management of the patient, the episode's services are copied and, in the second instance of the episode, the added field has the second practitioner's identifier. It should be noted that multiple practitioners may be assigned the same total role services.

The episodes specific to a condition of interest are then defined by the user of the medical practice pattern tool 100 in step 209. This step may be performed several times to provide analysis on several different groups of episodes of interest using the data compiled in the previous steps. It should be noted that by preserving in file 208 all episodes across all conditions for the entire group of practitioners, great flexibility is retained for analyses, because, at this step, conditions can be created by selecting episodes according to specific criteria not limited by the definitions of the original episode grouper.

The user employs clinical judgment to produce an operational definition of a group of episodes of interest, which may be from one or more ETGs output by the grouper. For example, in the specialty of allergists, the episodes of interest may be related to Allergic Rhinitis in the ETG 0332. A further example in the specialty of orthopedists, the episodes of interest may be Carpal Tunnel Syndrome with and without surgery, combining the ETGs 0174 and 1075. Alternatively, the episodes of interest may be a subset of an ETG defined by ICD-9 or by CPT. For example, in the specialty of dermatologists, benign neoplasm of skin (ETG 0682) could be analyzed without episodes containing the diagnosis of actinic keratoses, which would normally be included in ETG 0682. A further example in the specialty of orthopedics, knee derangement with or without surgery (ETGs 0742.02 and 0743.02), but including only episodes containing arthroscopy. In a further alternative, episodes of interest are defined to include multiple ETGs with multiple limitations. For example, an analysis in the specialty of dermatologists may include dermatitis in ETG 0678, minor inflammation of skin, episodes with diagnoses 690-693 plus ETG 0692, dermatological signs and symptoms, episodes with diagnosis 782.1, rash.

In step 210, the medical practice pattern tool 100 selects the services for the episodes of interest identified in step 209 and outputs a pre-analysis service set file 211 listing the services in the episodes of interest with identifiers for all practitioners to whom those episodes were attributed.

In step 212, the medical practice pattern tool 100 counts the number of episodes and their costs for all practitioners in the analysis and outputs a file 213 showing the episode counts and average cost by practitioner. In step 214, the user then optionally applies a volume threshold and/or other criteria to select a final list of practitioners to analyze. For example, the user may decide that practitioners who see fewer than 5 cases per year have atypical practices and should be excluded from analysis.

In step 215, the user assigns the practitioners into strata. The strata may be defined in numerous ways, such as by the total episode cost (the total cost of the episode regardless of the practitioner's contribution), responsible cost, by specialty, by geographic location (e.g. urban, suburban, rural), by type of practice (e.g. by group size), etc. For example, the physicians are ranked according to cost and separated into percentile groups (quartiles, quintiles, etc). The strata may be divided evenly, or the boundaries between strata may be selected using the user's judgment, for example at natural breaks in the data. In a particular embodiment, the strata are defined for the episodes of interest using the pre-analysis service table, by ranking all the relevant physicians from highest to lowest volume in terms of number of episodes, choosing a lower limit for number of episodes, re-sorting all physicians with greater than or equal to the minimum number of episodes by the average total cost per episode, lowest to highest. Physicians having an average total cost per episode that is unexpectedly high or low compared to the rest of the group of episodes of interest may be removed from the group. Similarly, physicians having a number of episodes that does not fit with the rest of the group are removed. The physicians are then divided into strata, such as cost quintiles. The medical practice pattern tool 100 outputs a practitioner stratum table that lists the practitioners in their respective strata and includes the total role episode count, the responsible role expense, the total role expense, the responsible role average cost per episode, and the total role expense per episode (see Table A4 in the example). The result is step 216, which outputs the practitioner stratum table 217. The medical practice pattern tool 100 also outputs a table 218 of episode count by stratum, which is a table of the number of episodes in each stratum.

In step 219, the medical practice pattern tool 100 then uses the final practitioner stratum table 216 and the pre-analysis service set 211 and selects episodes' services for only those practitioners in the final table 216. Each service is labeled with its attributed practitioner's stratum number. The result is file 220, the analysis service set.

In step 221, the medical practice pattern tool 100 then counts the beginning diagnosis for each episode in the analysis service set and produces a count of diagnoses by stratum, outputting the diagnosis list 222. This list can be used in conjunction with other outputs of the medical practice pattern tool 100 to perform additional analyses, such as determining whether the pattern of medical conditions by specific diagnosis had an effect on costs.

The medical practice pattern tool 100 then in step 223 finds the average cost and utilization for every service across all episodes in the entire analysis. To achieve this, the cost and service utilizations are totaled across all the episodes in the entire group of episodes of interest, which may be known as the analysis total. Each cost and service utilization is normalized by dividing by the total number of episodes in the group of episodes of interest to generate the cost per episode average and the service utilization per episode average across all the episodes in the analysis, which may be known as the analysis average. The number of episodes in the entire group of episodes of interest is the sum of the stratum episode counts in the table 218. The medical practice pattern tool 100 outputs a table of the costs and service utilizations per episode for all episodes of interest, resulting in file 224, the cost-service per episode file.

The medical practice pattern tool 100 then in step 225 determines the expected cost and expected service utilization for each service in each stratum from step 223. For each service, the system multiplies the number of episodes in the current stratum times the service cost per episode and service utilization per episode from the table 224 of costs and services per episode in the entire analysis. The result is the “expected” costs and service utilizations for each service in the current stratum (i.e.: as if the average cost and service utilization across all practitioners of interest had been delivered for the number of episodes in that stratum). In other words, the expected cost and expected utilization for every service in each stratum equals the average cost or utilization for a service across all episodes times that stratum's number of episodes from the stratum episode count table 218.

The medical practice pattern tool 100 then also in step 225 finds the difference between the actual and expected service cost or utilization for each service in each stratum. The expected cost and service utilization are subtracted, respectively, from the actual cost and service utilization of each service to find a cost and utilization difference per service. It should be noted that the actual service cost is defined herein as the sum of the cost of that service over every time the service occurred in a stratum. For example, if a service is consistently $200 and it occurred 100 times in a particular stratum, the total service cost is $20,000 for that stratum. It should be further noted that the service utilization is defined herein as the number of times a service was performed for the episodes in a given stratum. In the above example, the service utilization is 100.

The medical practice pattern tool 100 then generates a list of all the services attributed to the practitioners in the practitioner stratum table and then sorts and normalizes all the resultant services. For each service the tool shows the actual total cost and utilization, the expected cost and utilization, and the differences between the actual and expected costs (and optionally, utilizations). The tool then applies a normalization within each stratum by dividing both the total costs and utilizations and their differences from expected by the number of episodes in that stratum. The resulting output is a table 226, the MPPT file, sorted by stratum, high level category, and then service within each category from highest to lowest difference from expected cost or utilization.

In steps 227 and 230, the user may identify potential cost drivers and generate a report comparing the absolute values of the services. In step 227, the user applies a minimum threshold for the total cost for each service in each stratum or the service utilization for each service in each stratum. The threshold therefore may be, for example, a total cost of $10 per episode or a service utilization of 0.1 per episode. Any service that has a cost or service utilization above the threshold is stored in a potential cost drivers table. Thus, anomalous data are removed. The total service cost or service utilization for each of these potential cost drivers may be displayed in a graph, such as a bar graph, in step 229.

It often makes sense to group certain services together in the graph, for example, pharmaceutical claims. The user may use clinical judgment while examining the services to apply appropriate groupings, e.g.: complex radiology within radiology, antibiotics within pharmacy, consultations within examination and management, etc. Therefore it is beneficial to group the services by type within the strata formed in step 215. Further, in the steps following step 215, it is convenient to calculate the totals for each type of service as if the service type was an individual service. For example, the system calculates the total cost difference per episode for all antibiotics within pharmacy, as well as for the individual services within the pharmacy type.

The important cost differences are determined by setting a threshold for the cost difference per episode and removing the services that are below that threshold in step 230. For example, a cost difference per episode that is less than $2 may be considered to an insignificant difference and services below that threshold would be removed from the list. Thus, anomalous data are removed. The resulting output list, which indicates the total cost difference per quintile episode, groups similar services together within each stratum as discussed in step 227. For example, in allergic rhinitis allergy vaccines (“allergy shots”) appear within the ETG category of management costs while other management costs and evaluation are grouped separately. Likewise, all physical therapy services would be grouped together and all anesthesia services would be grouped together. The service group differences from expected can then be displayed as a graph 232 showing the variation from average of each service group for each stratum.

In alternative embodiments, the threshold step may be applied to other values. For instance, the utilization difference may be calculated similarly to the cost difference and the threshold may be applied to the utilization difference or the utilization difference divided by the number of episodes in the stratum. Alternatively, the threshold may be applied to the total cost or utilization. In a further alternative, the threshold is applied to the total cost of a service within a stratum divided by the total utilization of that service in that stratum. So the threshold may be applied to the total cost, the total utilization, the cost per episode, the utilization per episode, the cost difference, the utilization difference, the cost difference per episode, the utilization difference per episode, the cost per utilization, or variations and combinations thereof.

The final output of the medical practice pattern tool 100 comprises a report consisting of tables or graphs, such as bar graphs (outputs 229 and 232), comparing the cost drivers. The graph 232 displays the cost per episode of the cost drivers above and below the expected value for each stratum. The graph readily shows the differences between the strata. Thus step 116 (FIG. 1) is reviewing the table(s) and graph(s) and determining the services that drive the differences between the strata. For example, physicians in the first quintile may use less of service A than the average of the group of episodes of interest, thus showing a negative cost difference per episode for service A, and more of service B than the average of the group of episodes of interest, thus showing a positive cost difference per episode for service B. If the practitioners in the fifth quintile have a positive cost difference per episode for service A and a negative cost difference per episode for service B, and the first quintile is the least expensive quintile, then it stands to reason that physicians that choose to use more of service B and less of service A will have less expensive episodes of care for that group of episodes of interest on average.

It is possible to collect all of the results from several analyses of separate groups of episodes of interest and form a medical management blueprint for practitioners to follow. The blueprint provided in step 118 (FIG. 1) has a separate cell, such as the one shown in FIG. 3, for each analysis performed using the medical practice pattern tool 100. Each cell has a brief description of the episodes of interest, a list of two or three cost drivers, and a recommendation for treatment within that specialty. The description of the episodes of interest will indicate whether a single ETG, a combination of ETGs, or a subset of ETGs was used. The cells are placed in rows according to specialty, as shown by example in FIG. 4. Therefore, after making a diagnosis, a practitioner may consult the blueprint or a listing or guideline derived from the blueprint to determine what services for treating this diagnosis are favored. If the preferred services of the practitioner are not cost drivers in the analysis, then she proceeds according to her discretion. However, if the services are addressed in the blueprint, the practitioner is recommended to use the services utilized by the lower cost quintiles and to not use services that are not utilized by the lower cost quintiles. In addition or alternatively to providing recommendations to the practitioners, the blueprint may recommend that a practitioner or an organization renegotiate a contract with a service provider. For example, the medical practice pattern tool 100 may show that the inpatient physical therapy costs are exceedingly high for a particular hospital and the recommendation is for the managed care organization to renegotiate the costs for the therapy. In a general sense, an organization can use the blueprint to organize its efforts to manage costs.

An advantage of the medical practice pattern tool is that it reveals what services less expensive practitioners use and what services they do not use. It does not simply report which practitioners are expensive and which are inexpensive. Further, the medical practice pattern tool may have counterintuitive results. In particular, the recommendation may be to use a more expensive service over a less expensive service. This may be because the less expensive service is less effective than the more expensive service, or because the less expensive service is used much more frequently, causing higher total costs. For example, for the condition allergic rhinitis it has been found that physicians in the less expensive quintiles use less vaccine (“allergy shots”) and more pharmaceuticals to treat allergies while those in the expensive quintiles use more vaccinations and less pharmaceuticals. This result is counterintuitive because pharmaceuticals tend to drive expenses in other conditions.

It is possible for the results of an analysis to be skewed by certain factors. Patient severity could be systematically different from one stratum to another. ETGs are already constructed so as to be cost hom*ogenous, and those that are clinically hom*ogenous minimize the concerns further (e.g. ETG for HTN without complications).

Certain episode groupers include severity adjustment, or severity could be judged by separate analyses (e.g. through one of several standard severity adjustment methods such as age-gender, ERG, DCG, etc). The differences in physician practice patterns are usually apparent and larger than severity differences, due to the construction of ETGs. However, one could group episodes by patient-severity strata and then evaluate the differences in practice according to patient severity.

The invention has a major competitive edge over other analytic tools in the market. First, it discovers the general characteristics of practice patterns, rather than requiring multiple a priori hypotheses and analyses. A key goal of managed care organizations is identifying and defining “best practices.”

In addition, the inputs and outputs of the algorithm are clinically relevant and easy to present in graphic form. This facilitates the discussion of medical appropriateness and allows clinical judgment as to whether the service is under utilized, over utilized, or mis-used, based on medical evidence for or against the service in question. Therefore the invention allows the connection of cost containment to quality improvement.

Application of the algorithm shows potential savings of $250,000 to $1,250,000 among conditions in three specialties that have been examined. The potential cost savings for a medium-sized regional insurance plan are $10,000,000 to $30,000,000 per year (2 conditions×20 specialties×$250,000 average at the low end, 3×20×$500,000 average at the high end).

As described, the medical practice pattern tool focuses on the total role rather than the responsible role of a particular medical practitioner. For the purposes of this description, the total role comprises the total cost or utilization of the care of a particular patient, as opposed to the contribution of a single physician of interest, which is the responsible role. The advantage that the total role has over the responsible role is that the total role analysis captures all services in an episode while the responsible role analysis only considers services for which the practitioner of interest is responsible. Thus, if a particular practitioner does not typically order a particular service for a given ETG, and another practitioner typically does order that service, the first practitioner looks less expensive and the service at issue looks like a cost driver. A total role analysis may show that this is an incorrect result. For example, a first general practitioner may typically order an MRI for episodes in a particular ETG prior to sending the patients to a specialist. A second general practitioner may typically send the patients directly to the specialist for episodes in the same ETG, in which case, the specialist is responsible for the MRI. In a responsible role comparison of the two general practitioners, the first general practitioner looks more expensive and the MRI appears to be a cost driver, all else being equal. A total role analysis shows, however, that the MRI was ordered in all episodes regardless of whether the general practitioner or the specialist ordered it, and the MRI is eliminated as a potential cost driver. A responsible role analysis may be desirable in certain circ*mstances, and one skilled in the art will be able to modify the medical practice pattern tool described to provide such an analysis. Thus, the medical practice pattern tool with a responsible role focus is considered to be within the scope of the invention.

Further to the main MPPT analysis, an individual practitioner's practice pattern is discerned by a total role drilldown and a total role MPPT meta-drilldown. The total role drilldown for a practitioner lists all the services from the episodes in which this practitioner had a significant role. The episodes are from a single condition corresponding to an MPPT analysis, such as a modified ETG. The services are organized by high level category and, within each category, the services are ranked according to the total cost difference (i.e. the expected cost subtracted from the total cost).

The total role MPPT meta-drilldown lists all the services from the episodes in which the physician had a significant role for all the conditions analyzed. In other words, the MPPT analysis may be carried out for several conditions and an individual practitioner may have a significant role in episodes of a plurality of these conditions. The MPPT meta-drilldown combines all the episodes from all the conditions considered. Similarly to the total role drilldown for an individual condition, the services in the MPPT meta-drilldown are organized by high level category and within each category the services are ranked according to the total cost difference (i.e. the expected cost subtracted from the total cost). The expected cost and utilization for each service in the MPPT meta-drilldown is calculated by multiplying the average cost and utilization for the service in each condition (from step 223) times the number of episodes in which the physician had a significant role in that condition, then summing the result over all the conditions considered. This provides a case-mixed service cost and utilization, by service.

The organization and ranking of the services in the total role drilldown and the total role MPPT meta-drilldown thus readily show the physician's variation in one condition and across multiple conditions, respectively. The services that really make a difference to the cost of the physician's practice are revealed by normalizing by the number of episodes, as described in the main MPPT analysis. Most of the physician's services have a cost difference per service of close to $0, while services that truly affect costs have a non-zero cost difference per episode.

In an example, a number of episodes of care for the condition benign neoplasm of the skin, ETG 0682, are analyzed using the medical practice pattern tool. In this example, the medical practitioners are physicians in the specialty of dermatology associated with a medium sized regional managed care organization. The claims data input to the ETG grouper was from a period of two years.

The user chose to analyze complete episodes of care that were not cost outliers. In the data cleansing step the user had substituted uniform fees for outpatient hospital services. In choosing the top-level of groupings the user kept the Symmetry Grouper categories (ancillary, facility, management, pharmacy, and surgery) but split radiology costs out of ancillary to form a separate category. A sample of the resulting service group file 205 is shown in Table A1. Note that the data at this point contains all episodes from all ETGs for the specialty of dermatology.

In the example, the user had previously compiled a list of all dermatologists in the managed care organization and used that list as input 206. The user then found all episodes that were to be attributed to each dermatologist according to the user's chosen attribution rule, and inserted the attributed practitioner's identification number as the final field in the file 208, “total role all practitioners services details all episode,” sample shown in Table A2. Note that more than one practitioner could have been attributed in a given episode, and in that case the medical practice pattern tool would have made one or more additional copies of all the services in that episode and appended the second (and third and fourth, and so on as the case might be) practitioner identifier to the copied episode's services. For example, the services with claim IDs 56 through 60 in Table A2, which belong to episode number 1067490, were attributed to physician number CCP010000009 and CCP010000032. Thus, the services for this episode are listed twice with one set attributed to CCP010000009 and the other attributed to CCP010000032.

The user knew from prior experience that ETG 0682 contains episodes of actinic keratosis removal as well as non-actinic keratosis skin lesion removal. Because this mixed two medical conditions, the user, in step 209, specified that the condition of interest was those ETG 0682 episodes that did not contain a diagnosis of actinic keratoses (ICD9 702.xy where x is any fourth digit and y is any fifth digit). The medical practice pattern tool therefore at this step selected only episodes of 0683 without actinic keratosis diagnoses, producing the pre-analysis service set 211. Of the episodes shown in Tables A1 and A2, the episode with claim IDs 66 through 70 included a diagnosis of actinic keratoses and therefore were removed from the analysis.

The medical practice pattern tool at this point counts the episodes and their costs for all practitioners in the pre-analysis service set, producing the file 213, “practitioner zero or more episodes.” A sample of the file 213 is shown in Table A3. Note that the practitioners are ordered by volume so that the user can apply optional threshold and other criteria in step 214. In this case the user did not choose to apply any criteria. However, in this step there might have been a volume threshold, for example a minimum of 100 episodes, which would have removed seven practitioners. The user also could have removed any practitioners with an atypical practice, for example, anyone known to specialize in treatment of skin cancers, who might therefore a priori be considered to have more difficult patients referred for care.

In step 215 the decision was made to stratify the practitioners into quartiles according to average total episode cost. Other stratification schemes could have been applied, such as cost quintiles or urban/suburban/rural practice locations. The result was file 217, “practitioner stratum table,” as shown in Table A4 The MPPT counted the episodes in each stratum producing the stratum episode count table 218 as shown in Table A5. It is seen that there were a total of 22,358 episodes across all four quartiles, with 6,455 episodes in Quartile 1, 4,443 episodes in Quartile 2, 7,788 episodes in Quartile 3, and 3,672 episodes in Quartile 4.

The MPPT in step 219 would have selected only those services in the pre analysis service set 211 that were in episodes attributed to the physicians in the final practitioner stratum table, producing the analysis service set. In this example, since no physician was eliminated in step 214, the analysis service set was identical to the pre-analysis service set. The MPPT produced a count of diagnoses by stratum, output 222 “diagnosis list”, as shown in Table A6.

The MPPT then in step 223 found the costs and service count (utilization) per episode for every service in the analysis service set. A portion of the resulting “cost-service per episode” file 224 is shown in Table A7. Taking as an example service 11400, which is the CPT-4 identifier code for the procedure “excise, benign skin lesion, including margins, except skin tag, trunk/arms/legs,” it is seen that the service was performed 512 times in the entire analysis (that is, across the 22,358 episodes of all four quartiles). The total cost was $47,710. Therefore the average cost per episode for all dermatologists of interest (in this case, the entire specialty in the region of the managed care organization) was $47,710 divided by 22,358, or $2.13 per episode and the average utilization per episode was 512 divided by 22,358, or 0.0229 per episode. The other columns in Table A7 simply track the number of episodes in which the service occurred, the average cost of the service per episode in which it actually occurred, and the average number of times the service was ordered per episode in which it actually occurred. If fewer dermatologists were analyzed (e.g. if some were excluded in step 214 for small numbers of episodes or atypical practices), the denominator of 22,358 would have been smaller.

The MPPT then performs the step 225 consisting of listing the services by stratum, top-level category, and then service, counting the actual costs per service and occurrence (utilization) per service within each stratum, generating the expected costs and occurrences, generating the differences between actual and expected, and normalizing those by the number of episodes in the stratum. A portion of the output 226, the MPPT file, is shown in table A8. Continuing the example of service 11400, it is seen that for quartile 1 the service occurred 94 times in 6,455 episodes at a total cost of $10,400. If the service had occurred at the average rate of all analyzed practitioners of 0.0229 per episode, it would have occurred 147.82 times, the expected number of occurrences (0.0229 times 6,455). Similar calculations lead to an expected cost of $13,774 ($2.13 time 6,455), showing that in quartile 1 the service occurred at a lower rate than expected and a lower cost than expected. The cost difference between actual and expected was $3,734. The MPPT then normalized the actual cost and cost difference to the number of episodes in the quartile, yielding an actual cost per quartile episode of $1.55 (rounded in the table to $2) and a cost difference of $0.58 per episode below expected (rounded to −$1.00).

By similar calculations and reasoning it can be seen that in quartile 1 the service 17000, destruction of premalignant lesion, occurs more often than expected, at an actual cost per quartile episode of $13.37 (rounded to $13) and a cost difference of $1.03 per episode above expected (rounded to $1).

By similar calculations and reasoning it can be seen that in contrast to the lowest cost quartile, the service 11400 in quartile 4 is used at $4 per episode ($2 per episode above expected) and the service 17000 is used at $10 per episode ($3 per episode below average).

The user now applies thresholds to determine significant drivers of cost and variation. In this example a cost driver threshold of $2 (rounded) per episode was used and all services with costs below that threshold were removed. The medical practice pattern tool in this step removes (for example) all pharmacy and radiology services, showing that they were not significant cost drivers as defined by the user in setting that threshold. An alternative threshold of services per episode could have been used. A portion of the resulting report (file 228) is shown in table A9 and the corresponding graph shown in FIG. 5, which shows the absolute cost per the number of episodes in each stratum for the significant cost drivers. This report shows that the important cost drivers in the condition benign skin lesions are pathology costs, management costs, and procedure costs. Particularly, FIG. 5 shows that Quartile 1 spends much less on office visits and procedures than the more expensive quartiles.

Similarly the user could remove all cost differences under a threshold such as $1 to show that those services were not significant drivers of the variation in care among quartiles. An alternative threshold of service utilization difference could be used. In this example, the user also choose to use a separate cost difference threshold to select all services with a per episode cost difference of over $0.30 (absolute value). FIG. 6A shows the difference between the actual cost and the expected cost per the number of episodes in each stratum for the significant cost drivers. FIG. 6B shows the significant cost drivers within the procedure group of cost drivers: biopsy, shave excision, excision, destruction, and other. The graphs clearly show that Quartile 1 spends much less on office visits and procedures than the more expensive quartiles. More specifically, Quartile 1 spends less on excision procedures and more on destruction than the other quartiles.

It will be noted that in this example under surgical procedures there are several natural groupings of services, such as all excisions, all lesion destructions, etc. The user has sorted and subtotaled the costs for those groupings of services.

The resultant tables and corresponding graphs thus teach that the practice pattern of the lower quartile dermatologists consists of lower pathology costs, office visit costs, and procedure costs compared to those of the higher cost dermatologists, and further that the procedure costs are represented in general by higher excision-type procedures in the highest quartile dermatologists.

Therefore the medical practice pattern tool has uncovered a pattern of variation in care among cost quartiles in the use of office visits and lesion excision versus lesion destruction. This teaches that the practice pattern of the lower cost physicians is to do lesion destruction rather than lesion excision, and further that medical costs can be decreased by a medical guideline that suggests to practitioners to perform lesion destruction instead of excision as often as possible consistent with good medical practice.

One will note that Tables A8 and A9 include several columns that track data that were not necessarily used in the analysis. This data may be useful, however, for additional analysis and for providing context to the recipients of the medical practice pattern tool analysis. Particularly, the “stratum” column lists the stratum designation; for example: S1 is used for stratum 1 and Q1 is used for Quartile or Quintile 1. The “category” column lists the cost category, such as Ancillary (A), which includes labs, other testing, outpatient facility fees, etc., Evaluation and Management (M), which includes office visits, etc., Pharmacy (P), Radiology (R), Inpatient Facility (F), Physical Therapy (T), among others. The “service” column lists the service group designator, e.g. the CPT code, the medication group label, the DRG code, etc. The “procedure description” column simply lists the text description of the service group designator. The “total services” column lists the stratum service usage, which is the total number of times that service was provided for all episodes in the current stratum. The “your services” column lists the number of units of that service provided for all episodes in that stratum performed by the physicians with a significant role. This value is obtained by examining each episode and counting the services generated or ordered by the index physician, for those physicians with a significant role. The “other's services” column lists the number of that service provided for all episodes, obtained by examining each episode and counting the services generated or ordered by practitioners who were not in the significant role relative to the index practitioner.

The “expected services” column lists the number of services that would be expected if performed in this stratum at the average rate of services per episode in the entire analysis (i.e. across all strata). More particularly, the expected services is defined by the service usage for the entire analysis divided by the number of episodes in the analysis and multiplied by the number of episodes in the current stratum. The “stratum (or quartile or quintile) episodes” column lists the number of episodes in that stratum. The “total costs” column lists the actual total costs for all of that service in that stratum. The “your costs” column lists the actual costs for that service in that stratum for the physicians with significant roles. This is the costs for the services usage listed in the “your services” column. The “other costs” column lists the actual costs for all of that service in the current stratum for the other physicians without a significant role. This is the costs for the services usage listed in the “other services” column. The “expected costs” column lists the expected costs for that service, generated in the same manner as the expected services. Particularly, the expected cost is defined by the service cost for the entire analysis divided by the number of episodes in the analysis and multiplied by the number of episodes in the current stratum. The “total cost difference” column lists the total costs minus the expected costs and the “total costs per stratum episode” column lists the total costs divided by the number of episodes in the stratum.

The total cost “difference per stratum episodes” column lists the total costs divided by the number of episodes in the stratum. The “your costs per service” column lists the costs for physicians with a significant role (from the “your costs” column) divided by their number of services (from the “your services” column). The “other costs per svc” column lists the costs of the physicians who were not the significant role physicians for the episodes (from the “other's costs” column) divided by their number of services (from the “other's services” column). The “spec costs per svc” column lists the specialty costs per service, which is the sum of costs of all the physicians in the analysis (from the “total costs” column) divided by the number of that service in the entire analysis (from the “total services” column). The “episodes this service occurred” column lists the total number of episodes in the stratum in which the service was found. Tracking this additional data allows the user to perform additional analyses once the key cost drivers and the expensive practitioners are discovered. For example, the user may perform analyses related to the percentage use of a service by stratum episode, or the cost per service when service was actually used.

When reporting to an individual practitioner in the analysis, further analyses focused on the individual may be carried out. These include the total role drilldown and the total role MPPT meta-drilldown. The total role drilldown for physician #CCP010000014, who was assigned to the fourth quartile in the MPPT analysis, is shown in Table A10, wherein all the services from the episodes in which this physician had a significant role are listed. The episodes are from a single condition corresponding to an MPPT analysis, in this case the benign neoplasm of the skin, without actinic keratoses ETG 0682 of the present example. The services are organized by high level category and, within each category, the services are ranked according to the total cost difference (i.e. the expected cost subtracted from the total cost).

The total role MPPT meta-drilldown is shown by Table A11, which lists all the services from the episodes in which the physician had a significant role for all the conditions analyzed. In other words, the MPPT analysis may be carried out for several conditions (e.g.: ETGs or modified ETGs) and the present physician may have a significant role in episodes of a plurality of these conditions. The MPPT meta-drilldown combines all the episodes from all the conditions considered. Similarly to the total role drilldown, the services in the MPPT meta-drilldown are organized by high level category and within each category the services are ranked according to the total cost difference (i.e. the expected cost subtracted from the total cost). The expected cost and utilization for each service in the MPPT meta-drilldown is calculated by multiplying the average cost and utilization for the service in each condition (from step 223) times the number of episodes in which the physician had a significant role in that condition, then summing the result over all the conditions considered. This provides a case-mixed service cost and utilization, by service.

The organization and ranking of the services in the total role drilldown and the total role MPPT meta-drilldown thus readily show the physician's variation in one condition and across multiple conditions, respectively. The services that really make a difference to the cost of the physician's practice are revealed by normalizing by the number of episodes, as described in the main MPPT analysis. Most of the physician's services have a cost difference per service of close to $0, though services that truly affect costs have a non-zero cost difference per episode. Upon review of Tables A10 and A11, one will note that this physician is high in service number 11400 (excision) and low in service number 17000 (leasion destruction). This is in parallel to the MPPT part of the present example in which the fourth quartile was high in excision and low in lesion destruction, while the lower cost first quartile was low in excision and high in lesion destruction. Further, this physician tends to do more level 3 consults and office visits and fewer than expected level 2 of the same (see category “M” in Table A11).

Therefore, when reporting to the physician that the MPPT analysis indicates that higher quartile physicians tend to do more excisions than destruction, the user may also provide the physician's pattern in the same condition and across all conditions. In this case, the physician follows the fourth quartile pattern for the benign neoplasm of the skin without actinic keratoses condition and across all conditions. Further, the present physician codes much higher for office visits. Thus, the user may provide two concrete actions to lower the physician's costs.

For physicians in the lower quartiles, there may still be areas where they can lower costs and the total role drilldown and the MPPT meta-drilldown may reveal these areas in the physician's pattern. Thus the drilldowns may be valuable for all physicians in the analysis.

In further example, a number of episodes of care for the condition Allergic Rhinitis, ETG 0332, are analyzed using the medical practice pattern tool. In this example, the medical practitioners are physicians in the specialty of allergy associated with a medium sized regional managed care organization. The claims data input to the ETG grouper was from a period of two years. The system develops the practitioner episode percentage table using the output of the ETG grouper, which provides the list of physicians associated with episodes of care in ETG 0332. For each episode, the system calculates the percentage of involvement of each physician by dividing the sum of the costs of the services the physician is responsible for in that episode by the total cost of the episode. The system then calculates and stores the number of episodes for which each physician contributed to at least 25% of the cost; though, it should be noted that other attribution rules may be used. Now the system ranks the physicians and divides them into strata, in this case cost quintiles, as shown in Table B1. As one can see, the physicians are ranked according to the average cost of the episodes in which that physician had a significant role. The quintiles are evenly divided except that physician 10's total role expense per episode fit better in the fourth quintile than the third.

Referring to Table B1, physician 1 has a significant role in 181 episodes in ETG 0332 and the total cost of those episodes is $115,782, translating to about $640 per episode. This places physician 1 in the lowest cost quintile, Q1. Physician 12, on the other hand, has a total cost per episode of about $753, which results in physician 12's placement in a higher cost quintile, Q4. The responsible cost data is also included in Table B1.

The system now calculates the expected cost and service utilization (number of times a service is ordered) for each service in each quintile. The system totals the cost of each service for the entire ETG 0332 and then totals the service utilization for that service over ETG 0332. For instance, service reference number 95004 has an ETG total cost of $84,806 and an ETG total service utilization of 21,600. Each of these totals is then divided by the total number of episodes in the ETG, which is 2506 in the case of ETG 0332. This results in the cost per episode average of $33.84 and the service utilization per episode average of 8.62 for service reference number 95004. The cost per episode average is multiplied times the number of episodes in each quintile to calculate the expected cost of the service for that quintile. For instance, there are 472 episodes in quintile Q1, multiplied times the cost per episode average of 33.84 results in an expected cost of $15,973 for service 95004 in Q1. Similarly, the service utilization per episode average is multiplied times the number of episodes in each quintile to calculate the expected service utilization of the service for that quintile. Thus the expected service utilization for service 95004 in Q1 is 4068.32.

The expected cost and service utilization are reported in Table B2, which lists the services organized by quintile and by type. The services are grouped by type in each quintile with subtotals in Table B2 so that services may be easily grouped in the final analysis. For example, pharmaceuticals in general may be a cost driver and there may be less interest in the details of the specific pharmaceuticals. For each service, the system subtracts the expected cost from the actual cost also reported in Table B2 to calculate the total cost difference. This is divided by the number of episodes in the quintile to result in the total cost difference per quintile episode. For service 95004, the total cost difference is $4,703 and the total cost difference per quintile episode is $10, as reported in Table B2. A negative total cost difference per quintile episode, such as ($1) for service 95015 indicates that the actual cost was lower than the expected cost.

Once the total cost difference per quintile episode is calculated for every service in every quintile, a cost driver threshold is set. In this case, any service with a total cost difference per quintile episode having an absolute value of $2 or greater, is reported in Table B3, still organized by quintile and by type within each quintile.

FIG. 7 shows the bar graph of the potential cost drivers from Table B3. The user employs clinical judgment to combine certain services and produce a meaningful graph. For example, if pharmacy is a cost driver in general, a separate graph of the components of the pharmacy group is generated to compare the cost difference per episode of the components. In this example, allergy test services, which were previously grouped and the cost difference per episode totaled in Tables B2 and B3, are graphed in a group; and pharmacy services, which were similarly grouped in Tables B2 and B3, are graphed in a group. Evaluation and management (E&M) services and vaccine services were grouped together in Tables B2 and B3; however, it now makes sense to graph these separately. The cost difference per episode for E&M services, such as service reference numbers 99244, 99214, 99243, and 99213 in quintile Q1, are totaled and graphed. Similarly, the cost difference per episode for vaccine services, such as service reference numbers 95147, 95115, 95165, and 95117 in quintile Q1, are totaled and graphed. Illustrating that even a portion of Table B3 may be graphed to compare the cost difference per episode of certain services, FIG. 8 shows the bar graph of the cost difference per episode of nasal steroid services, leukotriene receptor antagonist (LTA) services, and antihistamines, which are components of the pharmacy group of services.

The results of the medical practice pattern tool analysis of ETG 0332, Allergic Rhinitis, reveals that among allergists the main cost drivers are vaccine costs (the manufacture and administration of “allergy shots”), and to a much lesser extent allergy tests and E&M visits. The lowest cost physicians use much less vaccine but the most medications. They have slightly higher allergy test and office visit costs per episode than other quintiles. The highest cost physicians test and consult less but treat with both vaccines and medications far more. The middle quintile uses more vaccine and less pharmacy, but that quintile is dominated by one physician with that practice pattern.

In pharmacy, nasal steroid costs are the main driver, followed by prescription antihistamines. Leukotriene receptor antagonists (LTAs) were a smaller factor. The lowest cost physicians use the most nasal steroids and LTAs. They use prescription antihistamines moderately. They may be recommending over-the-counter loratadine, which would not appear in claims data. This would be an important question to ask physicians in that quintile.

Other factors besides physician practice choices could be in play. The most obvious would be patient severity. If patients in quintile five were the most severely ill they might need both vaccine and medication. However quintiles 1 and 2 (the lowest cost quintiles) contain two national-level and one international-level expert in allergy and immunology. A priori one would expect them to attract and treat the most severe patients. In addition, the largest allergy group in analysis region has members in all five quintiles, with two of the most senior members in quintiles 1 and 2, and the third senior member in quintile 5.

In summary, the results of the medical practice pattern tool analysis suggest that the most cost-effective allergists test and counsel somewhat more, and use nasal steroids (and perhaps OTC Loratadine) in preference to vaccines. The potential savings, if all physicians followed the quintile 1 practice pattern, are $160,000 per year.

It should be noted that because the service utilization and expected service utilization for each service is included in Table B2, the service utilization difference per episode may be calculated and the analysis may be completed comparing the service utilization difference per episode.

In an alternative embodiment, the analysis is carried out for a set of medical practitioners except that the strata are set up so that each stratum is one practitioner. The result is a comparison of the practice patterns of individuals rather than a comparison of a group of low cost practitioners and higher cost practitioners as described in the previous embodiment.

In a further alternative embodiment, all the conditions of a specialty (e.g. all the ETGs related to dermatology) are combined. In other words, the group of episodes of interest comprises all the episodes in all the dermatology ETGs. The strata are divided such that each stratum includes only one practitioner. The result is the general tendency of a given practitioner, revealing that a particular practitioner uses more or less E&M, procedures, etc. than expected for his specialty.

In an even further embodiment, the stratification of one condition (e.g. a particular ETG) is based on the characteristics of a separate condition. The analysis is then carried out on the cost variation in one condition as it relates to the other condition. For example, one carpal tunnel syndrome (CTS)-related ETG includes surgery and another is without surgery. If the two ETGs are combined, episodes of carpal tunnel treatment with surgery will overshadow episodes without surgery. In other words, the episodes with surgery are much more expensive than episodes without surgery; therefore, the episodes without surgery will very rarely have a sufficient effect to be included in the cost driver analysis and a driver that prevents surgery will likely be missed.

To reveal these cost drivers, the MPPT analysis 100 is carried out on each of the two CTS ETGs separately through step 216 to result in the practitioner stratum tables (output 217) for both ETGs. The system then compares the practitioner stratum tables to reveal each practitioner's rate of carpal tunnel treatment with surgery episodes versus treatment without surgery. The analysis is completed on the ETG for carpal tunnel without surgery by stratifying the practitioners by this surgery rate. The resulting cost differences may reveal a way to avoid surgery, such as steroid injections. The differences may also reveal that a service is a waste of money, for example if steroid injections had no effect on lowering the surgery rate.

There is a similar issue with the treatment of bronchitis. The episodes that start with bronchitis but lead to pneumonia will only appear in the pneumonia episodes. Therefore, similarly to the carpal tunnel example, an alternative stratification method is needed. In this case, the practitioners for the bronchitis ETG are separated into two strata: one with episodes that led to pneumonia and one with episodes that did not lead to pneumonia. The MPPT analysis is then carried out comparing the two strata and potentially revealing a service that reduces the likelihood that a bronchitis episode will result in pneumonia.

While the invention has been described with reference to particular embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the scope of the invention. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope and spirit of the appended claims.

TABLE A1
CLAIM_IDMEM_IDSVC_PVservice dateSVC_EXP1SVC_EXP2CPTCPT_MODDX_1DX_2PV_TYPE
56855VM1YAM 00CCP01000000906-Oct-2003$66$6617110238.2078.10MD
57855VM1YAM 00CCP01000000906-Oct-2003$130$1309924325238.2078.10MD
58855VM1YAM 00CCP01000000012-Sep-2003$56$5699213216.9244.9MD
59855VM1YAM 00CCP01000003211-Nov-2003$140$14011440238.2MD
60855VM1YAM 00CCP01000000011-Nov-2003$31$318830590216.9IL
618RO29B9A4 02CCP01000002325-Sep-2003$77$771140251216.9MD
628RO29B9A4 02CCP01000002325-Sep-2003$77$771140251216.9MD
638RO29B9A4 02CCP01000002325-Sep-2003$165$16511403216.9MD
648RO29B9A4 02CCP01000000025-Sep-2003$92$928830590238.2IL
658RO29B9A4 02CCP01000002302-Sep-2003$86$8699242216.9MD
6694PY71739 01CCP01000002321-Mar-2003$84$8411311702.11MD
6794PY71739 01CCP01000002307-Mar-2003$58$5817110702.11MD
6894PY71739 01CCP01000000021-Mar-2003$31$318830590216.3IL
6994PY71739 01CCP01000002325-Apr-2003$20$2099211216.9MD
7094PY71739 01CCP01000002307-Mar-2003$86$869924225702.11MD
ResponsibleEpisode
CLAIM_IDetgnoepinoREC_TYPEFlagSVC_EXP3quantityvisit_typerunidservicein2PV_IDDATEFROM
5606821067490S.0000$6612.0000X1700P01000000912-Sep-2003
5706821067490M.0000$1301C2.000099243P01000000912-Sep-2003
5806821067490M.0000$561F2.000099213P01000000012-Sep-2003
5906821067490S.0000$14012.000011440P01000003212-Sep-2003
6006821067490A1.0000$3112.000088305P01000003212-Sep-2003
6106824631697S.0000$7714.000011402P01000002302-Sep-2003
6206824631697S.0000$7714.000011402P01000002302-Sep-2003
6306824631697S.0000$16514.000011403P01000002302-Sep-2003
6406824631697A1.0000$3134.000088305P01000002302-Sep-2003
6506824631697M.0000$861C4.000099242P01000002302-Sep-2003
6606826782814S.0000$8415.000011311P01000002307-Mar-2003
6706826782814S.0000$5815.0000X1700P01000002307-Mar-2003
6806826782814A1.0000$3115.000088305P01000002307-Mar-2003
6906826782814M.0000$201F5.000099211P01000002307-Mar-2003
7006826782814M.0000$861C5.000099242P01000002307-Mar-2003
Episode
CLAIM_IDDATETHRUDX_BEGINTOT_COSTCPT_ORIGSVC_GRPSVC_SET
5611-Nov-2003216.9$423X17001711017110
5711-Nov-2003216.9$423992439924399243
5811-Nov-2003216.9$423992139921399213
5911-Nov-2003216.9$423114401144011440
6011-Nov-2003216.9$423883058830588305
6125-Sep-2003216.9$497114021140211402
6225-Sep-2003216.9$497114021140211402
6325-Sep-2003216.9$497114031140311403
6425-Sep-2003216.9$497883058830588305
6525-Sep-2003216.9$497992429924299242
6625-Apr-2003702.11$279113111131111311
6725-Apr-2003702.11$279X17001711017110
6825-Apr-2003702.11$279883058830588305
6925-Apr-2003702.11$279992119921199211
7025-Apr-2003702.11$279992429924299242
TABLE A2
CLAIM_IDMEM_IDSVC_PVfrom dateSVC_EXP1SVC_EXP2CPTCPT_MODDX_1DX_2PV_TYPE
56855VM1YAM 00CCP01000000906-Oct-2003$66$6617110238.2078.10MD
57855VM1YAM 00CCP01000000906-Oct-2003$130$1309924325238.2078.10MD
58855VM1YAM 00CCP01000000012-Sep-2003$56$5699213216.9244.9MD
59855VM1YAM 00CCP01000003211-Nov-2003$140$14011440238.2MD
60855VM1YAM 00CCP01000000011-Nov-2003$31$318830590216.9IL
56855VM1YAM 00CCP01000000906-Oct-2003$66$6617110238.2078.10MD
57855VM1YAM 00CCP01000000906-Oct-2003$130$1309924325238.2078.10MD
58855VM1YAM 00CCP01000000012-Sep-2003$56$5699213216.9244.9MD
59855VM1YAM 00CCP01000003211-Nov-2003$140$14011440238.2MD
60855VM1YAM 00CCP01000000011-Nov-2003$31$318830590216.9IL
618RO29B9A4 02CCP01000002325-Sep-2003$77$771140251216.9MD
628RO29B9A4 02CCP01000002325-Sep-2003$77$771140251216.9MD
638RO29B9A4 02CCP01000002325-Sep-2003$165$16511403216.9MD
648RO29B9A4 02CCP01000000025-Sep-2003$92$928830590238.2IL
658RO29B9A4 02CCP01000002302-Sep-2003$86$8699242216.9MD
6694PY71739 01CCP01000002321-Mar-2003$84$8411311702.11MD
6794PY71739 01CCP01000002307-Mar-2003$58$5817110702.11MD
6894PY71739 01CCP01000000021-Mar-2003$31$318830590216.3IL
6994PY71739 01CCP01000002325-Apr-2003$20$2099211216.9MD
7094PY71739 01CCP01000002307-Mar-2003$86$869924225702.11MD
CLAIM_IDetgnoepinoREC_TYPERESPFLAGSVC_EXP3quantityvisit_typerunidservicein2PV_IDDATEFROM
5606821067490S.0000$6612.0000X1700P01000000912-Sep-2003
5706821067490M.0000$1301C2.000099243P01000000912-Sep-2003
5806821067490M.0000$561F2.000099213P01000000012-Sep-2003
5906821067490S.0000$14012.000011440P01000003212-Sep-2003
6006821067490A1.0000$3112.000088305P01000003212-Sep-2003
5606821067490S.0000$6612.0000X1700P01000000912-Sep-2003
5706821067490M.0000$1301C2.000099243P01000000912-Sep-2003
5806821067490M.0000$561F2.000099213P01000000012-Sep-2003
5906821067490S.0000$14012.000011440P01000003212-Sep-2003
6006821067490A1.0000$3112.000088305P01000003212-Sep-2003
6106824631697S.0000$7714.000011402P01000002302-Sep-2003
6206824631697S.0000$7714.000011402P01000002302-Sep-2003
6306824631697S.0000$16514.000011403P01000002302-Sep-2003
6406824631697A1.0000$3134.000088305P01000002302-Sep-2003
6506824631697M.0000$861C4.000099242P01000002302-Sep-2003
6606826782814S.0000$8415.000011311P01000002307-Mar-2003
6706826782814S.0000$5815.0000X1700P01000002307-Mar-2003
6806826782814A1.0000$3115.000088305P01000002307-Mar-2003
6906826782814M.0000$201F5.000099211P01000002307-Mar-2003
7006826782814M.0000$861C5.000099242P01000002307-Mar-2003
CLAIM_IDDATETHRUDX_BEGINTOT_COSTCPT_ORIGSVC_GRPSVC_SETTOTAL_ROLE_ID
5611-Nov-2003216.9$423X17001711017110CCP010000009
5711-Nov-2003216.9$423992439924399243CCP010000009
5811-Nov-2003216.9$423992139921399213CCP010000009
5911-Nov-2003216.9$423114401144011440CCP010000009
6011-Nov-2003216.9$423883058830588305CCP010000009
5611-Nov-2003216.9$423X17001711017110CCP010000032
5711-Nov-2003216.9$423992439924399243CCP010000032
5811-Nov-2003216.9$423992139921399213CCP010000032
5911-Nov-2003216.9$423114401144011440CCP010000032
6011-Nov-2003216.9$423883058830588305CCP010000032
6125-Sep-2003216.9$497114021140211402CCP010000023
6225-Sep-2003216.9$497114021140211402CCP010000023
6325-Sep-2003216.9$497114031140311403CCP010000023
6425-Sep-2003216.9$497883058830588305CCP010000023
6525-Sep-2003216.9$497992429924299242CCP010000023
6625-Apr-2003702.11$279113111131111311CCP010000023
6725-Apr-2003702.11$279X17001711017110CCP010000023
6825-Apr-2003702.11$279883058830588305CCP010000023
6925-Apr-2003702.11$279992119921199211CCP010000023
7025-Apr-2003702.11$279992429924299242CCP010000023
TABLE A3
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic keratoses diagnosis 702.xx
etg 0682
etg oftotaletg of interest
interestepisodespercent ofdoctoretg of interestresponsibletotal episode
episodeacross alltotalresponsibledoctor totaldollars perdollars per
Doctortotal role idcountetg'sepisodesdollarsepisode dollarsepisodeepisode
NAME28CCP010000028111368.1%$1,202$1,416$109$129
NAME34CCP0100000341311111.7%$1,534$1,801$118$139
NAME20CCP0100000201610415.4%$2,114$2,759$132$172
NAME33CCP010000033174141.5%$3,461$4,229$204$249
NAME31CCP0100000311811915.1%$2,210$2,714$123$151
NAME8CCP0100000084819424.7%$8,918$11,901$186$248
NAME22CCP0100000225334315.5%$6,029$7,665$114$145
NAME37CCP01000003711446824.4%$13,755$16,936$121$149
NAME1CCP01000000112454822.6%$12,875$15,931$104$128
NAME35CCP01000003516453430.7%$23,619$26,740$144$163
NAME6CCP0100000061961,15916.9%$23,183$28,251$118$144
NAME36CCP0100000362391,27718.7%$26,827$33,072$112$138
NAME2CCP01000000225274533.8%$24,030$25,788$95$102
NAME27CCP0100000272821,49718.8%$42,615$45,645$151$162
NAME7CCP0100000072851,34221.2%$57,853$59,968$203$210
NAME24CCP0100000243571,63821.8%$51,656$55,213$145$155
NAME26CCP0100000264412,64316.7%$52,503$59,788$119$136
NAME4CCP0100000044481,32833.7%$51,131$53,399$114$119
NAME13CCP0100000134782,87816.6%$89,603$99,854$187$209
NAME5CCP0100000055122,72818.8%$72,851$81,939$142$160
NAME30CCP0100000305161,68530.6%$72,469$82,939$140$161
NAME23CCP0100000235412,06326.2%$109,318$112,946$202$209
NAME3CCP0100000035971,18450.4%$55,838$59,244$94$99
NAME32CCP0100000326172,59023.8%$107,442$121,776$174$197
NAME29CCP0100000297112,41629.4%$88,267$99,224$124$140
NAME25CCP0100000257312,34831.1%$120,207$125,768$164$172
NAME19CCP0100000198173,77421.6%$117,096$122,392$143$150
NAME11CCP0100000118432,23737.7%$85,965$94,409$102$112
NAME16CCP0100000168552,31836.9%$124,612$132,612$146$155
NAME18CCP0100000188814,10821.4%$105,119$116,862$119$133
NAME14CCP0100000149392,54037.0%$165,757$173,593$177$185
NAME21CCP0100000211,1622,68943.2%$116,606$124,819$100$107
NAME15CCP0100000151,2803,14140.8%$100,439$110,545$78$86
NAME9CCP0100000091,6924,87034.7%$224,567$255,154$133$151
NAME12CCP0100000121,7384,77636.4%$181,431$190,528$104$110
NAME10CCP0100000101,7955,04535.6%$255,935$264,955$143$148
NAME17CCP0100000172,5755,79644.4%$376,755$387,526$146$150
TABLE A4
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic keratoses diagnosis 702.xx
etg 0682
etg of
interestetg of interestetg of interestresponsibletotal episode
episodedoctor responsibledoctor total episodedollars perdollars percost
Doctortotal role idcountdollarsdollarsepisodeepisoderankquartile
NAME15CCP0100000151,280$100,439$110,545$78$861Q1
NAME3CCP010000003597$55,838$59,244$94$992Q1
NAME2CCP010000002252$24,030$25,788$95$1023Q1
NAME21CCP0100000211,162$116,606$124,819$100$1074Q1
NAME12CCP0100000121,738$181,431$190,528$104$1105Q1
NAME11CCP010000011843$85,965$94,409$102$1126Q1
NAME4CCP010000004448$51,131$53,399$114$1197Q1
NAME1CCP010000001124$12,875$15,931$104$1288Q1
NAME28CCP01000002811$1,202$1,416$109$1299Q1
Q1 Count 9
NAME18CCP010000018881$105,119$116,862$119$13310Q2
NAME26CCP010000026441$52,503$59,788$119$13611Q2
NAME36CCP010000036239$26,827$33,072$112$13812Q2
NAME34CCP01000003413$1,534$1,801$118$13913Q2
NAME29CCP010000029711$88,267$99,224$124$14014Q2
NAME6CCP010000006196$23,183$28,251$118$14415Q2
NAME22CCP01000002253$6,029$7,665$114$14516Q2
NAME10CCP0100000101,795$255,935$264,955$143$14817Q2
NAME37CCP010000037114$13,755$16,936$121$14918Q2
Q2 Count 9
NAME19CCP010000019817$117,096$122,392$143$15019Q3
NAME17CCP0100000172,575$376,755$387,526$146$15020Q3
NAME31CCP01000003118$2,210$2,714$123$15121Q3
NAME9CCP0100000091,692$224,567$255,154$133$15122Q3
NAME24CCP010000024357$51,656$55,213$145$15523Q3
NAME16CCP010000016855$124,612$132,612$146$15524Q3
NAME5CCP010000005512$72,851$81,939$142$16025Q3
NAME30CCP010000030516$72,469$82,939$140$16126Q3
NAME27CCP010000027282$42,615$45,645$151$16227Q3
NAME35CCP010000035164$23,619$26,740$144$16328Q3
Q3 Count 10
NAME25CCP010000025731$120,207$125,768$164$17229Q4
NAME20CCP01000002016$2,114$2,759$132$17230Q4
NAME14CCP010000014939$165,757$173,593$177$18531Q4
NAME32CCP010000032617$107,442$121,776$174$19732Q4
NAME23CCP010000023541$109,318$112,946$202$20933Q4
NAME13CCP010000013478$89,603$99,854$187$20934Q4
NAME7CCP010000007285$57,853$59,968$203$21035Q4
NAME8CCP01000000848$8,918$11,901$186$24836Q4
NAME33CCP01000003317$3,461$4,229$204$24937Q4
22,358Q4 Count 9
Grand Count 37
TABLE A5
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic
keratoses diagnosis 702.xx etg 0682
(5 or more episodes)
quartile
episode
Quartileetg brief namecount
Q1benign_lesions_without_actinic keratoses6,455
Q2benign_lesions_without_actinic keratoses4,443
Q3benign_lesions_without_actinic keratoses7,788
Q4benign_lesions_without_actinic keratoses3,672
Total of quartile, doctor, episode level22,358
TABLE A6
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic keratoses diagnosis 702.xx
etg 0682
begin
quar-diag-episodediagnosis
tilenosiscountexpensemediumlong
Q1214.11$387LIPOMA OTH SKIN/SUBQ TISSUELIPOMA OF OTHER SKIN AND SUBCUTANEOUS TISSUE
Q1214.92$480LIPOMA UNS SITELIPOMA UNSPECIFIED SITE
Q1215.91$76OTH BENIGN NEO CONNEC SOFT TISSOTHER BENIGN NEOPLASM OF CONNECTIVE AND
UNSOTHER SOFT TISSUE SITE
Q1216.017$2,650BENIGN NEO SKIN LIPBENIGN NEOPLASM OF SKIN OF LIP
Q1216.122$3,492BENIGN NEO EYELID INC CANTHUSBENIGN NEOPLASM OF EYELID INCLUDING CANTHUS
Q1216.216$2,131BENIGN NEO EAR SKINBENIGN NEOPLASM OF EAR AND EXTERNAL
AUDITORY CANAL
Q1216.3260$35,232BENIGN NEO SKIN OTH/UNS PARTSBENIGN NEOPLASM OF SKIN OF OTHER AND
FACEUNSPECIFIED PARTS OF FACE
Q1216.4177$21,392BENIGN NEO SCALP/SKIN NECKBENIGN NEOPLASM OF SCALP AND SKIN OF NECK
Q1216.5565$78,097BENIGN NEO SKIN TRUNK EX SCROTUMBENIGN NEOPLASM OF SKIN OF
TRUNK EXCEPT SCROTUM
Q1216.6164$23,016BEN NEO SKIN UPPER LIMBBENIGN NEOPLASM OF SKIN OF UPPER LIMB
INCLUDING SHOULDER
Q1216.7172$22,699BENIGN NEO SKIN LOWER LIMB INC HIPBENIGN NEOPLASM OF SKIN OF LOWER
LIMB INCLUDING HIP
Q1216.816$2,917BENIGN NEO OTHER SITES SKINBENIGN NEOPLASM OF OTHER SPECIFIED
SITES OF SKIN
Q1216.9652$69,688BENIGN NEO SKIN SITE UNSBENIGN NEOPLASM OF SKIN SITE UNSPECIFIED
Q1228.016$884HEMANGIOMA SKIN/SUBQ TISSUEHEMANGIOMA OF SKIN AND SUBCUTANEOUS TISSUE
Q1228.11$130LYMPHANGIOMA ANY SITELYMPHANGIOMA ANY SITE
Q1238.24,334$406,694UNCERT BEHAVIOR NEO SKINNEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
Q1239.21$56BONE/SKIN UNSP BEHAVIOR NEONEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT
TISSUE AND SKIN
Q1448.134$6,058NEVUS NON-NEOPLASTICNEVUS NON-NEOPLASTIC
Q2214.02$265LIPOMA SKIN/SUBQ TISSUE FACELIPOMA OF SKIN AND SUBCUTANEOUS
TISSUE OF FACE
Q2214.17$1,148LIPOMA OTH SKIN/SUBQ TISSUELIPOMA OF OTHER SKIN AND SUBCUTANEOUS TISSUE
Q2215.83$292OTH BEN NEO CONNEC SOFT TISSUE OTOTHER BENIGN NEOPLASM OF CONNECTIVE AND
OTHER SOFT TISSUE OF OTHER SPECIFIED SITES
Q2215.91$112OTH BENIGN NEO CONNEC SOFTOTHER BENIGN NEOPLASM OF CONNECTIVE AND
TISS UNSOTHER SOFT TISSUE SITE UNSPECIFIED
Q2216.014$1,862BENIGN NEO SKIN LIPBENIGN NEOPLASM OF SKIN OF LIP
Q2216.19$1,653BENIGN NEO EYELID INC CANTHUSBENIGN NEOPLASM OF EYELID INCLUDING CANTHUS
Q2216.24$465BENIGN NEO EAR SKINBENIGN NEOPLASM OF EAR AND EXTERNAL
AUDITORY CANAL
Q2216.3179$26,569BENIGN NEO SKIN OTH/UNS PARTSBENIGN NEOPLASM OF SKIN OF OTHER AND
FACEUNSPECIFIED PARTS OF FACE
Q2216.4123$18,970BENIGN NEO SCALP/SKIN NECKBENIGN NEOPLASM OF SCALP AND SKIN OF NECK
Q2216.5284$44,678BENIGN NEO SKIN TRUNK EX SCROTUMBENIGN NEOPLASM OF SKIN OF TRUNK
EXCEPT SCROTUM
Q2216.6107$15,845BEN NEO SKIN UPPER LIMBBENIGN NEOPLASM OF SKIN OF UPPER LIMB
INCLUDING SHOULDER
Q2216.7103$14,578BENIGN NEO SKIN LOWER LIMB INC HIPBENIGN NEOPLASM OF SKIN OF LOWER LIMB
INCLUDING HIP
Q2216.856$7,571BENIGN NEO OTHER SITES SKINBENIGN NEOPLASM OF OTHER SPECIFIED
SITES OF SKIN
Q2216.9816$115,075BENIGN NEO SKIN SITE UNSBENIGN NEOPLASM OF SKIN SITE UNSPECIFIED
Q2228.0137$4,636HEMANGIOMA SKIN/SUBQ TISSUEHEMANGIOMA OF SKIN AND SUBCUTANEOUS TISSUE
Q2228.11$171LYMPHANGIOMA ANY SITELYMPHANGIOMA ANY SITE
Q2238.22,606$360,120UNCERT BEHAVIOR NEO SKINNEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
Q2239.23$837BONE/SKIN UNSP BEHAVIOR NEONEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT
TISSUE AND SKIN
Q2448.172$13,707NEVUS NON-NEOPLASTICNEVUS NON-NEOPLASTIC
Q3210.03$486BENIGN NEO LIPBENIGN NEOPLASM OF LIP
Q3214.05$1,124LIPOMA SKIN/SUBQ TISSUE FACELIPOMA OF SKIN AND SUBCUTANEOUS
TISSUE OF FACE
Q3214.113$2,875LIPOMA OTH SKIN/SUBQ TISSUELIPOMA OF OTHER SKIN AND SUBCUTANEOUS TISSUE
Q3214.82$320LIPOMA OTHER SITESLIPOMA OF OTHER SPECIFIED SITES
Q3214.99$1,618LIPOMA UNS SITELIPOMA UNSPECIFIED SITE
Q3215.81$71OTH BEN NEO CONNEC SOFT TISSUE OTOTHER BENIGN NEOPLASM OF CONNECTIVE AND
OTHER SOFT TISSUE OF OTHER SPECIFIED SITES
Q3215.92$180OTH BENIGN NEO CONNEC SOFT TISSOTHER BENIGN NEOPLASM OF CONNECTIVE AND
UNSOTHER SOFT TISSUE SITE
Q3216.1$372BENIGN NEOPLASM OF SKINBENIGN NEOPLASM OF SKIN
Q3216.09$1,376BENIGN NEO SKIN LIPBENIGN NEOPLASM OF SKIN OF LIP
Q3216.116$3,892BENIGN NEO EYELID INC CANTHUSBENIGN NEOPLASM OF EYELID INCLUDING CANTHUS
Q3216.213$2,583BENIGN NEO EAR SKINBENIGN NEOPLASM OF EAR AND EXTERNAL
AUDITORY CANAL
Q3216.3325$50,703BENIGN NEO SKIN OTH/UNS PARTSBENIGN NEOPLASM OF SKIN OF OTHER AND
FACEUNSPECIFIED PARTS OF FACE
Q3216.4111$22,575BENIGN NEO SCALP/SKIN NECKBENIGN NEOPLASM OF SCALP AND SKIN OF NECK
Q3216.5438$74,330BENIGN NEO SKIN TRUNK EX SCROTUMBENIGN NEOPLASM OF SKIN OF TRUNK
EXCEPT SCROTUM
Q3216.673$13,441BEN NEO SKIN UPPER LIMBBENIGN NEOPLASM OF SKIN OF UPPER LIMB
INCLUDING SHOULDER
Q3216.799$18,208BENIGN NEO SKIN LOWER LIMB INC HIPBENIGN NEOPLASM OF SKIN OF LOWER
LIMB INCLUDING HIP
Q3216.828$4,922BENIGN NEO OTHER SITES SKINBENIGN NEOPLASM OF OTHER SPECIFIED
SITES OF SKIN
Q3216.91,473$218,510BENIGN NEO SKIN SITE UNSBENIGN NEOPLASM OF SKIN SITE UNSPECIFIED
Q3228.0196$17,043HEMANGIOMA SKIN/SUBQ TISSUEHEMANGIOMA OF SKIN AND SUBCUTANEOUS TISSUE
Q3228.11$260LYMPHANGIOMA ANY SITELYMPHANGIOMA ANY SITE
Q3238.24,980$741,410UNCERT BEHAVIOR NEO SKINNEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
Q3239.24$783BONE/SKIN UNSP BEHAVIOR NEONEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT
TISSUE AND SKIN
Q3448.180$15,792NEVUS NON-NEOPLASTICNEVUS NON-NEOPLASTIC
Q4210.01$129BENIGN NEO LIPBENIGN NEOPLASM OF LIP
Q4214.02$295LIPOMA SKIN/SUBQ TISSUE FACELIPOMA OF SKIN AND SUBCUTANEOUS
TISSUE OF FACE
Q4214.13$620LIPOMA OTH SKIN/SUBQ TISSUELIPOMA OF OTHER SKIN AND SUBCUTANEOUS TISSUE
Q4214.92$473LIPOMA UNS SITELIPOMA UNSPECIFIED SITE
Q4215.88$1,739OTH BEN NEO CONNEC SOFT TISSUE OTOTHER BENIGN NEOPLASM OF CONNECTIVE AND
OTHER SOFT TISSUE OF OTHER SPECIFIED SITES
Q4215.97$1,477OTH BENIGN NEO CONNEC SOFT TISSOTHER BENIGN NEOPLASM OF CONNECTIVE AND
UNSOTHER SOFT TISSUE SITE
Q4216.06$1,310BENIGN NEO SKIN LIPBENIGN NEOPLASM OF SKIN OF LIP
Q4216.110$2,452BENIGN NEO EYELID INC CANTHUSBENIGN NEOPLASM OF EYELID INCLUDING CANTHUS
Q4216.210$1,757BENIGN NEO EAR SKINBENIGN NEOPLASM OF EAR AND EXTERNAL
AUDITORY CANAL
Q4216.3106$25,030BENIGN NEO SKIN OTH/UNS PARTSBENIGN NEOPLASM OF SKIN OF OTHER AND
FACEUNSPECIFIED PARTS OF FACE
Q4216.460$13,613BENIGN NEO SCALP/SKIN NECKBENIGN NEOPLASM OF SCALP AND SKIN OF NECK
Q4216.5382$74,703BENIGN NEO SKIN TRUNK EX SCROTUMBENIGN NEOPLASM OF SKIN OF TRUNK
EXCEPT SCROTUM
Q4216.658$10,812BEN NEO SKIN UPPER LIMBBENIGN NEOPLASM OF SKIN OF UPPER LIMB
INCLUDING SHOULDER
Q4216.759$11,764BENIGN NEO SKIN LOWER LIMB INC HIPBENIGN NEOPLASM OF SKIN OF LOWER LIMB
INCLUDING HIP
Q4216.882$17,728BENIGN NEO OTHER SITES SKINBENIGN NEOPLASM OF OTHER SPECIFIED
SITES OF SKIN
Q4216.91,246$244,793BENIGN NEO SKIN SITE UNSBENIGN NEOPLASM OF SKIN SITE UNSPECIFIED
Q4228.0189$15,747HEMANGIOMA SKIN/SUBQ TISSUEHEMANGIOMA OF SKIN AND SUBCUTANEOUS TISSUE
Q4228.13$977LYMPHANGIOMA ANY SITELYMPHANGIOMA ANY SITE
Q4238.21,403$259,521UNCERT BEHAVIOR NEO SKINNEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
Q4239.23$554BONE/SKIN UNSP BEHAVIOR NEONEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT
TISSUE AND SKIN
Q4448.1128$27,300NEVUS NON-NEOPLASTICNEVUS NON-NEOPLASTIC
TABLE A7
specialtytotal roletotal role
total rolespecialtyspecialtystrataexpectedexpected
episodetotal roletotal rolespecialtyspecialtysumexpenseservices
serviceoccurred inaverageaveragetotal roletotal roleepisodeperper
PAIRED_ETGNOgroupcountexpenseservicesexpenseservicescountepisodeepisode
benign_lesions_without_actinic keratoses003002$290.001$580222,358$0.0259.00008945
benign_lesions_without_actinic keratoses004001$225.001$225122,358$0.0101.00004473
benign_lesions_without_actinic keratoses008201$315.001$315122,358$0.0141.00004473
benign_lesions_without_actinic keratoses03011$39.001$39122,358$0.0017.00004473
benign_lesions_without_actinic keratoses03201$34.001$34122,358$0.0015.00004473
benign_lesions_without_actinic keratoses04901$336.006$336622,358$0.0150.00026836
benign_lesions_without_actinic keratoses05511$425.005$425522,358$0.0190.00022363
benign_lesions_without_actinic keratoses09691$8.002$8222,358$0.0004.00008945
benign_lesions_without_actinic keratoses100221$100.001$100122,358$0.0045.00004473
benign_lesions_without_actinic keratoses110001$53.001$53122,358$0.0024.00004473
benign_lesions_without_actinic keratoses110422$84.501$169222,358$0.0076.00008945
benign_lesions_without_actinic keratoses111001,699$89.421$151,9311,77022,358$6.7954.07916629
benign_lesions_without_actinic keratoses11101423$61.892$26,18163622,358$1.1710.02844619
benign_lesions_without_actinic keratoses112003$50.001$150322,358$0.0067.00013418
benign_lesions_without_actinic keratoses112011$140.004$140422,358$0.0063.00017891
benign_lesions_without_actinic keratoses113001,068$67.392$71,9691,63622,358$3.2189.07317291
benign_lesions_without_actinic keratoses113011,858$90.661$168,4382,72422,358$7.5337.12183558
benign_lesions_without_actinic keratoses11302475$96.641$45,90456922,358$2.0531.02544950
benign_lesions_without_actinic keratoses1130327$118.741$3,2063222,358$0.1434.00143126
benign_lesions_without_actinic keratoses11305471$64.232$30,25076322,358$1.3530.03412649
benign_lesions_without_actinic keratoses11306513$102.812$52,74183222,358$2.3589.03721263
benign_lesions_without_actinic keratoses1130794$95.781$9,0039922,358$0.4027.00442795
benign_lesions_without_actinic keratoses1130811$102.911$1,1321122,358$0.0506.00049199
benign_lesions_without_actinic keratoses11310548$78.141$42,82272422,358$1.9153.03238215
benign_lesions_without_actinic keratoses11311561$106.091$59,51975822,358$2.6621.03390285
benign_lesions_without_actinic keratoses11312106$109.691$11,62711822,358$0.5200.00527775
benign_lesions_without_actinic keratoses113133$140.001$420322,358$0.0188.00013418
benign_lesions_without_actinic keratoses11400428$111.471$47,71051222,358$2.1339.02290008
benign_lesions_without_actinic keratoses11401745$137.401$102,36296622,358$4.5783.04320601
benign_lesions_without_actinic keratoses11402466$156.191$72,78653122,358$3.2555.02374989
benign_lesions_without_actinic keratoses11403106$183.321$19,43211922,358$0.8691.00532248
benign_lesions_without_actinic keratoses1140431$215.261$6,6733422,358$0.2985.00152071
benign_lesions_without_actinic keratoses1140612$252.921$3,0351322,358$0.1357.00058145
benign_lesions_without_actinic keratoses1142088$111.851$9,84311022,358$0.4402.00491994
benign_lesions_without_actinic keratoses11421111$131.811$14,63112222,358$0.6544.00545666
benign_lesions_without_actinic keratoses1142257$157.561$8,9816322,358$0.4017.00281778
benign_lesions_without_actinic keratoses1142321$192.191$4,0362322,358$0.1805.00102871
benign_lesions_without_actinic keratoses114246$222.171$1,333622,358$0.0596.00026836
benign_lesions_without_actinic keratoses114262$261.501$523222,358$0.0234.00008945
benign_lesions_without_actinic keratoses11440216$148.581$32,09327322,358$1.4354.01221039
benign_lesions_without_actinic keratoses11441136$165.091$22,45215222,358$1.0042.00679846
benign_lesions_without_actinic keratoses1144255$178.071$9,7945722,358$0.4381.00254942
benign_lesions_without_actinic keratoses1144313$242.381$3,1511522,358$0.1409.00067090
benign_lesions_without_actinic keratoses114442$293.501$587222,358$0.0263.00008945
benign_lesions_without_actinic keratoses114461$371.001$371122,358$0.0166.00004473
benign_lesions_without_actinic keratoses116001$160.001$160122,358$0.0072.00004473
benign_lesions_without_actinic keratoses116023$162.671$488322,358$0.0218.00013418
benign_lesions_without_actinic keratoses116032$162.001$324222,358$0.0145.00008945
benign_lesions_without_actinic keratoses116041$244.001$244122,358$0.0109.00004473
benign_lesions_without_actinic keratoses117552$59.501$119222,358$0.0053.00008945
benign_lesions_without_actinic keratoses1190021$51.761$1,0872322,358$0.0486.00102871
benign_lesions_without_actinic keratoses1190111$54.361$5981122,358$0.0267.00049199
benign_lesions_without_actinic keratoses12031104$189.341$19,69111622,358$0.8807.00518830
benign_lesions_without_actinic keratoses1203295$227.111$21,5759922,358$0.9650.00442795
benign_lesions_without_actinic keratoses1205112$219.081$2,6291222,358$0.1176.00053672
benign_lesions_without_actinic keratoses131018$319.251$2,554822,358$0.1142.00035781
benign_lesions_without_actinic keratoses131312$315.001$630222,358$0.0282.00008945
benign_lesions_without_actinic keratoses170004,018$68.661$275,8884,42422,358$12.3396.19787101
benign_lesions_without_actinic keratoses170032,635$11.033$29,0697,26822,358$1.3002.32507380
benign_lesions_without_actinic keratoses1700433$62.361$2,0583422,358$0.0920.00152071
benign_lesions_without_actinic keratoses1710614$367.431$5,1441422,358$0.2301.00062617
benign_lesions_without_actinic keratoses171102,499$59.611$148,9532,65722,358$6.6622.11883889
benign_lesions_without_actinic keratoses1711120$39.401$7882022,358$0.0352.00089453
benign_lesions_without_actinic keratoses172811$144.001$144122,358$0.0064.00004473
benign_lesions_without_actinic keratoses273271$539.001$539122,358$0.0241.00004473
benign_lesions_without_actinic keratoses301002$94.501$189222,358$0.0085.00008945
benign_lesions_without_actinic keratoses364151$6.001$6122,358$0.0003.00004473
benign_lesions_without_actinic keratoses4049021$123.141$2,5862322,358$0.1157.00102871
benign_lesions_without_actinic keratoses540504$159.751$639522,358$0.0286.00022363
benign_lesions_without_actinic keratoses540567$160.141$1,121722,358$0.0501.00031309
benign_lesions_without_actinic keratoses540601$278.001$278122,358$0.0124.00004473
benign_lesions_without_actinic keratoses541002$194.001$388222,358$0.0174.00008945
benign_lesions_without_actinic keratoses566058$90.001$720822,358$0.0322.00035781
benign_lesions_without_actinic keratoses6781025$190.441$4,7612822,358$0.2129.00125235
benign_lesions_without_actinic keratoses6910014$83.141$1,1641422,358$0.0521.00062617
benign_lesions_without_actinic keratoses769422$98.501$197222,358$0.0088.00008945
benign_lesions_without_actinic keratoses800024$5.001$20422,358$0.0009.00017891
benign_lesions_without_actinic keratoses800032$5.001$10222,358$0.0004.00008945
benign_lesions_without_actinic keratoses800041$5.001$5122,358$0.0002.00004473
benign_lesions_without_actinic keratoses800052$5.001$10222,358$0.0004.00008945
benign_lesions_without_actinic keratoses800121$6.001$6122,358$0.0003.00004473
benign_lesions_without_actinic keratoses8004878$3.291$2578122,358$0.0115.00362286
benign_lesions_without_actinic keratoses8005027$14.001$3782722,358$0.0169.00120762
benign_lesions_without_actinic keratoses800512$4.001$8222,358$0.0004.00008945
benign_lesions_without_actinic keratoses80053119$5.131$61012222,358$0.0273.00545666
benign_lesions_without_actinic keratoses8006191$8.091$7369222,358$0.0329.00411486
benign_lesions_without_actinic keratoses802993$13.331$40422,358$0.0018.00017891
benign_lesions_without_actinic keratoses810008$5.381$43822,358$0.0019.00035781
benign_lesions_without_actinic keratoses820404$5.751$23422,358$0.0010.00017891
benign_lesions_without_actinic keratoses8224820$2.151$432022,358$0.0019.00089453
benign_lesions_without_actinic keratoses8227039$3.441$1344122,358$0.0060.00183380
benign_lesions_without_actinic keratoses823102$4.001$8222,358$0.0004.00008945
benign_lesions_without_actinic keratoses8256512$4.751$571322,358$0.0025.00058145
benign_lesions_without_actinic keratoses8294727$2.261$612722,358$0.0027.00120762
benign_lesions_without_actinic keratoses840752$4.001$8222,358$0.0004.00008945
benign_lesions_without_actinic keratoses841001$8.001$8122,358$0.0004.00004473
benign_lesions_without_actinic keratoses841552$3.001$6222,358$0.0003.00008945
benign_lesions_without_actinic keratoses844362$4.001$8222,358$0.0004.00008945
benign_lesions_without_actinic keratoses8443911$8.001$881122,358$0.0039.00049199
benign_lesions_without_actinic keratoses8444348$7.001$3364822,358$0.0150.00214688
benign_lesions_without_actinic keratoses8445023$3.481$802422,358$0.0036.00107344
benign_lesions_without_actinic keratoses8446057$4.541$2596322,358$0.0116.00281778
benign_lesions_without_actinic keratoses844786$4.001$24822,358$0.0011.00035781
benign_lesions_without_actinic keratoses845201$3.001$3122,358$0.0001.00004473
benign_lesions_without_actinic keratoses850133$5.001$15322,358$0.0007.00013418
benign_lesions_without_actinic keratoses8501411$2.181$241222,358$0.0011.00053672
benign_lesions_without_actinic keratoses850181$6.001$6122,358$0.0003.00004473
benign_lesions_without_actinic keratoses85025109$3.571$38912722,358$0.0174.00568029
benign_lesions_without_actinic keratoses8502774$2.271$1687622,358$0.0075.00339923
benign_lesions_without_actinic keratoses850441$6.002$6222,358$0.0003.00008945
benign_lesions_without_actinic keratoses850451$4.002$4222,358$0.0002.00008945
benign_lesions_without_actinic keratoses850491$2.001$2122,358$0.0001.00004473
benign_lesions_without_actinic keratoses8561018$4.832$872922,358$0.0039.00129707
benign_lesions_without_actinic keratoses856515$2.001$10522,358$0.0004.00022363
benign_lesions_without_actinic keratoses856524$2.001$8422,358$0.0004.00017891
benign_lesions_without_actinic keratoses857306$3.001$18622,358$0.0008.00026836
benign_lesions_without_actinic keratoses861405$3.001$15522,358$0.0007.00022363
benign_lesions_without_actinic keratoses861412$10.001$20222,358$0.0009.00008945
benign_lesions_without_actinic keratoses865802$7.501$15222,358$0.0007.00008945
benign_lesions_without_actinic keratoses866183$12.001$36322,358$0.0016.00013418
benign_lesions_without_actinic keratoses866443$18.671$56422,358$0.0025.00017891
benign_lesions_without_actinic keratoses866451$28.002$28222,358$0.0013.00008945
benign_lesions_without_actinic keratoses867771$8.001$8122,358$0.0004.00004473
benign_lesions_without_actinic keratoses868502$19.501$39222,358$0.0017.00008945
benign_lesions_without_actinic keratoses869002$2.001$4222,358$0.0002.00008945
benign_lesions_without_actinic keratoses869012$2.001$4222,358$0.0002.00008945
benign_lesions_without_actinic keratoses871016$8.001$48622,358$0.0021.00026836
benign_lesions_without_actinic keratoses871064$4.001$16422,358$0.0007.00017891
benign_lesions_without_actinic keratoses873401$7.001$7122,358$0.0003.00004473
benign_lesions_without_actinic keratoses873901$8.001$8122,358$0.0004.00004473
benign_lesions_without_actinic keratoses881061$21.001$21122,358$0.0009.00004473
benign_lesions_without_actinic keratoses881732$39.502$79322,358$0.0035.00013418
benign_lesions_without_actinic keratoses8830477$16.251$1,2518322,358$0.0560.00371232
benign_lesions_without_actinic keratoses883056,637$50.112$332,60210,75622,358$14.8762.48108060
benign_lesions_without_actinic keratoses883072$68.001$136222,358$0.0061.00008945
benign_lesions_without_actinic keratoses8831235$28.372$9936222,358$0.0444.00277306
benign_lesions_without_actinic keratoses8832113$91.541$1,1901422,358$0.0532.00062617
benign_lesions_without_actinic keratoses8834216$296.632$4,7463222,358$0.2123.00143126
benign_lesions_without_actinic keratoses920021$76.001$76122,358$0.0034.00004473
benign_lesions_without_actinic keratoses920121$68.001$68122,358$0.0030.00004473
benign_lesions_without_actinic keratoses9300017$30.821$5241722,358$0.0234.00076035
benign_lesions_without_actinic keratoses930055$51.601$258522,358$0.0115.00022363
benign_lesions_without_actinic keratoses930105$27.201$136522,358$0.0061.00022363
benign_lesions_without_actinic keratoses939711$154.001$154122,358$0.0069.00004473
benign_lesions_without_actinic keratoses940101$124.001$124122,358$0.0055.00004473
benign_lesions_without_actinic keratoses942401$125.001$125122,358$0.0056.00004473
benign_lesions_without_actinic keratoses947202$82.501$165222,358$0.0074.00008945
benign_lesions_without_actinic keratoses958101$295.001$295122,358$0.0132.00004473
benign_lesions_without_actinic keratoses958161$159.001$159122,358$0.0071.00004473
benign_lesions_without_actinic keratoses958191$116.001$116122,358$0.0052.00004473
benign_lesions_without_actinic keratoses969101$59.001$59122,358$0.0026.00004473
benign_lesions_without_actinic keratoses992011$38.001$38122,358$0.0017.00004473
benign_lesions_without_actinic keratoses9920293$70.821$6,5869922,358$0.2946.00442795
benign_lesions_without_actinic keratoses99203156$108.701$16,95716022,358$0.7584.00715628
benign_lesions_without_actinic keratoses9920411$143.911$1,5831122,358$0.0708.00049199
benign_lesions_without_actinic keratoses992051$164.001$164122,358$0.0073.00004473
benign_lesions_without_actinic keratoses9921111$24.361$2681122,358$0.0120.00049199
benign_lesions_without_actinic keratoses992121,230$41.791$51,4021,31122,358$2.2990.05863673
benign_lesions_without_actinic keratoses992136,470$58.101$375,8866,81422,358$16.8121.30476787
benign_lesions_without_actinic keratoses99214116$91.591$10,62411722,358$0.4752.00523303
benign_lesions_without_actinic keratoses992154$162.501$650522,358$0.0291.00022363
benign_lesions_without_actinic keratoses992331$86.001$86122,358$0.0038.00004473
benign_lesions_without_actinic keratoses99241105$53.001$5,56510522,358$0.2489.00469631
benign_lesions_without_actinic keratoses992422,122$99.171$210,4412,16622,358$9.4123.09687807
benign_lesions_without_actinic keratoses992434,196$131.131$550,2254,26422,358$24.6098.19071473
benign_lesions_without_actinic keratoses9924415$184.331$2,7651522,358$0.1237.00067090
benign_lesions_without_actinic keratoses992452$237.001$474222,358$0.0212.00008945
benign_lesions_without_actinic keratoses992521$79.001$79122,358$0.0035.00004473
benign_lesions_without_actinic keratoses992532$107.501$215222,358$0.0096.00008945
benign_lesions_without_actinic keratoses992541$154.001$154122,358$0.0069.00004473
benign_lesions_without_actinic keratoses993121$65.001$65122,358$0.0029.00004473
benign_lesions_without_actinic keratoses993855$56.001$280522,358$0.0125.00022363
benign_lesions_without_actinic keratoses993862$56.001$112222,358$0.0050.00008945
benign_lesions_without_actinic keratoses993911$56.001$56122,358$0.0025.00004473
benign_lesions_without_actinic keratoses993943$56.001$168322,358$0.0075.00013418
benign_lesions_without_actinic keratoses9939518$56.001$1,0081822,358$0.0451.00080508
benign_lesions_without_actinic keratoses9939650$56.001$2,8005022,358$0.1252.00223634
benign_lesions_without_actinic keratoses996011$95.001$95122,358$0.0042.00004473
benign_lesions_without_actinic keratosesA04251$60.0010$601022,358$0.0027.00044727
benign_lesions_without_actinic keratosesA04291$325.001$325122,358$0.0145.00004473
benign_lesions_without_actinic keratosesA45501$49.001$49122,358$0.0022.00004473
benign_lesions_without_actinic keratosesA46463$73.001$219322,358$0.0098.00013418
benign_lesions_without_actinic keratosesA46491$73.001$73122,358$0.0033.00004473
benign_lesions_without_actinic keratosesAS6$226.171$1,357622,358$0.0607.00026836
benign_lesions_without_actinic keratosesCL1$163.002$163222,358$0.0073.00008945
benign_lesions_without_actinic keratosesER4$123.001$492422,358$0.0220.00017891
benign_lesions_without_actinic keratosesH0A2$48.0028$965522,358$0.0043.00245997
benign_lesions_without_actinic keratosesH3A799$20.8216$16,63512,96322,358$0.7440.57979247
benign_lesions_without_actinic keratosesH6J8$25.1315$20111722,358$0.0090.00523303
benign_lesions_without_actinic keratosesJ22501$28.001$28122,358$0.0013.00004473
benign_lesions_without_actinic keratosesJ30101$1.001$1122,358$0.0000.00004473
benign_lesions_without_actinic keratosesJ330115$13.531$2032122,358$0.0091.00093926
benign_lesions_without_actinic keratosesJ705010$4.501$451122,358$0.0020.00049199
benign_lesions_without_actinic keratosesJ9A8$6.5021$5216822,358$0.0023.00751409
benign_lesions_without_actinic keratosesL1A1$161.003$161322,358$0.0072.00013418
benign_lesions_without_actinic keratosesL1B3$336.3330$1,0099022,358$0.0451.00402540
benign_lesions_without_actinic keratosesL9B133$62.8626$8,3613,44022,358$0.3740.15385992
benign_lesions_without_actinic keratosesQ5N98$125.3427$12,2832,66622,358$0.5494.11924143
benign_lesions_without_actinic keratosesS063011$41.271$4541122,358$0.0203.00049199
benign_lesions_without_actinic keratosesS2B91$56.5343$5,1443,90522,358$0.2301.17465784
benign_lesions_without_actinic keratosesZ2A7$32.5716$22811422,358$0.0102.00509885
benign_lesions_without_actinic keratosesZ2G70$201.2629$14,0882,03622,358$0.6301.09106360
TABLE A8
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic keratoses diagnosis 702.xx
etg 0682
TotalYourOther
quartilecategoryservicesservice descriptionSvcsSvcsSvcs
Q1A00300ANESTHESIA, HEAD, NECK, POST TRUNK INTEGUMENTARY, MUSCLE220
NERVES
Q1A94720CARBON MONOXIDE DIFFUSING CAPACITY220
Q1A94240FUNCTIONAL RESIDUAL CAPACITY/VOLUME: HELIUM/NITROGEN OPEN110
CIRCUIT/OTHER
Q1A94010SPIROMETRY W/GRAPHIC RECORD/VITAL CAPACITY/FLOW RATE W/WO110
MAXIMAL VOLUN
Q1AA4646202
Q1A99601HOME INFUSION/SPECIALTY DRUG ADMINISTRATION, PER VISIT (TO 2 HRS);110
.......
.......
.......
Q1A88321CONSULTATION & REPORT, REFERRED SLIDES PREPARED ELSEWHERE101
Q1A88342IMMUNOCYTOCHEMISTRY (W/TISSUE IMMUNOPEROXIDASE), EACH 330
ANTIBODY
Q1A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,0081,723285
A Total2,3561,776580
Q1M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; EXPAND PROB2,3562,184172
Q1M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED 453114
EXAM;
Q1M99205OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS:COMPREHENSIVE 101
HX;COMPREHENSIV
.......
.......
.......
Q1M99241OFFICE CONSULTATION, 3 KEY COMPONENTS: PROB FOCUS HX; PROB 110
FOCUS EXAM;
Q1M99202OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; 202
EXPAND
Q1M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX; 1037
DETAILED EXAM;
Q1M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;25322924
PROB FOCUS EX
Q1M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB34132714
FOCUS HX;EXPAND PROB
Q1M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX;53651026
DETAILED EXAM; MED
M Total3,5683,288280
Q1PL9BVITAMIN A DERIVATIVES1,9001,736164
Q1PH3AANALGESICS, NARCOTICS4,4327953,637
.......
.......
.......
Q1PJ9AINTESTINAL MOTILITY STIMULANTS32032
Q1PH0ALOCAL ANESTHETICS25025
Q1PS2BNSAIDS, CYCLOOXYGENASE INHIBITOR—TYPE875200675
P Total8,9194,1714,748
Q1R76942US GUIDANCE, NEEDLE PLACEMENT, RADIOLOGICAL S&I101
R Total101
Q1S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/1,3431,32023
CUTANEOUS VASC P
Q1S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<52450915
Q1S17004DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/13130
CUTANEOUS VASC P
Q1S54060DESTRUCTION, PENILE LESION, SIMPLE; SURGICAL EXCISION110
.......
.......
.......
Q1S11442EXCISE, BENIGN SKIN LESION, INCL MARGINS, 312
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q1S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/550
HANDS/FEET/GE
Q1S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, 94895
TRUNK/ARMS/L
Q1S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION95869
Q1S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION46544817
Q1S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS 1241186
MEMBRANE; DIAME
Q1S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, 541
TRUNK/ARMS/L
Q1S12031LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES;541
2.5 CM/<
Q1S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, 1165
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q1S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, 13103
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q1S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM58557312
Q1S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM50500
Q1S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, 67634
TRUNK/ARMS/L
Q1S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 50473
0.6-1.0
Q1S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS 64613
MEMBRANE; DIAME
Q1S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, 98935
TRUNK/ARMS/L
S Total6,6166,446170
Q1 Total21,46015,6815,779
Q2A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,8232,414409
Q2A88342IMMUNOCYTOCHEMISTRY (W/TISSUE IMMUNOPEROXIDASE), EACH 1055
ANTIBODY
Q2A00820ANESTHESIA, PROC, LOWER POSTERIOR ABDOMINAL WALL101
.......
.......
.......
Q2A80053COMPREHENSIVE METABOLIC PANEL22022
Q2A84460TRANSFERASE; ALANINE AMINO (ALT) (SGPT)10010
Q2A84443THYROID STIMULATING HORMONE (TSH)505
Q2A80050GENERAL HEALTH PANEL202
A Total3,0292,449580
Q2M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS44541728
HX; EXPAND PROB
Q2M99204OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: COMPREHENSIVE HX; 404
COMPREHENSIVE E
Q2M99245OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;101
COMPREHENSIVE E
.......
.......
.......
Q2M99241OFFICE CONSULTATION, 3 KEY COMPONENTS: PROB FOCUS HX; PROB FOCUS EXAM321
Q2M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX;13211
DETAILED EXAM;
Q2M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; 18315033
PROB FOCUS EX
Q2M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX;77975623
DETAILED EXAM; MED
Q2M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; 999776223
EXPAND PROB
M Total2,4852,114371
Q2PS2BNSAIDS, CYCLOOXYGENASE INHIBITOR—TYPE899132767
Q2PZ2GIMMUNOMODULATORS44338558
.......
.......
.......
Q2PJ7050Infusion, normal saline solution, 250 cc110
Q2PZ2AANTIHISTAMINES862
Q2PL9BVITAMIN A DERIVATIVES34126774
P Total4,9101,9922,918
Q2S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION58056713
Q2S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM2362342
Q2S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION3073025
Q2S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM67165417
Q2S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; 28527411
DIAMETER 0.5 CM/<
Q2S11312SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/51510
MUCOUS MEMBRANE; DIAME
Q2S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<37435717
Q2S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/1671652
MUCOUS MEMBRANE; DIAME
Q2S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN97961
TAG, TRUNK/ARMS/L
Q2S11603EXCISION, MALIGNANT LESION, INCL MARGINS, TRUNK/ARMS/LEGS;220
EXCISED DIAM
Q2S11307SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; 23230
DIAMETER 1.1-2.0
.......
.......
.......
Q2S40490BX, LIP440
Q2S11900INJECTION, INTRALESIONAL; UP TO & INCL 7 LESIONS220
Q2S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/1401355
MUCOUS MEMBRANE; DIAME
Q2S17004DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/110
CUTANEOUS VASC P
Q2S11420EXCISE BENIGN SKIN LESION W/MARG, EXCPT SKIN TAG SCALP/NECK15150
HANDS/FEET/
.......
.......
.......
Q2S11442EXCISE, BENIGN SKIN LESION, INCL MARGINS, 321
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q2S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;1441395
DIAMETER 0.6-1.0
Q2S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/880
HANDS/FEET/GE
Q2S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/35332
NOSE/LIPS/M
Q2S12032LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES; 2.6-752
7.5 CM
Q2S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L550
Q2S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M972
Q2S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L1451369
Q2S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L72693
Q2S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/75872236
CUTANEOUS VASC P
S Total4,8324,668164
Q2 Total15,25611,2234,033
Q3A0551SKILLED NURSING—PER VISIT550
Q3A88321CONSULTATION & REPORT, REFERRED SLIDES PREPARED ELSEWHERE871
Q3A88342IMMUNOCYTOCHEMISTRY (W/TISSUE IMMUNOPEROXIDASE),1468
EACH ANTIBODY
Q3A0490AMBULATORY SURGICAL CARE GENERAL CLASSIFICATION660
.......
.......
.......
Q3AASAmbulatory Surgery211
Q3A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM3,0562,549507
A Total3,5312,658873
Q3M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAIL2,0131,98330
EXAM; MED
Q3M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;2,4642,063401
EXPAND PROB
Q3M99241OFFICE CONSULTATION, 3 KEY COMPONENTS: PROB FOCUS HX; 100991
PROB FOCUS EXAM;
Q3M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;51143972
PROB FOCUS EX
Q3M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX;825725
DETAILED EXAM;
Q3M99202OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: EXPAND PROB FOCUS513714
HX; EXPAND
.......
.......
.......
Q3M99204OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS:202
COMPREHENSIVE HX;COMPREHENSIV
Q3M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;312
COMPREHENSIVE E
Q3M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX;23320
DETAILED EXAM;
Q3M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX;70568025
EXPAND PROB
M Total6,0025,364638
Q3pL1BACNE AGENTS, SYSTEMIC60600
Q3pL1AANTIPSORIATIC AGENTS, SYSTEMIC330
Q3pZ2AANTIHISTAMINES60060
.......
.......
.......
Q3pZ2GIMMUNOMODULATORS56450856
Q3pH3AANALGESICS, NARCOTICS3,7609342,826
Q3pQ5NTOPICAL ANTINEOPLASTIC & PREMALIGNANT LESION AGNTS5805800
P Total7,4873,0434,444
Q3S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;5215183
DIAMETER 0.6-1.0
Q3S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/4444386
MUCOUS MEMBRANE; DIAME
Q3S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN 1,7111,68328
TAGS/CUTANEOUS VASC P
Q3S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM1,1301,09238
Q3S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN75714
TAG, TRUNK/ARMS/L
Q3S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, 13211913
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q3S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/32731710
MUCOUS MEMBRANE; DIAME
Q3S11404EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT25214
SKIN TAG, TRUNK/ARMS/L
Q3S17106DESTRUCTION, CUTANEOUS VASCULAR PROLIFERATIVE LESIONS; 12120
<10 SQ CM
.......
.......
.......
Q3S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, 63621
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q3S12031LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES; 2 CM/<47434
Q3S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN1931858
TAG, TRUNK/ARMS/L
Q3S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM1911874
Q3S54056DESTRUCTION, PENILE LESION, SIMPLE; CRYOSURGERY660
Q3S11424EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/440
HANDS/FEET/GE
Q3S67810BX, EYELID880
.......
.......
.......
Q3S11901INJECTION, INTRALESIONAL; >7 LESIONS770
Q3S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT33531718
SKIN TAG, TRUNK/ARMS/L
Q3S11426EXCISE BENIGN SKIN LESION W/MARG, EXCEPT SKIN110
TAG SCALP/NECK/HANDS/FT/G
Q3S17004DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT15150
SKIN TAGS/CUTANEOUS/VASC P
Q3S11444EXCISE, BENIGN SKIN LESION, INCL MARGINS, 110
FACE/EARS/EYELIDS/NOSE/LIPS/M
.......
.......
.......
Q3S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;1671607
DIAMETER 0.5 CM/<
Q3S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION1109614
Q3S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, 1301255
TRUNK/ARMS/L
Q3S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<25923821
Q3S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION36732542
S Total9,3138,900413
Q3 Total26,33319,9656,368
Q4A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,8692,614255
Q4AASAmbulatory Surgery220
Q4AEREmergency220
Q4AS0630Removal of sutures by a physician other than the physician who originall550
.......
.......
.......
Q4A85025BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, 13013
WBC, & PLATELET) &
Q4A84460TRANSFERASE; ALANINE AMINO (ALT) (SGPT)303
Q4A80053COMPREHENSIVE METABOLIC PANEL14014
Q4A80061LIPID PANEL808
Q4A88321CONSULTATION & REPORT, REFERRED SLIDES PREPARED ELSEWHERE101
A Total3,0502,669381
Q4M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX;EXPAND PROB67566411
Q4M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED93690729
HX; DETAILED EXAM; MED
Q4M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; 36430757
PROB FOCUS EX
Q4M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX; 553520
DETAILED EXAM;
Q4M99202OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: EXPAND PROB FOCUS 322012
HX; EXPAND
Q4M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX;322012
DETAILED EXAM;
.......
.......
.......
Q4M99395PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/202
EXAM, EST PT; 18-39
Q4M99204OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: COMPREHENSIVE 101
HX;COMPREHENSIV
Q4M99241OFFICE CONSULTATION, 3 KEY COMPONENTS: PROB FOCUS HX; 110
PROB FOCUS EXAM;
Q4M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; 995742253
EXPAND PROB
M Total3,1172,703414
Q4PQ5NTOPICAL ANTINEOPLASTIC & PREMALIGNANT LESION AGNTS67665620
Q4PJ3301Injection, triamcinolone acetonide, per 10 mg1284
.......
.......
.......
Q4PL9BVITAMIN A DERIVATIVES1727795
P Total4,2751,5182,757
Q4R76942US GUIDANCE, NEEDLE PLACEMENT, RADIOLOGICAL S&I101
R Total101
Q4S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN 38837810
TAG, TRUNK/ARMS/L
Q4S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN 1991945
TAG, TRUNK/ARMS/L
Q4S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN1911901
TAG, TRUNK/ARMS/L
Q4S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<4794736
Q4S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, 69672
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q4S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/68680
HANDS/FEET/GE
Q4S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, 93921
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q4S12031LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES; 2 CM/<47443
Q4S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION35833424
Q4S11422EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/34340
HANDS/FEET/GE
Q4S11420EXCISE BENIGN SKIN LESION W/MARG, EXCPT SKIN55550
TAG SCALP/NECK/HANDS/FEET/
Q4S12032LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES;27261
2.6-7.5 CM
Q4S13101REPAIR, COMPLEX, TRUNK; 2.6 TO 7.5 CM880
Q4S11442EXCISE, BENIGN SKIN LESION, INCL MARGINS, 19181
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q4S11307SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;35350
DIAMETER 1.1-2.0
Q4S11312SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/34340
MUCOUS MEMBRANE; DIAME
Q4S67810BX, EYELID18180
Q4S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN34331
TAG, TRUNK/ARMS/L
Q4S11406EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN761
TAG, TRUNK/ARMS/L
Q4S40490BX, LIP13130
Q4S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/1331249
MUCOUS MEMBRANE; DIAME
Q4S11308SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; 990
DIAMETER > 2.0 CM
Q4S11303SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER >2.0 CM12111
Q4S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;1471434
DIAMETER 0.5 CM/<
Q4S13131REPAIR, COMPLEX, FOREHEAD/CHEEKS/CHIN/MOUTH/NECK/220
AXILLAE/GENITALIA/HAND
Q4S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION1241186
Q4S12051LAYER CLOSURE, WOUNDS, FACE/EARS/EYELIDS/NOSE/LIPS/431
MUCOUS MEMBRANES; 2.
.......
.......
.......
Q4S17106DESTRUCTION, CUTANEOUS VASCULAR PROLIFERATIVE LESIONS; <10 SQ CM220
Q4S54056DESTRUCTION, PENILE LESION, SIMPLE; CRYOSURGERY110
Q4S11404EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN541
TAG, TRUNK/ARMS/L
Q4S11443EXCISE, BENIGN SKIN LESION, INCL MARGINS, 110
FACE/EARS/EYELIDS/NOSE/LIPS/M
Q4S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM92875
Q4S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; 1171134
DIAMETER 0.6-1.0
Q4S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/83821
MUCOUS MEMBRANE; DIAME
Q4S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM3383344
Q4S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/61258923
CUTANEOUS VASC P
S Total5,0384,893145
Q4 Total15,48111,7833,698
Grand Total78,53058,65219,878
Total Costs
ExpectedStratumTotal Costper stratum
quartilecategoryservicesSvcsepisodesTotal CostsYour CostsOthers CostsExpected CostsDifferenceepisodes
Q1A00300.586,455$580$580$0$167$413$0
Q1A94720.586,455$165$165$0$48$117$0
Q1A94240.296,455$125$125$0$36$89$0
Q1A94010.296,455$124$124$0$36$88$0
Q1AA4646.876,455$149$0$149$63$86$0
Q1A99601.296,455$95$95$0$27$68$0
...........
...........
...........
Q1A883214.046,455$85$0$85$344($259)$0
Q1A883429.246,455$476$476$0$1,370($894)$0
Q1A883053105.386,455$62,122$53,278$8,844$96,026($33,904)$10
A Total3435.95$66,375$55,690$10,685$100,909($34,534)$10
Q1M992131967.286,455$130,482$121,036$9,446$108,522$21,960$20
Q1M9921433.786,455$3,973$2,734$1,239$3,067$906$1
Q1M99205.296,455$164$0$164$47$117$0
...........
...........
...........
Q1M9924130.316,455$53$53$0$1,607($1,554)$0
Q1M9920228.586,455$119$0$119$1,901($1,782)$0
Q1M9920346.196,455$1,020$302$718$4,896($3,876)$0
Q1M99212378.506,455$9,866$8,935$931$14,840($4,974)$2
Q1M99242625.356,455$32,863$31,514$1,349$60,757($27,894)$5
Q1M992431231.066,455$69,132$65,789$3,343$158,856($89,724)$11
M Total4371.37$249,522$230,790$18,732$357,088($107,566)$39
Q1PL9B993.176,455$4,900$4,397$503$2,414$2,486$1
Q1PH3A3742.566,455$5,607$1,073$4,534$4,803$804$1
...........
...........
...........
Q1PJ9A48.506,455$8$0$8$15($7)$0
Q1PH0A15.886,455$10$0$10$28($18)$0
Q1PS2B1127.426,455$1,355$468$887$1,485($130)$0
P Total7386.96$20,728$13,487$7,241$16,845$3,883$3
Q1R76942.586,455$39$0$39$57($18)$0
R Total.58$39$0$39$57($18)$0
Q1S170001277.266,455$86,301$84,932$1,369$79,652$6,649$13
Q1S11300472.336,455$24,845$24,100$745$20,778$4,067$4
Q1S170049.826,455$858$858$0$594$264$0
Q1S54060.296,455$278$278$0$80$198$0
...........
...........
...........
Q1S1144216.466,455$396$198$198$2,828($2,432)$0
Q1S1142135.226,455$676$676$0$4,224($3,548)$0
Q1S11400147.826,455$10,040$9,466$574$13,774($3,734)$2
Q1S11101183.626,455$3,596$3,242$354$7,559($3,963)$1
Q1S11100511.026,455$39,576$38,139$1,437$43,864($4,288)$6
Q1S11310209.036,455$7,985$7,608$377$12,363($4,378)$1
Q1S1140334.366,455$825$646$179$5,610($4,785)$0
Q1S1203133.496,455$899$713$186$5,685($4,786)$0
Q1S1144143.886,455$1,496$797$699$6,482($4,986)$0
Q1S1144078.826,455$1,751$1,358$393$9,266($7,515)$0
Q1S11301786.456,455$39,819$39,200$619$48,630($8,811)$6
Q1S11302164.286,455$4,274$4,274$0$13,253($8,979)$1
Q1S11402153.316,455$9,737$9,105$632$21,014($11,277)$2
Q1S11306240.216,455$3,848$3,631$217$15,227($11,379)$1
Q1S11311218.846,455$5,715$5,430$285$17,184($11,469)$1
Q1S11401278.896,455$10,989$10,532$457$29,553($18,564)$2
S Total7399.95$280,871$271,549$9,322$397,845($116,974)$44
Q1 Total22594.81$617,535$571,516$46,019$872,743($255,208)$96
Q2A883052137.444,443$87,190$74,527$12,663$66,095$21,095$20
Q2A883426.364,443$1,587$793$794$943$644$0
Q2A00820.204,443$315$0$315$63$252$0
...........
...........
...........
Q2A8005324.244,443$110$0$110$121($11)$0
Q2A8446012.524,443$34$0$34$51($17)$0
Q2A844439.544,443$35$0$35$67($32)$0
Q2A800505.374,443$28$0$28$75($47)$0
A Total2348.48$91,878$76,951$14,927$69,078$22,800$21
Q2M99242430.434,443$43,318$40,616$2,702$41,819$1,499$10
Q2M992042.194,443$586$0$586$315$271$0
Q2M99245.404,443$234$0$234$94$140$0
...........
...........
...........
Q2M9924120.874,443$159$106$53$1,106($947)$0
Q2M9920331.804,443$1,289$205$1,084$3,370($2,081)$0
Q2M99212260.524,443$7,280$5,990$1,290$10,215($2,935)$2
Q2M99243847.354,443$100,552$97,581$2,971$109,341($8,789)$23
Q2M992131354.084,443$55,484$43,371$12,113$74,696($19,212)$12
M Total3013.20$213,438$188,618$24,820$246,083($32,645)$48
Q2PS2B776.004,443$1,316$238$1,078$1,022$294$0
Q2PZ2G404.604,443$3,074$2,775$299$2,800$274$1
...........
...........
...........
Q2PJ70502.194,443$7$7$0$9($2)$0
Q2PZ2A22.654,443$26$18$8$45($19)$0
Q2PL9B683.604,443$669$552$117$1,662($993)$0
P Total5062.41$11,384$7,127$4,257$11,354$30$3
Q2S11100351.744,443$51,962$50,826$1,136$30,192$21,770$12
Q2S11302113.074,443$17,768$17,591$177$9,122$8,646$4
Q2S11101126.394,443$13,545$13,367$178$5,203$8,342$3
Q2S11301541.324,443$38,844$37,832$1,012$33,472$5,372$9
Q2S11305151.624,443$10,542$10,043$499$6,011$4,531$2
Q2S1131223.454,443$5,154$5,154$0$2,311$2,843$1
Q2S11300325.114,443$16,356$15,573$783$14,302$2,054$4
Q2S11311150.634,443$13,139$12,949$190$11,828$1,311$3
Q2S11400101.754,443$10,317$10,210$107$9,481$836$2
Q2S11603.404,443$324$324$0$64$260$0
Q2S1130719.674,443$2,010$2,010$0$1,789$221$0
...........
...........
...........
Q2S404904.574,443$411$411$0$514($103)$0
Q2S119004.574,443$104$104$0$216($112)$0
Q2S11310143.874,443$8,226$7,886$340$8,510($284)$2
Q2S170046.764,443$66$66$0$409($343)$0
Q2S1142021.864,443$1,573$1,573$0$1,956($383)$0
...........
...........
...........
Q2S1144211.334,443$412$230$182$1,946($1,534)$0
Q2S11306165.344,443$8,946$8,558$388$10,481($1,535)$2
Q2S1142124.244,443$992$992$0$2,907($1,915)$0
Q2S1144054.254,443$4,240$4,030$210$6,378($2,138)$1
Q2S1203219.674,443$1,562$1,120$442$4,287($2,725)$0
Q2S1140323.654,443$914$914$0$3,862($2,948)$0
Q2S1144130.214,443$1,481$1,143$338$4,462($2,981)$0
Q2S11401191.964,443$17,276$16,281$995$20,341($3,065)$4
Q2S11402105.524,443$11,261$10,858$403$14,464($3,203)$3
Q2S17000879.144,443$45,979$43,698$2,281$54,825($8,846)$10
S Total5091.23$294,660$283,572$11,088$273,829$20,831$66
Q2 Total15515.33$611,360$556,268$55,092$600,343$11,017$138
Q3A05511.747,788$425$425$0$148$277$0
Q3A883214.887,788$680$595$85$415$265$0
Q3A8834211.157,788$1,890$951$939$1,653$237$0
Q3A04902.097,788$336$336$0$117$219$0
...........
...........
...........
Q3AAS2.097,788$284$219$65$473($189)$0
Q3A883053746.667,788$94,768$79,088$15,680$115,856($21,088)$12
A Total4150.72$102,204$83,082$19,122$121,893($19,689)$13
Q3M992431485.297,788$259,400$255,556$3,844$191,661$67,739$33
Q3M992132373.537,788$134,726$113,540$21,186$130,933$3,793$17
Q3M9924136.577,788$5,300$5,247$53$1,938$3,362$1
Q3M99212456.667,788$20,119$17,403$2,716$17,905$2,214$3
Q3M9920355.737,788$7,797$5,422$2,375$5,907$1,890$1
Q3M9920234.487,788$3,054$2,264$790$2,294$760$0
...........
...........
...........
Q3M992043.837,788$293$0$293$551($258)$0
Q3M992445.227,788$554$185$369$963($409)$0
Q3M9921440.757,788$2,071$265$1,806$3,701($1,630)$0
Q3M99242754.497,788$68,631$66,197$2,434$73,303($4,672)$9
M Total5281.41$504,876$466,125$38,751$431,288$73,588$65
Q3pL1B31.357,788$582$582$0$351$231$0
Q3pL1A1.047,788$161$161$0$56$105$0
Q3pZ2A39.717,788$112$0$112$79$33$0
...........
...........
...........
Q3pZ2G709.207,788$4,246$3,962$284$4,907($661)$1
Q3pH3A4515.427,788$4,958$1,420$3,538$5,794($836)$1
Q3pQ5N928.657,788$2,375$2,375$0$4,279($1,904)$0
P Total8895.00$16,796$10,593$6,203$20,356($3,560)$2
Q3S11306289.817,788$31,883$31,670$213$18,371$13,512$4
Q3S11311264.047,788$34,032$33,524$508$20,732$13,300$4
Q3S170001541.027,788$107,753$106,108$1,645$96,101$11,652$14
Q3S11301948.867,788$69,328$66,961$2,367$58,672$10,656$9
Q3S1140341.457,788$13,183$12,672$511$6,769$6,414$2
Q3S1144095.097,788$15,293$13,920$1,373$11,179$4,114$2
Q3S11310252.197,788$18,610$18,126$484$14,916$3,694$2
Q3S1140411.847,788$4,994$4,161$833$2,324$2,670$1
Q3S171064.887,788$4,362$4,362$0$1,792$2,570$1
...........
...........
...........
Q3S1144152.957,788$9,204$9,043$161$7,821$1,383$1
Q3S1203140.417,788$7,821$7,252$569$6,859$962$1
Q3S11402184.967,788$26,296$25,237$1,059$25,354$942$3
Q3S11302198.207,788$16,910$16,582$328$15,990$920$2
Q3S540562.447,788$1,000$1,000$0$390$610$0
Q3S114242.097,788$919$919$0$464$455$0
Q3S678109.757,788$2,057$2,057$0$1,658$399$0
...........
...........
...........
Q3S119013.837,788$343$343$0$208$135$0
Q3S11401336.497,788$35,760$34,110$1,650$35,656$104$5
Q3S11426.707,788$282$282$0$182$100$0
Q3S1700411.847,788$814$814$0$717$97$0
Q3S11444.707,788$280$280$0$204$76$0
...........
...........
...........
Q3S11305265.787,788$6,227$5,943$284$10,537($4,310)$1
Q3S11101221.547,788$4,223$3,697$526$9,120($4,897)$1
Q3S11400178.357,788$11,277$10,908$369$16,619($5,342)$1
Q3S11300569.877,788$11,209$10,330$879$25,069($13,860)$1
Q3S11100616.557,788$31,241$28,008$3,233$52,922($21,681)$4
S Total8974.42$518,752$499,077$19,675$489,127$29,625$67
Q3 Total27301.54$1,142,628$1,058,877$83,751$1,062,664$79,964$147
Q4A883051766.533,672$88,522$80,632$7,890$54,625$33,897$24
Q4AAS.993,672$513$513$0$223$290$0
Q4AER.663,672$305$305$0$81$224$0
Q4AS06301.813,672$216$216$0$75$141$0
...........
...........
...........
Q4A8502520.863,672$39$0$39$64($25)$0
Q4A8446010.353,672$13$0$13$43($30)$0
Q4A8005320.043,672$70$0$70$100($30)$0
Q4A8006115.113,672$64$0$64$121($57)$0
Q4A883212.303,672$85$0$85$195($110)$0
A Total1945.71$92,174$83,419$8,755$57,213$34,961$25
Q4M99242355.743,672$65,629$64,578$1,051$34,562$31,067$18
Q4M99243700.303,672$121,141$117,517$3,624$90,367$30,774$33
Q4M99212215.313,672$14,137$11,867$2,270$8,442$5,695$4
Q4M9920326.283,672$6,851$4,826$2,025$2,785$4,066$2
Q4M9920216.263,672$2,474$1,740$734$1,082$1,392$1
Q4M9921419.223,672$3,077$1,766$1,311$1,745$1,332$1
...........
...........
...........
Q4M993952.963,672$112$0$112$166($54)$0
Q4M992041.813,672$147$0$147$260($113)$0
Q4M9924117.243,672$53$53$0$914($861)$0
Q4M992131119.113,672$55,194$41,218$13,976$61,734($6,540)$15
M Total2486.87$271,026$244,855$26,171$203,021$68,005$74
Q4PQ5N437.853,672$3,602$3,515$87$2,017$1,585$1
Q4PJ33013.453,672$80$60$20$33$47$0
...........
...........
...........
Q4PL9B564.973,672$427$159$268$1,373($946)$0
P Total4131.53$9,627$6,095$3,532$9,359$268$3
Q4R76942.333,672$158$0$158$32$126$0
R Total.33$158$0$158$32$126$0
Q4S11401158.653,672$38,337$37,510$827$16,812$21,525$10
Q4S1140287.213,672$25,492$24,873$619$11,954$13,538$7
Q4S1140084.093,672$16,076$15,974$102$7,836$8,240$4
Q4S11300268.693,672$19,559$19,344$215$11,820$7,739$5
Q4S1144124.963,672$10,271$10,038$233$3,687$6,584$3
Q4S1142120.043,672$8,103$8,103$0$2,403$5,700$2
Q4S1144044.843,672$10,809$10,686$123$5,271$5,538$3
Q4S1203119.053,672$8,025$7,589$436$3,234$4,791$2
Q4S11100290.703,672$29,152$27,305$1,847$24,953$4,199$8
Q4S1142210.353,672$4,979$4,979$0$1,475$3,504$1
Q4S1142018.073,672$4,806$4,806$0$1,617$3,189$1
Q4S1203216.263,672$5,932$5,770$162$3,543$2,389$2
Q4S131011.313,672$2,554$2,554$0$419$2,135$1
Q4S114429.363,672$3,483$3,315$168$1,609$1,874$1
Q4S1130716.263,672$3,126$3,126$0$1,479$1,647$1
Q4S1131219.383,672$3,459$3,459$0$1,910$1,549$1
Q4S678104.603,672$2,138$2,138$0$782$1,356$1
Q4S1140319.543,672$4,510$4,312$198$3,191$1,319$1
Q4S114062.143,672$1,591$1,339$252$498$1,093$0
Q4S404903.783,672$1,473$1,473$0$425$1,048$0
Q4S11310118.913,672$8,001$7,555$446$7,033$968$2
Q4S113081.813,672$926$926$0$186$740$0
Q4S113035.263,672$1,196$1,104$92$527$669$0
Q4S11305125.313,672$5,579$5,417$162$4,968$611$2
Q4S13131.333,672$630$630$0$103$527$0
Q4S11101104.453,672$4,817$4,592$225$4,300$517$1
Q4S120511.973,672$904$672$232$432$472$0
...........
...........
...........
Q4S171062.303,672$782$782$0$845($63)$0
Q4S540561.153,672$121$121$0$184($63)$0
Q4S114045.583,672$846$737$109$1,096($250)$0
Q4S114432.463,672$222$222$0$518($296)$0
Q4S1130293.453,672$6,952$6,621$331$7,539($587)$2
Q4S11306136.643,672$8,064$7,920$144$8,662($598)$2
Q4S11311124.493,672$6,633$6,593$40$9,775($3,142)$2
Q4S11301447.383,672$20,447$20,270$177$27,664($7,217)$6
Q4S17000726.583,672$35,855$34,605$1,250$45,311($9,456)$10
S Total4235.33$316,052$307,155$8,897$231,346$84,706$86
Q4 Total12799.77$689,037$641,524$47,513$500,971$188,066$188
Grand Total78211.45$3,060,560$2,828,185$232,375$3,036,722$23,838$568
episodes
DifferenceOtherthis
per stratumYour costscosts perSpec costsservice
quartilecategoryservicesepisodesper svcsvcper svcoccurred
Q1A00300$0$290$0$2902
Q1A94720$0$83$0$832
Q1A94240$0$125$0$1251
Q1A94010$0$124$0$1241
Q1AA4646$0$0$75$732
Q1A99601$0$95$0$951
........
........
........
Q1A88321($0)$0$85$851
Q1A88342($0)$159$0$1482
Q1A88305($5)$31$31$311,403
A Total($5)
Q1M99213$3$55$55$552,261
Q1M99214$0$88$89$9145
Q1M99205$0$0$164$1641
........
........
........
Q1M99241($0)$53$0$531
Q1M99202($0)$0$60$672
Q1M99203($1)$101$103$10610
Q1M99212($1)$39$39$39249
Q1M99242($4)$96$96$97339
Q1M99243($14)$129$129$129529
M Total($17)
Q1PL9B$0$3$3$279
Q1PH3A$0$1$1$1233
........
........
........
Q1PJ9A($0)$0$0$02
Q1PH0A($0)$0$0$21
Q1PS2B($0)$2$1$121
P Total$1
Q1R76942($0)$0$39$991
R Total($0)
Q1S17000$1$64$60$621,215
Q1S11300$1$47$50$44398
Q1S17004$0$66$0$6113
Q1S54060$0$278$0$2781
........
........
........
Q1S11442($0)$198$99$1723
Q1S11421($1)$135$0$1205
Q1S11400($1)$106$115$9388
Q1S11101($1)$38$39$4183
Q1S11100($1)$85$85$86458
Q1S11310($1)$64$63$59105
Q1S11403($1)$162$179$1634
Q1S12031($1)$178$186$1705
Q1S11441($1)$133$140$14810
Q1S11440($1)$136$131$11812
Q1S11301($1)$68$52$62462
Q1S11302($1)$85$0$8145
Q1S11402($2)$145$158$13764
Q1S11306($2)$77$72$6343
Q1S11311($2)$89$95$7960
Q1S11401($3)$113$91$10692
S Total($18)
Q1 Total($40)
Q2A88305$5$31$31$311,760
Q2A88342$0$159$159$1487
Q2A00820$0$0$315$3151
........
........
........
Q2A80053($0)$0$5$521
Q2A84460($0)$0$3$410
Q2A84443($0)$0$7$75
Q2A80050($0)$0$14$142
A Total$5
Q2M99242$0$97$97$97440
Q2M99204$0$0$147$1444
Q2M99245$0$0$234$2371
........
........
........
Q2M99241($0)$53$53$533
Q2M99203($0)$103$99$10613
Q2M99212($1)$40$39$39173
Q2M99243($2)$129$129$129767
Q2M99213($4)$56$54$55959
M Total($7)
Q2PS2B$0$2$1$118
Q2PZ2G$0$7$5$717
........
........
........
Q2PJ7050($0)$7$0$41
Q2PZ2A($0)$3$4$23
Q2PL9B($0)$2$2$29
P Total$0
Q2S11100$5$90$87$86574
Q2S11302$2$75$89$81183
Q2S11101$2$44$36$41181
Q2S11301$1$58$60$62437
Q2S11305$1$37$45$40126
Q2S11312$1$101$0$9947
Q2S11300$0$44$46$44247
Q2S11311$0$78$95$79137
Q2S11400$0$106$107$9392
Q2S11603$0$162$0$1622
Q2S11307$0$87$0$9120
........
........
........
Q2S40490($0)$103$0$1123
Q2S11900($0)$52$0$472
Q2S11310($0)$58$68$59104
Q2S17004($0)$66$0$611
Q2S11420($0)$105$0$8915
........
........
........
Q2S11442($0)$115$182$1723
Q2S11306($0)$62$78$63104
Q2S11421($0)$124$0$1207
Q2S11440($0)$122$105$11829
Q2S12032($1)$224$221$2187
Q2S11403($1)$183$0$1635
Q2S11441($1)$163$169$1489
Q2S11401($1)$120$111$106129
Q2S11402($1)$157$134$13770
Q2S17000($2)$61$63$62707
S Total$5
Q2 Total$2
Q3A0551$0$85$0$851
Q3A88321$0$85$85$858
Q3A88342$0$159$117$1487
Q3A0490$0$56$0$561
........
........
........
Q3AAS($0)$219$65$2262
Q3A88305($3)$31$31$312,048
A Total($3)
Q3M99243$9$129$128$1292,004
Q3M99213$0$55$53$552,351
Q3M99241$0$53$53$53100
Q3M99212$0$40$38$39488
Q3M99203$0$95$95$10682
Q3M99202$0$61$56$6751
........
........
........
Q3M99204($0)$0$147$1442
Q3M99244($0)$185$185$1843
Q3M99214($0)$88$90$9123
Q3M99242($1)$97$97$97699
M Total$9
Q3pL1B$0$10$0$112
Q3pL1A$0$54$0$541
Q3pZ2A$0$0$2$21
........
........
........
Q3pZ2G($0)$8$5$722
Q3pH3A($0)$2$1$1272
Q3pQ5N($0)$4$0$516
P Total($0)
Q3S11306$2$61$71$63283
Q3S11311$2$77$85$79297
Q3S17000$1$63$59$621,580
Q3S11301$1$61$62$62742
Q3S11403$1$178$128$16369
Q3S11440$1$117$106$118108
Q3S11310$0$57$48$59251
Q3S11404$0$198$208$19624
Q3S17106$0$364$0$36712
........
........
........
Q3S11441$0$146$161$14858
Q3S12031$0$169$142$17044
Q3S11402$0$136$132$137177
Q3S11302$0$89$82$81174
Q3S54056$0$167$0$1606
Q3S11424$0$230$0$2224
Q3S67810$0$257$0$1707
........
........
........
Q3S11901$0$49$0$547
Q3S11401$0$108$92$106270
Q3S11426$0$282$0$2621
Q3S17004$0$54$0$6115
Q3S11444$0$280$0$2941
........
........
........
Q3S11305($1)$37$41$40119
Q3S11101($1)$39$38$4178
Q3S11400($1)$87$74$93102
Q3S11300($2)$43$42$44189
Q3S11100($3)$86$77$86350
S Total$4
Q3 Total$10
Q4A88305$9$31$31$311,581
Q4AAS$0$257$0$2262
Q4AER$0$153$0$1232
Q4AS0630$0$43$0$415
........
........
........
Q4A85025($0)$0$3$313
Q4A84460($0)$0$4$43
Q4A80053($0)$0$5$514
Q4A80061($0)$0$8$88
Q4A88321($0)$0$85$851
A Total$10
Q4M99242$8$97$96$97672
Q4M99243$8$130$125$129931
Q4M99212$2$39$40$39331
Q4M99203$1$138$101$10655
Q4M99202$0$87$61$6732
Q4M99214$0$88$109$9131
........
........
........
Q4M99395($0)$0$56$562
Q4M99204($0)$0$147$1441
Q4M99241($0)$53$0$531
Q4M99213($2)$56$55$55939
M Total$19
Q4PQ5N$0$5$4$529
Q4PJ3301$0$8$5$1010
........
........
........
Q4PL9B($0)$2$3$29
P Total$0
Q4R76942$0$0$158$991
R Total$0
Q4S11401$6$99$83$106270
Q4S11402$4$128$124$137169
Q4S11400$2$84$102$93151
Q4S11300$2$41$36$44264
Q4S11441$2$150$117$14861
Q4S11421$2$119$0$12062
Q4S11440$2$116$123$11874
Q4S12031$1$172$145$17044
Q4S11100$1$82$77$86355
Q4S11422$1$146$0$14332
Q4S11420$1$87$0$8945
Q4S12032$1$222$162$21827
Q4S13101$1$319$0$3198
Q4S11442$1$184$168$17219
Q4S11307$0$89$0$9133
Q4S11312$0$102$0$9933
Q4S67810$0$119$0$17016
Q4S11403$0$131$198$16332
Q4S11406$0$223$252$2337
Q4S40490$0$113$0$11212
Q4S11310$0$61$50$59100
Q4S11308$0$103$0$1039
Q4S11303$0$100$92$10010
Q4S11305$0$38$41$40101
Q4S13131$0$315$0$3152
Q4S11101$0$39$38$4195
Q4S12051$0$224$232$2194
........
........
........
Q4S17106($0)$391$0$3672
Q4S54056($0)$121$0$1601
Q4S11404($0)$184$109$1965
Q4S11443($0)$222$0$2101
Q4S11302($0)$76$66$8177
Q4S11306($0)$70$36$6391
Q4S11311($1)$80$40$7974
Q4S11301($2)$61$44$62250
Q4S17000($3)$59$54$62552
S Total$23
Q4 Total$51
Grand Total$24
TABLE A9
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role benign neoplasm of the skin without actinic keratoses diagnosis 702.xx
etg 0682
Cost driver threshold $2 (rounded value)
quartilecategoryservicesservice descriptionTotal SvcsYour Svcs
Q1A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,0081,723
A Total2,0081,723
Q1M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;2,3562,184
EXPAND PROB
Q1M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;253229
PROB FOCUS EX
Q1M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS341327
HX;EXPAND PROB
Q1M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX;536510
DETAILED EXAM; MED
M Total3,4863,250
Q1S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/1,3431,320
CUTANEOUS VASC P
Q1S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<524509
Q1S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,9489
TRUNK/ARMS/L
Q1S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION465448
Q1S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM585573
Q1S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,6763
TRUNK/ARMS/L
Q1S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,9893
TRUNK/ARMS/L
S Total3,1763,095
Q1 Total8,6708,068
Q2A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,8232,414
A Total2,8232,414
Q2M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS445417
HX;EXPAND PROB
Q2M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;183150
PROB FOCUS EX
Q2M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX;779756
DETAILED EXAM; MED
Q2M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;999776
EXPAND PROB
M Total2,4062,099
Q2S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION580567
Q2S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM236234
Q2S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADDL LESION307302
Q2S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM671654
Q2S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;285274
DIAMETER 0.5 CM/<
Q2S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<374357
Q2S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS167165
MEMBRANE; DIAME
Q2S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,9796
TRUNK/ARMS/L
Q2S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS140135
MEMBRANE; DIAME
Q2S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;144139
DIAMETER 0.6-1.0
Q2S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,145136
TRUNK/ARMS/L
Q2S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,7269
TRUNK/ARMS/L
Q2S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/758722
CUTANEOUS VASC P
S Total3,9763,850
Q2 Total9,2058,363
Q3A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM3,0562,549
A Total3,0562,549
Q3M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX:2,0131,983
DETAILED EXAM; MED
Q3M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;2,4642,063
EXPAND PROB
Q3M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;511439
PROB FOCUS EX
Q3M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS705680
HX; EXPAND PROB
M Total5,6935,165
Q3S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;521518
DIAMETER 0.6-1.0
Q3S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS444438
MEMBRANE; DIAME
Q3S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/1,7111,683
CUTANEOUS VASC P
Q3S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM1,1301,092
Q3S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,7571
TRUNK/ARMS/L
Q3S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/132119
NOSE/LIPS/M
Q3S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS327317
MEMBRANE; DIAME
Q3S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,193185
TRUNK/ARMS/L
Q3S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM191187
Q3S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,335317
TRUNK/ARMS/L
Q3S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION367325
S Total5,4265,252
Q3 Total14,17512,966
Q4A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM2,8692,614
A Total2,8692,614
Q4M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS675664
HX;EXPAND PROB
Q4M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX;936907
DETAILED HX; DETAILED EXAM; MED
Q4M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX;364307
PROB FOCUS EX
Q4M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX;5535
DETAILED EXAM;
Q4M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;995742
EXPAND PROB
M Total3,0252,655
Q4S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,388378
TRUNK/ARMS/L
Q4S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,199194
TRUNK/ARMS/L
Q4S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG,191190
TRUNK/ARMS/L
Q4S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<479473
Q4S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/6967
NOSE/LIPS/M
Q4S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/6868
HANDS/FEET/GE
Q4S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/9392
EYELIDS/NOSE/LIPS/M
Q4S12031LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES;4744
2.5 CM/<
Q4S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION358334
Q4S12032LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES;2726
2.6-7.5 CM
Q4S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS133124
MEMBRANE; DIAME
Q4S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;147143
DIAMETER 0.5 CM/<
Q4S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM9287
Q4S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA;117113
DIAMETER 0.6-1.0
Q4S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS8382
MEMBRANE; DIAME
Q4S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM338334
Q4S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/612589
CUTANEOUS VASC P
S Total3,4413,338
Q4 Total9,3358,607
Grand Total41,38538,004
OtherExpectedQuartileOthersTotal Cost
quartilecategoryservicesSvcsSvcsepisodesTotal CostsYour CostsCostsExpected CostsDifference
Q1A883052853105.386,455$62,122$53,278$8,844$96,026($33,904)
A Total285$62,122$53,278$8,844$96,026($33,904)
Q1M992131721967.286,455$130,482$121,036$9,446$108,522$21,960
Q1M9921224378.506,455$9,866$8,935$931$14,840($4,974)
Q1M9924214625.356,455$32,863$31,514$1,349$60,757($27,894)
Q1M99243261231.066,455$69,132$65,789$3,343$158,856($89,724)
M Total236$242,343$227,274$15,069$342,975($100,632)
Q1S17000231277.266,455$86,301$84,932$1,369$79,652$6,649
Q1S1130015472.336,455$24,845$24,100$745$20,778$4,067
Q1S114005147.826,455$10,040$9,466$574$13,774($3,734)
Q1S1110017511.026,455$39,576$38,139$1,437$43,864($4,288)
Q1S1130112786.456,455$39,819$39,200$619$48,630($8,811)
Q1S114024153.316,455$9,737$9,105$632$21,014($11,277)
Q1S114015278.896,455$10,989$10,532$457$29,553($18,564)
S Total81$221,307$215,474$5,833$257,266($35,959)
Q1 Total602$525,772$496,026$29,746$696,267($170,495)
Q2A883054092137.444,443$87,190$74,527$12,663$66,095$21,095
A Total409$87,190$74,527$12,663$66,095$21,095
Q2M9924228430.434,443$43,318$40,616$2,702$41,819$1,499
Q2M9921233260.524,443$7,280$5,990$1,290$10,215($2,935)
Q2M9924323847.354,443$100,552$97,581$2,971$109,341($8,789)
Q2M992132231354.084,443$55,484$43,371$12,113$74,696($19,212)
M Total307$206,634$187,558$19,076$236,071($29,437)
Q2S1110013351.744,443$51,962$50,826$1,136$30,192$21,770
Q2S113022113.074,443$17,768$17,591$177$9,122$8,646
Q2S111015126.394,443$13,545$13,367$178$5,203$8,342
Q2S1130117541.324,443$38,844$37,832$1,012$33,472$5,372
Q2S1130511151.624,443$10,542$10,043$499$6,011$4,531
Q2S1130017325.114,443$16,356$15,573$783$14,302$2,054
Q2S113112150.634,443$13,139$12,949$190$11,828$1,311
Q2S114001101.754,443$10,317$10,210$107$9,481$836
Q2S113105143.874,443$8,226$7,886$340$8,510($284)
Q2S113065165.344,443$8,946$8,558$388$10,481($1,535)
Q2S114019191.964,443$17,276$16,281$995$20,341($3,065)
Q2S114023105.524,443$11,261$10,858$403$14,464($3,203)
Q2S1700036879.144,443$45,979$43,698$2,281$54,825($8,846)
S Total126$264,161$255,672$8,489$228,231$35,930
Q2 Total842$557,985$517,757$40,228$530,397$27,588
Q3A883055073746.667,788$94,768$79,088$15,680$115,856($21,088)
A Total507$94,768$79,088$15,680$115,856($21,088)
Q3M99243301485.297,788$259,400$255,556$3,844$191,661$67,739
Q3M992134012373.537,788$134,726$113,540$21,186$130,933$3,793
Q3M9921272456.667,788$20,119$17,403$2,716$17,905$2,214
Q3M9924225754.497,788$68,631$66,197$2,434$73,303($4,672)
M Total528$482,876$452,696$30,180$413,802$69,074
Q3S113063289.817,788$31,883$31,670$213$18,371$13,512
Q3S113116264.047,788$34,032$33,524$508$20,732$13,300
Q3S17000281541.027,788$107,753$106,108$1,645$96,101$11,652
Q3S1130138948.867,788$69,328$66,961$2,367$58,672$10,656
Q3S11403441.457,788$13,183$12,672$511$6,769$6,414
Q3S114401395.097,788$15,293$13,920$1,373$11,179$4,114
Q3S1131010252.197,788$18,610$18,126$484$14,916$3,694
Q3S114028184.967,788$26,296$25,237$1,059$25,354$942
Q3S113024198.207,788$16,910$16,582$328$15,990$920
Q3S1140118336.497,788$35,760$34,110$1,650$35,656$104
Q3S1110042616.557,788$31,241$28,008$3,233$52,922($21,681)
S Total174$400,289$386,918$13,371$356,662$43,627
Q3 Total1,209$977,933$918,702$59,231$886,320$91,613
Q4A883052551766.533,672$88,522$80,632$7,890$54,625$33,897
A Total255$88,522$80,632$7,890$54,625$33,897
Q4M9924211355.743,672$65,629$64,578$1,051$34,562$31,067
Q4M9924329700.303,672$121,141$117,517$3,624$90,367$30,774
Q4M9921257215.313,672$14,137$11,867$2,270$8,442$5,695
Q4M992032026.283,672$6,851$4,826$2,025$2,785$4,066
Q4M992132531119.113,672$55,194$41,218$13,976$61,734($6,540)
M Total370$262,952$240,006$22,946$197,890$65,062
Q4S1140110158.653,672$38,337$37,510$827$16,812$21,525
Q4S11402587.213,672$25,492$24,873$619$11,954$13,538
Q4S11400184.093,672$16,076$15,974$102$7,836$8,240
Q4S113006268.693,672$19,559$19,344$215$11,820$7,739
Q4S11441224.963,672$10,271$10,038$233$3,687$6,584
Q4S11421020.043,672$8,103$8,103$0$2,403$5,700
Q4S11440144.843,672$10,809$10,686$123$5,271$5,538
Q4S12031319.053,672$8,025$7,589$436$3,234$4,791
Q4S1110024290.703,672$29,152$27,305$1,847$24,953$4,199
Q4S12032116.263,672$5,932$5,770$162$3,543$2,389
Q4S113109118.913,672$8,001$7,555$446$7,033$968
Q4S113054125.313,672$5,579$5,417$162$4,968$611
Q4S11302593.453,672$6,952$6,621$331$7,539($587)
Q4S113064136.643,672$8,064$7,920$144$8,662($598)
Q4S113111124.493,672$6,633$6,593$40$9,775($3,142)
Q4S113014447.383,672$20,447$20,270$177$27,664($7,217)
Q4S1700023726.583,672$35,855$34,605$1,250$45,311($9,456)
S Total103$263,287$256,173$7,114$202,465$60,822
Q4 Total728$614,761$576,811$37,950$454,980$159,781
Grand Total3,381$2,676,451$2,509,296$167,155$2,567,965$108,486
episodes
Total CostsDifferenceOtherSpecthis
per stratumper stratumYour costscosts percosts perservice
quartilecategoryservicesepisodesepisodesper svcsvcsvcoccurred
Q1A88305$10($5)$31$31$3111,403
A Total$10($5)1,403
Q1M99213$20$3$55$55$552,261
Q1M99212$2($1)$39$39$39249
Q1M99242$5($4)$96$96$97339
Q1M99243$11($14)$129$129$129529
M Total$38($16)3,378
Q1S17000$13$1$64$60$621,215
Q1S11300$4$1$47$50$44398
Q1S11400$2($1)$106$115$9388
Q1S11100$6($1)$85$85$86458
Q1S11301$6($1)$68$52$62462
Q1S11402$2($2)$145$158$13764
Q1S11401$2($3)$113$91$10692
S Total$34($6)2,777
Q1 Total$81($26)7,558
Q2A88305$20$5$31$31$311,760
A Total$20$51,760
Q2M99242$10$0$97$97$97440
Q2M99212$2($1)$40$39$39173
Q2M99243$23($2)$129$129$129767
Q2M99213$12($4)$56$54$55959
M Total$47($7)2,339
Q2S11100$12$5$90$87$86574
Q2S11302$4$2$75$89$81183
Q2S11101$3$2$44$36$41181
Q2S11301$9$1$58$60$62437
Q2S11305$2$1$37$45$40126
Q2S11300$4$0$44$46$44247
Q2S11311$3$0$78$95$79137
Q2S11400$2$0$106$107$9392
Q2S11310$2($0)$58$68$59104
Q2S11306$2($0)$62$78$63104
Q2S11401$4($1)$120$111$106129
Q2S11402$3($1)$157$134$13770
Q2S17000$10($2)$61$63$62707
S Total$59$83,091
Q2 Total$126$67,190
Q3A88305$12($3)$31$31$312,048
A Total$12($3)2,048
Q3M99243$33$9$129$128$1292,004
Q3M99213$17$0$55$53$552,351
Q3M99212$3$0$40$38$39488
Q3M99242$9($1)$97$97$97699
M Total$62$95,542
Q3S11306$4$2$61$71$63283
Q3S11311$4$2$77$85$79297
Q3S17000$14$1$63$59$621,580
Q3S11301$9$1$61$62$62742
Q3S11403$2$1$178$128$16369
Q3S11440$2$1$117$106$118108
Q3S11310$2$0$57$48$59251
Q3S11402$3$0$136$132$137177
Q3S11302$2$0$89$82$81174
Q3S11401$5$0$108$92$106270
Q3S11100$4($3)$86$77$86350
S Total$51$64,301
Q3 Total$126$1211,891
Q4A88305$24$9$31$31$311,581
A Total$24$91,581
Q4M99242$18$8$97$96$97672
Q4M99243$33$8$130$125$129931
Q4M99212$4$2$39$40$39331
Q4M99203$2$1$138$101$10655
Q4M99213$15($2)$56$55$55939
M Total$72$182,928
Q4S11401$10$6$99$83$106270
Q4S11402$7$4$128$124$137169
Q4S11400$4$2$84$102$93151
Q4S11300$5$2$41$36$44264
Q4S11441$3$2$150$117$14861
Q4S11421$2$2$119$0$12062
Q4S11440$3$2$116$123$11874
Q4S12031$2$1$172$145$17044
Q4S11100$8$1$82$77$86355
Q4S12032$2$1$222$162$21827
Q4S11310$2$0$61$50$59100
Q4S11305$2$0$38$41$40101
Q4S11302$2($0)$76$66$8177
Q4S11306$2($0)$70$36$6391
Q4S11311$2($1)$80$40$7974
Q4S11301$6($2)$61$44$62250
Q4S17000$10($3)$59$54$62552
S Total$72$172,722
Q4 Total$167$447,231
Grand Total$500$3533,870
TABLE A10
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total role benign neoplasm of the skin, without actinic keratoses
etg 0682
Total
Provider IDcategoryservicesservice descriptionSvcs
CCP010000014A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM645
CCP010000014AS0630Removal of sutures by a physician other than the physician who originall3
CCP010000014AA4649Surgical supply; miscellaneous1
CCP010000014A88307LEVEL V—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM1
CCP010000014A93000ELECTROCARDIOGRAM, ROUTINE W/AT LEAST 12 LEADS; W/INTERPRETATION & REPO2
CCP010000014AA4550Surgical trays1
CCP010000014A88312SPECIAL STAINS; GROUP I, MICROORGANISMS, EACH4
CCP010000014A86644ANTIBODY; CYTOMEGALOVIRUS (CMV)1
CCP010000014A86777ANTIBODY; TOXOPLASMA1
CCP010000014A82947GLUCOSE; QUANTITATIVE, BLOOD (EXCEPT REAGENT STRIP)2
CCP010000014A86140C-REACTIVE PROTEIN2
CCP010000014A85025BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, WBC, & PLATELET) &7
CCP010000014A800031
CCP010000014A800051
CCP010000014A82040ALBUMIN; SERUM1
CCP010000014A80051ELECTROLYTE PANEL1
CCP010000014A85651SEDIMENTATION RATE, ERYTHROCYTE; NON-AUTOMATED2
CCP010000014A84450TRANSFERASE; ASPARTATE AMINO (AST) (SGOT)2
CCP010000014A82565CREATININE; BLOOD1
CCP010000014A85730THROMBOPLASTIN TIME, PARTIAL (PTT); PLASMA/WHOLE BLOOD1
CCP010000014A85652SEDIMENTATION RATE, ERYTHROCYTE; AUTOMATED1
CCP010000014A85014BLOOD COUNT; HEMATOCRIT1
CCP010000014A80053COMPREHENSIVE METABOLIC PANEL5
CCP010000014A80048BASIC METABOLIC PANEL3
CCP010000014A80050GENERAL HEALTH PANEL1
CCP010000014A85027BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, WBC, & PLATELET)2
CCP010000014A82270BLOOD, OCCULT, BY PEROXIDASE ACTIVITY, QUALITATIVE; FECES, 1-3 SIMULTAN1
CCP010000014A88304LEVEL III—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM3
CCP010000014A80061LIPID PANEL2
A Total699
CCP010000014M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED EXAM; MED255
CCP010000014M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX; DETAILED EXAM:33
CCP010000014M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; EXPAND PROB129
CCP010000014M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; EXPAND PROB320
CCP010000014M99202OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; EXPAND15
CCP010000014M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED EXAM;8
CCP010000014M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE, TYPICALLY 52
CCP010000014M99395PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, EST PT; 18-391
CCP010000014M99396PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, EST PT; 40-641
CCP010000014M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB FOCUS EX32
M Total796
CCP010000014PJ3301Injection, triamcinolone acetonide, per 10 mg1
CCP010000014PZ2AANTIHISTAMINES1
CCP010000014PS2BNSAIDS, CYCLOOXYGENASE INHIBITOR—TYPE157
CCP010000014PL9BVITAMIN A DERIVATIVES55
CCP010000014PH3AANALGESICS, NARCOTICS502
CCP010000014PZ2GIMMUNOMODULATORS28
P Total744
CCP010000014S11401EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L131
CCP010000014S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L113
CCP010000014S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M42
CCP010000014S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M48
CCP010000014S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE35
CCP010000014S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L39
CCP010000014S11420EXCISE BENIGN SKIN LESION W/MARG, EXCPT SKIN TAG SCALP/NECK/HANDS/FEET/34
CCP010000014S11422EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE12
CCP010000014S11442EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M9
CCP010000014S11307SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 1.1-2.012
CCP010000014S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 0.6-1.041
CCP010000014S11308SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER >2.0 CM7
CCP010000014S11303SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER >2.0 CM6
CCP010000014S11446EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11444EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11312SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME7
CCP010000014S11423EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE2
CCP010000014S11424EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE1
CCP010000014S11443EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11900INJECTION, INTRALESIONAL; UP TO & INCL 7 LESIONS2
CCP010000014S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L5
CCP010000014S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME22
CCP010000014S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION19
CCP010000014S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 0.5 CM/<22
CCP010000014S12032LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES; 2.6-7.5 CM1
CCP010000014S17003DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/CUTANEOUS VASC P31
CCP010000014S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM8
CCP010000014S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME15
CCP010000014S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<30
CCP010000014S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM77
CCP010000014S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION29
CCP010000014S17110DESTRUCTION, FLAT WARTS, MOLLUSCUM CONTAGIOSUM/MILIA; UP TO 14 LESIONS8
CCP010000014S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/CUTANEOUS VASC P7
S Total818
CCP010000014 Total3,057
ExpectedPractitioner
Provider IDcategoryservicesYour SvcsOther SvcsSvcsepisodesTotal CostsYour CostsOthers CostsExpected Costs
CCP010000014A883056387451.73939$19,902$19,685$217$13,969
CCP010000014AS063030.46939$148$148$0$19
CCP010000014AA464910.04939$73$73$0$3
CCP010000014A8830710.08939$68$68$0$6
CCP010000014A9300002.71939$79$0$79$22
CCP010000014AA455010.04939$49$49$0$2
CCP010000014A88312402.60939$64$64$0$42
CCP010000014A8664401.17939$14$0$14$2
CCP010000014A8677701.04939$8$0$8$0
CCP010000014A82947021.13939$8$0$8$3
CCP010000014A8614002.21939$6$0$6$1
CCP010000014A85025075.33939$21$0$21$16
CCP010000014A8000301.08939$5$0$5$0
CCP010000014A8000501.08939$5$0$5$0
CCP010000014A8204001.17939$5$0$5$1
CCP010000014A8005101.08939$4$0$4$0
CCP010000014A8565102.21939$4$0$4$0
CCP010000014A84450021.01939$6$0$6$3
CCP010000014A8256501.55939$5$0$5$2
CCP010000014A8573001.25939$3$0$3$1
CCP010000014A8565201.17939$2$0$2$0
CCP010000014A8501401.50939$2$0$2$1
CCP010000014A80053055.12939$25$0$25$26
CCP010000014A80048033.40939$9$0$9$11
CCP010000014A80050011.13939$14$0$14$16
CCP010000014A85027023.19939$4$0$4$7
CCP010000014A82270011.72939$2$0$2$6
CCP010000014A88304303.49939$45$45$0$53
CCP010000014A80061023.86939$16$0$16$31
A Total65148487.60$20,596$20,132$464$14,243
CCP010000014M992432523179.08939$33,762$33,384$378$23,109
CCP010000014M992032946.72939$4,725$4,241$484$712
CCP010000014M99242127290.97939$12,829$12,653$176$8,838
CCP010000014M9921326654286.18939$18,609$15,059$3,550$15,787
CCP010000014M992021504.16939$1,395$1,395$0$277
CCP010000014M99214174.91939$904$88$816$446
CCP010000014M9921102.46939$70$0$70$11
CCP010000014M9939501.76939$56$0$56$42
CCP010000014M99396012.10939$56$0$56$118
CCP010000014M9921223955.06939$1,328$912$416$2,159
M Total71383630.40$73,734$67,732$6,002$51,498
CCP010000014PJ330110.88939$25$25$0$9
CCP010000014PZ2A104.79939$5$5$0$10
CCP010000014PS2B20137164.00939$65$15$50$216
CCP010000014PL9B055144.47939$191$0$191$351
CCP010000014PH3A60442544.43939$483$83$400$699
CCP010000014PZ2G02885.51939$134$0$134$592
P Total82662944.08$903$128$775$1,876
CCP010000014S11401128340.57939$14,782$14,574$208$4,299
CCP010000014S11400113021.50939$10,270$10,270$0$2,004
CCP010000014S114414116.38939$6,485$6,337$148$943
CCP010000014S1144048011.47939$6,017$6,017$0$1,348
CCP010000014S114213505.12939$4,541$4,541$0$614
CCP010000014S1140239022.30939$6,600$6,600$0$3,057
CCP010000014S114203404.62939$2,950$2,950$0$413
CCP010000014S114221202.65939$2,034$2,034$0$377
CCP010000014S11442902.39939$1,912$1,912$0$411
CCP010000014S113071204.16939$1,106$1,106$0$378
CCP010000014S1130641034.94939$2,887$2,887$0$2,215
CCP010000014S1130870.46939$696$696$0$48
CCP010000014S11303601.34939$549$549$0$135
CCP010000014S1144610.04939$371$371$0$16
CCP010000014S1144410.08939$307$307$0$25
CCP010000014S11312704.96939$766$766$0$488
CCP010000014S1142320.97939$390$390$0$170
CCP010000014S1142410.25939$244$244$0$56
CCP010000014S1144310.63939$222$222$0$132
CCP010000014S1190020.97939$55$55$0$46
CCP010000014S11403505.00939$755$755$0$816
CCP010000014S1131021130.41939$1,435$1,365$70$1,798
CCP010000014S1110119026.71939$734$734$0$1,100
CCP010000014S1130522032.04939$850$850$0$1,270
CCP010000014S12032104.16939$223$223$0$906
CCP010000014S17003283305.24939$87$60$27$1,221
CCP010000014S113028023.90939$683$683$0$1,928
CCP010000014S1131115031.83939$1,233$1,233$0$2,500
CCP010000014S1130030068.71939$1,300$1,300$0$3,023
CCP010000014S11301770114.40939$4,307$4,307$0$7,074
CCP010000014S1110028174.34939$2,608$2,524$84$6,381
CCP010000014S1711080111.59939$507$507$0$6,256
CCP010000014S1700061185.80939$454$396$58$11,587
S Total808101179.94$78,360$77,765$595$63,034
CCP010000014 Total2,2548033242.02$173,593$165,757$7,836$130,651
Total CostsDifferenceepisodes this
Total Costper stratumper stratumYour costsOther costsSpec costsservice
Provider IDcategoryservicesDifferenceepisodesepisodesper svcper svcper svcoccurred
CCP010000014A88305$5,933$21$6$31$31$31349
CCP010000014AS0630$129$0$0$49$0$413
CCP010000014AA4649$70$0$0$73$0$731
CCP010000014A88307$62$0$0$68$0$681
CCP010000014A93000$57$0$0$0$40$312
CCP010000014AA4550$47$0$0$49$0$491
CCP010000014A88312$22$0$0$16$0$162
CCP010000014A86644$12$0$0$0$14$141
CCP010000014A86777$8$0$0$0$8$81
CCP010000014A82947$5$0$0$0$4$22
CCP010000014A86140$5$0$0$0$3$32
CCP010000014A85025$5$0$0$0$3$37
CCP010000014A80003$5$0$0$0$5$51
CCP010000014A80005$5$0$0$0$5$51
CCP010000014A82040$4$0$0$0$5$61
CCP010000014A80051$4$0$0$0$4$41
CCP010000014A85651$4$0$0$0$2$22
CCP010000014A84450$3$0$0$0$3$31
CCP010000014A82565$3$0$0$0$5$41
CCP010000014A85730$2$0$0$0$3$31
CCP010000014A85652$2$0$0$0$2$21
CCP010000014A85014$1$0$0$0$2$21
CCP010000014A80053($1)$0($0)$0$5$55
CCP010000014A80048($2)$0($0)$0$3$33
CCP010000014A80050($2)$0($0)$0$14$141
CCP010000014A85027($3)$0($0)$0$2$22
CCP010000014A82270($4)$0($0)$0$2$31
CCP010000014A88304($8)$0($0)$15$0$153
CCP010000014A80061($15)$0($0)$0$8$82
A Total$6,353$22$7
CCP010000014M99243$10,653$36$11$132$126$129254
CCP010000014M99203$4,013$5$4$146$121$10633
CCP010000014M99242$3,991$14$4$100$88$97129
CCP010000014M99213$2,822$20$3$57$66$55311
CCP010000014M99202$1,118$1$1$93$0$6715
CCP010000014M99214$458$1$0$88$117$918
CCP010000014M99211$59$0$0$0$35$242
CCP010000014M99395$14$0$0$0$56$561
CCP010000014M99396($62)$0($0)$0$56$561
CCP010000014M99212($831)$1($1)$40$46$3932
M Total$22,236$79$24
CCP010000014PJ3301$16$0$0$25$0$101
CCP010000014PZ2A($5)$0($0)$5$0$21
CCP010000014PS2B($151)$0($0)$1$0$16
CCP010000014PL9B($160)$0($0)$0$3$23
CCP010000014PH3A($216)$1($0)$1$1$135
CCP010000014PZ2G($458)$0($0)$0$5$71
P Total($973)$1($1)
CCP010000014S11401$10,483$16$11$114$69$106100
CCP010000014S11400$8,266$11$9$91$0$9390
CCP010000014S11441$5,542$7$6$155$148$14838
CCP010000014S11440$4,669$6$5$125$0$11838
CCP010000014S11421$3,927$5$4$130$0$12031
CCP010000014S11402$3,543$7$4$169$0$13738
CCP010000014S11420$2,537$3$3$87$0$8927
CCP010000014S11422$1,657$2$2$170$0$14312
CCP010000014S11442$1,501$2$2$212$0$1729
CCP010000014S11307$728$1$1$92$0$9110
CCP010000014S11306$672$3$1$70$0$6328
CCP010000014S11308$648$1$1$99$0$1037
CCP010000014S11303$414$1$0$92$0$1004
CCP010000014S11446$355$0$0$371$0$3711
CCP010000014S11444$282$0$0$307$0$2941
CCP010000014S11312$278$1$0$109$0$997
CCP010000014S11423$220$0$0$195$0$1752
CCP010000014S11424$188$0$0$244$0$2221
CCP010000014S11443$90$0$0$222$0$2101
CCP010000014S11900$9$0$0$28$0$472
CCP010000014S11403($61)$1($0)$151$0$1635
CCP010000014S11310($363)$2($0)$65$70$5917
CCP010000014S11101($366)$1($0)$39$0$4116
CCP010000014S11305($420)$1($0)$39$0$4014
CCP010000014S12032($683)$0($1)$223$0$2181
CCP010000014S17003($1,134)$0($1)$2$9$47
CCP010000014S11302($1,245)$1($1)$85$0$817
CCP010000014S11311($1,267)$1($1)$82$0$7912
CCP010000014S11300($1,723)$1($2)$43$0$4418
CCP010000014S11301($2,767)$5($3)$56$0$6248
CCP010000014S11100($3,773)$3($4)$90$84$8629
CCP010000014S17110($5,749)$1($6)$63$0$568
CCP010000014S17000($11,133)$0($12)$66$58$627
S Total$15,326$83$16
CCP010000014 Total$42,942$185$46
TABLE A11
Dermatology
Dates of Service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total role MPPT Meta Drilldown all etg's
Total
Provider IDcategoryservicesservice descriptionSvcs
CCP010000014A88305LEVEL IV—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM762
CCP010000014ACLClinic/TreatmDermatology/Testing28
CCP010000014AASAmbulatory Surgery2
CCP010000014A93000ELECTROCARDIOGRAM, ROUTINE W/AT LEAST 12 LEADS; W/INTERPRETATION & REPO7
CCP010000014A82627DEHYDROEPIANDROSTERONE-SULFATE (DHEA-S)12
CCP010000014A00300ANESTHESIA, HEAD, NECK, POST TRUNK INTEGUMENTARY, MUSCLES/NERVES1
CCP010000014A84402TESTOSTERONE; FREE8
CCP010000014AS0630Removal of sutures by a physician other than the physician who originall3
CCP010000014A83550IRON BINDING CAPACITY21
CCP010000014A88312SPECIAL STAINS; GROUP I, MICROORGANISMS, EACH27
CCP010000014A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY NUMBER22
CCP010000014A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY NUMBER44
CCP010000014A86376MICROSOMAL ANTIBODIES, EACH8
CCP010000014A84443THYROID STIMULATING HORMONE (TSH)34
CCP010000014A86038ANTINUCLEAR ANTIBODIES (ANA)26
CCP010000014AEREmergency6
CCP010000014AA4550Surgical trays2
CCP010000014A93017CARDIOVASCULAR STRESS TEST W/ECG MONITOR; TRACING ONLY, W/O INTERPRETAT1
CCP010000014A84403TESTOSTERONE; TOTAL9
CCP010000014A80053COMPREHENSIVE METABOLIC PANEL41
CCP010000014A85652SEDIMENTATION RATE, ERYTHROCYTE; AUTOMATED38
CCP010000014A87101CULTURE, FUNGI (MOLD/YEAST) ISOLATION, W/PRESUMPTIVE ID OF ISOLATES; SK24
CCP010000014A88307LEVEL V—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM1
CCP010000014AA4649Surgical supply; miscellaneous1
CCP010000014A86235EXTRACTABLE NUCLEAR ANTIGEN, ANTIBODY TO, ANY METHOD, EACH ANTIBODY19
CCP010000014A86618ANTIBODY; BORRELIA BURGDORFERI (LYME DISEASE)5
CCP010000014A83540IRON22
CCP010000014A80076HEPATIC FUNCTION PANEL24
CCP010000014A86644ANTIBODY; CYTOMEGALOVIRUS (CMV)3
CCP010000014A83735MAGNESIUM7
CCP010000014A80050GENERAL HEALTH PANEL9
CCP010000014A83498HYDROXYPROGESTERONE, 17-D3
CCP010000014A86665ANTIBODY; EPSTEIN-BARR (EB) VIRUS, VIRAL CAPSID (VCA)4
CCP010000014A86617ANTIBODY; BORRELIA BURGDORFERI (LYME DISEASE) CONFIRMATORY TEST1
CCP010000014A86039ANTINUCLEAR ANTIBODIES (ANA); TITER5
CCP010000014A93005ELECTROCARDIOGRAM, ROUTINE W/AT LEAST 12 LEADS; TRACING ONLY W/O INTER1
CCP010000014A82550CREATINE KINASE (CK), (CPK); TOTAL7
CCP010000014A87620INFECTIOUS AGENT, NUCLEIC ACID (DNA/RNA); HUMAN PAPILLOMAVIRUS, DIRECT1
CCP010000014A86431RHEUMATOID FACTOR; QUANTITATIVE5
CCP010000014A850211
CCP010000014A86580SKIN TEST; TUBERCULOSIS, INTRADERMAL2
CCP010000014A87107CULTURE, FUNGI, DEFINITIVE ID, EACH ORGANISM; MOLD2
CCP010000014A93010ELECTROCARDIOGRAM, ROUTINE W/AT LEAST 12 LEADS; INTERPRETATION & REPORT1
CCP010000014A86777ANTIBODY; TOXOPLASMA1
CCP010000014A850233
CCP010000014A82728FERRITIN4
CCP010000014A82947GLUCOSE; QUANTITATIVE, BLOOD (EXCEPT REAGENT STRIP)6
CCP010000014A800051
CCP010000014A84450TRANSFERASE; ASPARTATE AMINO (AST) (SGOT)6
CCP010000014A86787ANTIBODY; VARICELLA-ZOSTER1
CCP010000014A85014BLOOD COUNT; HEMATOCRIT3
CCP010000014A86140C-REACTIVE PROTEIN2
CCP010000014A83036HEMOGLOBIN; GLYCATED3
CCP010000014A86765ANTIBODY; RUBEOLA1
CCP010000014A85651SEDIMENTATION RATE, ERYTHROCYTE; NON-AUTOMATED9
CCP010000014A85008BLOOD COUNT; BLOOD SMEAR, MICROSCOP EXAM W/O MANUAL DIFFERENTIAL1
WBC CO
CCP010000014A800031
CCP010000014A85730THROMBOPLASTIN TIME, PARTIAL (PTT); PLASMA/WHOLE BLOOD2
CCP010000014A82950GLUCOSE; POST GLUCOSE DOSE (INCLUDES GLUCOSE)1
CCP010000014A80051ELECTROLYTE PANEL1
CCP010000014A87206SMEAR, PRIME SRCE, W/INTERPR; FLUORESC &/OR ACID FAST STAIN, BACTERIA/F1
CCP010000014A81050VOLUME MEASUREMENT, TIMED COLLECTION, EACH1
CCP010000014A83002GONADOTROPIN; LUTEINIZING HORMONE (LH)1
CCP010000014A84146PROLACTIN1
CCP010000014A85025BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, WBC, & PLATELET) &46
CCP010000014A86308HETEROPHILE ANTIBODIES; SCREENING1
CCP010000014A81003URINALYSIS, DIP STICK/TABLET REAGENT; AUTOMATED, W/O MICROSCOPY1
CCP010000014A84478TRIGLYCERIDES10
CCP010000014A81000URINALYSIS, DIP STICK/TABLET REAGENT; NON-AUTOMATED W/MICROSCOPY2
CCP010000014A81002URINALYSIS, DIP STICK/TABLET REAGENT; NON-AUTOMATED, W/O MICROSCOPY3
CCP010000014A83615LACTATE DEHYDROGENASE (LD), (LDH)2
CCP010000014A87210SMEAR, PRIMARY SOURCE W/INTERPRETATION; WET MOUNT, FOR INFECTIOUS AGENT27
CCP010000014A84436THYROXINE; TOTAL1
CCP010000014A82565CREATININE; BLOOD1
CCP010000014A81001URINALYSIS, DIP STICK/TABLET REAGENT; AUTOMATED W/O MICROSCOPY1
CCP010000014A83001GONADOTROPIN; FOLLICLE STIMULATING HORMONE (FSH)1
CCP010000014A87081CULTURE, PRESUMPTIVE, PATHOGENIC ORGANISMS, SCREENING ONLY5
CCP010000014A86162COMPLEMENT; TOTAL HEMOLYTIC (CH50)1
CCP010000014A82248BILIRUBIN; DIRECT1
CCP010000014A82270BLOOD, OCCULT, BY PEROXIDASE ACTIVITY, QUALITATIVE; FECES, 1-3 SIMULTAN2
CCP010000014A85027BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, WBC, & PLATELET)15
CCP010000014A82040ALBUMIN; SERUM2
CCP010000014A80048BASIC METABOLIC PANEL9
CCP010000014A87106CULTURE, FUNGI, DEFINITIVE ID, EACH ORGANISM; YEAST2
CCP010000014A87186SUSCEPT STUDIES, ANTIMICROB AGNT; MICRODILUT/AGAR DILUT (MIC/BRKPNT), E3
CCP010000014A80061LIPID PANEL15
CCP010000014A84439THYROXINE; FREE2
CCP010000014A86225DEOXYRIBONUCLEIC ACID (DNA) ANTIBODY; NATIVE/DOUBLE STRANDED2
CCP010000014A84460TRANSFERASE; ALANINE AMINO (ALT) (SGPT)1
CCP010000014A86160COMPLEMENT; ANTIGEN, EACH COMPONENT1
CCP010000014A87252VIRUS ISOLATION; TISSUE CULTURE INOCULATION, OBSERVATION & PRESUMPTIVE2
CCP010000014A87070CULTURE, BACTERIAL; ANY OTHER SOURCE EXCEPT URINE/BLOOD/STOOL, AEROBIC,12
CCP010000014A88304LEVEL III—SURGICAL PATHOLOGY, GROSS & MICROSCOPIC EXAM13
CCP010000014A95044PATCH/APPLICATION TEST(S) (SPECIFY NUMBER)216
A Total1,700
CCP010000014M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED EXAM; MED671
CCP010000014M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; EXPAND PROB1,565
CCP010000014M99203OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: DETAILED HX; DETAILED EXAM;77
CCP010000014M99202OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; EXPAND40
CCP010000014M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED EXAM;36
CCP010000014M96910PHOTOCHEMOTHERAPY; TAR & UVB/PETROLATUM & UVB23
CCP010000014M99245OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX; COMPREHENSIVE E1
CCP010000014M99385INITIAL COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, NEW PT; 18-393
CCP010000014M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE, TYPICALLY 54
CCP010000014M99215OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: COMPREHENSIVE HX; COMPREHENSIV2
CCP010000014M99204OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: COMPREHENSIVE HX; COMPREHENSIV2
CCP010000014M99201OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: PROB FOCUS HX; PROB FOCUS EX1
CCP010000014M99386INITIAL COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, NEW PT; 40-641
CCP010000014M99395PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, EST PT; 18-393
CCP010000014M99396PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, EST PT; 40-645
CCP010000014M99394PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM, EST PT; 12-171
CCP010000014M92012OPHTHALMOLOGICAL MEDICAL EXAM & EVAL; INTERMEDIATE, ESTABLISHED2
PATIENT
CCP010000014M99241OFFICE CONSULTATION, 3 KEY COMPONENTS: PROB FOCUS HX; PROB FOCUS EXAM;2
CCP010000014M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; EXPAND PROB274
CCP010000014M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB FOCUS EX172
M Total2,885
CCP010000014PQ5PTOPICAL ANTI-INFLAMMATORY STEROIDAL12,473
CCP010000014PW1DMACROLIDES3,320
CCP010000014PZ2EIMMUNOSUPPRESSIVES150
CCP010000014PJ3301Injection, triamcinolone acetonide, per 10 mg27
CCP010000014PQ5HTOPICAL LOCAL ANESTHETICS390
CCP010000014PP4LBONE RESORPTION INHIBITORS360
CCP010000014PQ5WTOPICAL ANTIBIOTICS4,872
CCP010000014PH3DANALGESIC/ANTIPYRETICS, SALICYLATES98
CCP010000014PW1QQUINOLONES28
CCP010000014PQ8FOTIC PREPARATIONS, ANTI-INFLAMMATORY-ANTIBIOTICS5
CCP010000014PQ4Fvagin*L ANTIFUNGALS17
CCP010000014PW1WCEPHALOSPORINS—1ST GENERATION1,011
CCP010000014PJ1030Injection, methylprednisolone acetate, 40 mg4
CCP010000014PW3AANTIFUNGAL ANTIBIOTICS30
CCP010000014PL5GROSACEA AGENTS, TOPICAL1,839
CCP010000014PJ9AINTESTINAL MOTILITY STIMULANTS51
CCP010000014PJ9260Methotrexate sodium, 50 mg1
CCP010000014PH2UTRICYCLIC ANTIDEPRESSANTS & REL. NON-SEL. RU-INHIB360
CCP010000014PH4BANTICONVULSANTS338
CCP010000014PQ5RTOPICAL ANTIPARASITICS20
CCP010000014PH6JANTIEMETIC/ANTIVERTIGO AGENTS20
CCP010000014PQ8WEAR PREPARATIONS, ANTIBIOTICS5
CCP010000014PS2ACOLCHICINE60
CCP010000014PH0ALOCAL ANESTHETICS5
CCP010000014PD1APERIODONTAL COLLAGENASE INHIBITORS30
CCP010000014PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS255
CCP010000014PU6WBULK CHEMICALS30
CCP010000014PJ5FANAPHYLAXIS THERAPY AGENTS21
CCP010000014PS2BNSAIDS, CYCLOOXYGENASE INHIBITOR—TYPE2,954
CCP010000014PL3PANTIPRURITICS, TOPICAL20
CCP010000014PH3AANALGESICS, NARCOTICS994
CCP010000014PW4EANAEROBIC ANTIPROTOZOAL-ANTIBACTERIAL AGENTS45
CCP010000014PP5AGLUCOCORTICOIDS632
CCP010000014P  015
CCP010000014PW1APENICILLINS1,289
CCP010000014PW3BANTIFUNGAL AGENTS473
CCP010000014PV1BANTIMETABOLITES277
CCP010000014PL5EANTISEBORRHEIC AGENTS60
CCP010000014PW1KLINCOSAMIDES52
CCP010000014PZ2AANTIHISTAMINES5,696
CCP010000014PR1HPOTASSIUM SPARING DIURETICS30
CCP010000014PL2AEMOLLIENTS110
CCP010000014PCLClinic/TreatmDermatology/Testing1
CCP010000014PL9ATOPICAL AGENTS, MISCELLANEOUS30
CCP010000014PW5AANTIVIRALS, GENERAL353
CCP010000014PQ5FTOPICAL ANTIFUNGALS2,015
CCP010000014PL1BACNE AGENTS, SYSTEMIC90
CCP010000014PQ5STOPICAL SULFONAMIDES245
CCP010000014PL5AKERATOLYTICS202
CCP010000014PQ5KTOPICAL IMMUNOSUPPRESSIVE AGENTS1,041
CCP010000014PZ2GIMMUNOMODULATORS70
CCP010000014PW1CTETRACYCLINES18,225
CCP010000014PL9BVITAMIN A DERIVATIVES1,010
CCP010000014PL5HACNE AGENTS, TOPICAL240
CCP010000014PL5FANTIPSORIATICS AGENTS310
P Total62,299
CCP010000014R73630RADIOLOGIC EXAM, FOOT; COMPLETE, 3+ VIEWS3
CCP010000014R73130RADIOLOGIC EXAM, HAND; 3+ VIEWS2
R Total5
CCP010000014S11400EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L124
CCP010000014S11441EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M46
CCP010000014S11440EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M50
CCP010000014S11402EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L88
CCP010000014S11421EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE35
CCP010000014S11420EXCISE BENIGN SKIN LESION W/MARG, EXCPT SKIN TAG SCALP/NECK/HANDS/FEET/36
CCP010000014S11442EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M11
CCP010000014S11422EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE14
CCP010000014S11641EXCISION, MALIGNANT LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M8
CCP010000014S11306SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 0.6-1.044
CCP010000014S11643EXCISION, MALIGNANT LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M3
CCP010000014S14040ADJACENT TISSUE TRANSFER, FOREHEAD/CHEEKS/CHIN/MOUTH/NECK/AXILLAE/2
GENIT
CCP010000014S11308SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER >2.0 CM7
CCP010000014S11307SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 1.1-2.012
CCP010000014S11603EXCISION, MALIGNANT LESION, INCL MARGINS, TRUNK/ARMS/LEGS; EXCISED DIAM4
CCP010000014S11303SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER >2.0 CM6
CCP010000014S11644EXCISION, MALIGNANT LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11446EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11622EXCISION, MALIGNANT LESION, INCL MARGINS, SCALP/NECK/HANDS/FEET/GENITAL2
CCP010000014S11444EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S14020ADJACENT TISSUE TRANSFER/REARRANGEMENT, SCALP, ARMS &/OR LEGS; DEFECT 11
CCP010000014S11770EXCISION, PILONIDAL CYST/SINUS; SIMPLE1
CCP010000014S13132REPAIR, COMPLEX, FOREHEAD/CHEEKS/CHIN/MOUTH/NECK/AXILLAE/GENITALIA/HAND1
CCP010000014S11312SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME7
CCP010000014S17110DESTRUCTION, FLAT WARTS, MOLLUSCUM CONTAGIOSUM/MILIA; UP TO 14 LESIONS250
CCP010000014S11623EXCISION, MALIGNANT LESION, INCL MARGINS, SCALP/NECK/HANDS/FEET/GENITAL1
CCP010000014S11424EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE1
CCP010000014S11621EXCISION, MALIGNANT LESION, INCL MARGINS, SCALP/NECK/HANDS/FEET/GENITAL2
CCP010000014S11730AVULSION, NAIL PLATE, PARTIAL/COMPLETE, SIMPLE; SINGLE3
CCP010000014S11900INJECTION, INTRALESIONAL; UP TO & INCL 7 LESIONS35
CCP010000014S11640EXCISION, MALIGNANT LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S56605BX, VULVA/PERINEUM (SEP PROC); 1 LESION1
CCP010000014S11732AVULSION, NAIL PLATE, PARTIAL/COMPLETE, SIMPLE; ADD'L NAIL PLATE2
CCP010000014S20550INJECTION(S); SINGLE TENDON SHEATH, LIGAMENT, APONEUROSIS1
CCP010000014S11443EXCISE, BENIGN SKIN LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11423EXCISE BEN SKIN LESION W/MARG, EXCEPT SKIN TAG SCALP/NECK/HANDS/FEET/GE2
CCP010000014S11601EXCISION, MALIGNANT LESION, INCL MARGINS, TRUNK/ARMS/LEGS; EXCISED DIAM1
CCP010000014S11602EXCISION, MALIGNANT LESION, INCL MARGINS, TRUNK/ARMS/LEGS; EXCISED DIAM3
CCP010000014S10060INCISION & DRAINAGE, ABSCESS; SIMPLE/SINGLE5
CCP010000014S11642EXCISION, MALIGNANT LESION, INCL MARGINS, FACE/EARS/EYELIDS/NOSE/LIPS/M1
CCP010000014S11403EXCISE, BENIGN SKIN LESION, INCL MARGINS, EXCEPT SKIN TAG, TRUNK/ARMS/L5
CCP010000014S17111DESTRUCTION, FLAT WARTS, MOLLUSCUM CONTAGIOSUM/MILIA; 15 +2
CCP010000014S11310SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME23
CCP010000014S11305SHAVING SKIN LESION, SCALP/NECK/HANDS/FEET/GENITALIA; DIAMETER 0.5 CM/<22
CCP010000014S11101BX, SKIN, SUBQ/MUCOUS MEMBRANE (SEP PROC); ADD'L LESION22
CCP010000014S12032LAYER CLOSURE, WOUNDS, SCALP/AXILLAE/TRUNK/EXTREMITIES; 2.6-7.5 CM1
CCP010000014S11901INJECTION, INTRALESIONAL; >7 LESIONS4
CCP010000014S11302SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 1.1-2.0 CM8
CCP010000014S11311SHAVING SKIN LESION, FACE/EARS/EYELIDS/NOSE/LIPS/MUCOUS MEMBRANE; DIAME16
CCP010000014S11300SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.5 CM/<31
CCP010000014S17003DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/CUTANEOUS VASC P245
CCP010000014S17304CHEMOSURGERY (MOHS MICROGRAPHIC TECHNIQUE); 1ST STAGE, FRESH TISSUE, TO1
CCP010000014S11301SHAVING SKIN LESION, TRUNK/ARMS/LEGS; DIAMETER 0.6-1.0 CM80
CCP010000014S11100BX, SKIN, SUBQ/MUCOUS MEMBRANE; SINGLE LESION35
CCP010000014S17000DESTRUCTION, BENIGN/PREMALIG LESIONS, EXCEPT SKIN TAGS/CUTANEOUS VASC P47
S Total1,493
CCP010000014T 0421PHYSICAL THEAPY VISIT CHARGE3
T Total3
CCP010000014 Total68,385
ExpectedPractitioner
Provider IDcategoryservicesYour SvcsOther SvcsSvcsepisodesTotal CostsYour CostsOthers CostsExpected Costs
CCP010000014A8830574814509.992,540$23,516$23,083$433$15,764
CCP010000014ACL26216.332,540$1,221$543$678$580
CCP010000014AAS021.942,540$1,198$0$1,198$755
CCP010000014A93000073.882,540$311$0$311$115
CCP010000014A82627483.602,540$264$88$176$79
CCP010000014A0030001.452,540$360$0$360$178
CCP010000014A84402262.872,540$224$56$168$81
CCP010000014AS063030.552,540$148$148$0$21
CCP010000014A835508134.152,540$147$56$91$29
CCP010000014A8831226119.652,540$432$416$16$315
CCP010000014A950240222.112,540$125$0$125$13
CCP010000014A9500404412.592,540$166$0$166$54
CCP010000014A86376441.002,540$128$64$64$16
CCP010000014A84443142018.032,540$238$98$140$128
CCP010000014A8603862013.872,540$208$48$160$112
CCP010000014AER336.892,540$1,048$435$613$953
CCP010000014AA455011.072,540$98$49$49$3
CCP010000014A9301701.072,540$93$0$93$7
CCP010000014A84403274.982,540$180$40$140$104
CCP010000014A80053132826.642,540$205$65$140$134
CCP010000014A8565216225.162,540$76$32$44$11
CCP010000014A8710171715.952,540$191$56$135$127
CCP010000014A8830710.102,540$68$68$0$7
CCP010000014AA464910.072,540$73$73$0$13
CCP010000014A8623581111.242,540$141$60$81$81
CCP010000014A86618141.252,540$60$12$48$15
CCP010000014A835408148.302,540$66$24$42$25
CCP010000014A8007681611.492,540$72$24$48$34
CCP010000014A8664403.352,540$42$0$42$5
CCP010000014A83735071.042,540$35$0$35$5
CCP010000014A80050276.682,540$126$28$98$97
CCP010000014A83498031.212,540$48$0$48$19
CCP010000014A8666504.692,540$32$0$32$6
CCP010000014A8661701.242,540$32$0$32$8
CCP010000014A86039232.392,540$45$18$27$21
CCP010000014A9300510.732,540$54$54$0$38
CCP010000014A82550073.882,540$28$0$28$16
CCP010000014A8762001.032,540$12$0$12$0
CCP010000014A86431142.182,540$20$4$16$9
CCP010000014A8502110.072,540$11$11$0$0
CCP010000014A8658002.932,540$18$0$18$8
CCP010000014A8710702.282,540$10$0$10$1
CCP010000014A93010101.252,540$31$31$0$23
CCP010000014A8677701.102,540$8$0$8$1
CCP010000014A8502303.662,540$9$0$9$2
CCP010000014A82728043.182,540$32$0$32$25
CCP010000014A82947154.642,540$16$2$14$10
CCP010000014A8000501.212,540$5$0$5$1
CCP010000014A84450064.292,540$20$0$20$16
CCP010000014A8678701.622,540$10$0$10$6
CCP010000014A85014122.112,540$9$5$4$5
CCP010000014A8614002.862,540$6$0$6$3
CCP010000014A83036032.392,540$15$0$15$12
CCP010000014A8676501.802,540$15$0$15$12
CCP010000014A85651457.302,540$18$8$10$16
CCP010000014A8500801.032,540$2$0$2$0
CCP010000014A8000301.622,540$5$0$5$3
CCP010000014A85730021.382,540$6$0$6$4
CCP010000014A8295001.212,540$2$0$2$0
CCP010000014A8005101.622,540$4$0$4$2
CCP010000014A8720601.762,540$5$0$5$4
CCP010000014A8105001.522,540$2$0$2$1
CCP010000014A8300201.932,540$12$0$12$11
CCP010000014A8414601.972,540$11$0$11$11
CCP010000014A85025123444.912,540$138$36$102$138
CCP010000014A8630801.592,540$4$0$4$4
CCP010000014A81003011.562,540$1$0$1$2
CCP010000014A844784610.212,540$30$12$18$31
CCP010000014A81000113.252,540$16$6$10$17
CCP010000014A81002213.702,540$12$8$4$14
CCP010000014A83615022.422,540$6$0$6$9
CCP010000014A8721027029.822,540$201$201$0$205
CCP010000014A84436101.762,540$4$4$0$8
CCP010000014A82565012.152,540$5$0$5$9
CCP010000014A81001013.222,540$2$0$2$6
CCP010000014A83001011.562,540$8$0$8$12
CCP010000014A87081056.122,540$20$0$20$25
CCP010000014A86162101.382,540$15$15$0$21
CCP010000014A82248014.222,540$2$0$2$9
CCP010000014A82270023.492,540$4$0$4$11
CCP010000014A8502731218.722,540$30$6$24$39
CCP010000014A82040023.812,540$10$0$10$21
CCP010000014A800480912.112,540$27$0$27$38
CCP010000014A87106204.912,540$8$8$0$20
CCP010000014A87186125.472,540$15$5$10$28
CCP010000014A8006121317.162,540$120$16$104$137
CCP010000014A84439114.502,540$16$8$8$36
CCP010000014A86225023.742,540$24$0$24$45
CCP010000014A84460016.572,540$5$0$5$26
CCP010000014A86160012.732,540$13$0$13$35
CCP010000014A87252113.742,540$30$15$15$56
CCP010000014A8707021017.582,540$74$12$62$111
CCP010000014A8830412118.032,540$198$183$15$272
CCP010000014A950442160437.812,540$1,722$1,722$0$3,460
A Total1,2124881435.61$34,573$27,956$6,617$25,003
CCP010000014M9924365318456.362,540$88,094$85,793$2,301$58,791
CCP010000014M992131,2822831434.122,540$92,196$73,944$18,252$78,728
CCP010000014M99203641319.272,540$10,618$9,211$1,407$1,958
CCP010000014M9920239118.582,540$3,687$3,618$69$1,183
CCP010000014M9921413529.132,540$3,458$88$3,370$2,578
CCP010000014M9691023012.352,540$1,255$1,255$0$637
CCP010000014M9924501.482,540$239$0$239$110
CCP010000014M9938503.762,540$168$0$168$43
CCP010000014M99211042.942,540$140$0$140$67
CCP010000014M99215021.492,540$259$0$259$189
CCP010000014M99204021.632,540$294$0$294$235
CCP010000014M9920101.282,540$61$0$61$11
CCP010000014M9938601.352,540$56$0$56$19
CCP010000014M99395032.842,540$168$0$168$159
CCP010000014M99396055.022,540$280$0$280$281
CCP010000014M99394011.252,540$56$0$56$70
CCP010000014M92012021.002,540$20$0$20$43
CCP010000014M992410212.522,540$126$0$126$665
CCP010000014M992422659293.292,540$27,510$26,602$908$28,438
CCP010000014M9921211854329.102,540$7,450$5,009$2,441$12,820
M Total2,4454402622.76$236,135$205,520$30,615$187,026
CCP010000014PQ5P10,8811,59210633.522,540$33,903$32,099$1,804$22,958
CCP010000014PW1D2,9154051519.472,540$7,180$6,449$731$2,298
CCP010000014PZ2E150092.832,540$1,024$1,024$0$356
CCP010000014PJ330127023.322,540$672$672$0$177
CCP010000014PQ5H31575252.952,540$1,153$783$370$757
CCP010000014PP4L90270208.602,540$824$201$623$462
CCP010000014PQ5W4,2775954063.452,540$5,507$4,650$857$5,255
CCP010000014PH3D09832.902,540$194$0$194$49
CCP010000014PW1Q28016.092,540$276$276$0$152
CCP010000014PQ8F05.212,540$73$0$73$5
CCP010000014PQ4F314.862,540$68$37$31$5
CCP010000014PW1W91299590.982,540$645$450$195$595
CCP010000014PJ103040.482,540$32$32$0$6
CCP010000014PW3A30088.052,540$224$224$0$199
CCP010000014PL5G1,6801591932.062,540$5,162$4,643$519$5,142
CCP010000014PJ9A05121.042,540$25$0$25$8
CCP010000014PJ926010.382,540$15$15$0$2
CCP010000014PH2U30330202.712,540$48$5$43$36
CCP010000014PH4B0338153.762,540$102$0$102$91
CCP010000014PQ5R20037.162,540$159$159$0$151
CCP010000014PH6J61424.322,540$104$75$29$108
CCP010000014PQ8W058.622,540$18$0$18$25
CCP010000014PS2A06081.652,540$10$0$10$23
CCP010000014PH0A0523.732,540$16$0$16$33
CCP010000014PD1A30047.052,540$65$65$0$100
CCP010000014PZ4B90165245.962,540$622$201$421$662
CCP010000014PU6W30058.922,540$16$16$0$62
CCP010000014PJ5F21022.802,540$181$181$0$234
CCP010000014PS2B3962,5582552.632,540$4,147$646$3,501$4,206
CCP010000014PL3P20044.742,540$72$72$0$135
CCP010000014PH3A287707867.532,540$1,068$450$618$1,136
CCP010000014PW4E2223110.612,540$31$15$16$104
CCP010000014PP5A405227663.782,540$281$97$184$355
CCP010000014P  015070.102,540$48$48$0$186
CCP010000014PW1A9113781254.692,540$1,343$632$711$1,483
CCP010000014PW3B44033265.962,540$1,191$1,122$69$1,339
CCP010000014PV1B18988397.092,540$251$215$36$400
CCP010000014PL5E060175.042,540$16$0$16$247
CCP010000014PW1K421097.572,540$220$194$26$475
CCP010000014PZ2A3,0042,6926474.402,540$11,822$6,103$5,719$12,298
CCP010000014PR1H030458.542,540$18$0$18$552
CCP010000014PL2A0110494.802,540$168$0$168$723
CCP010000014PCL1016.332,540$7$7$0$580
CCP010000014PL9A030388.752,540$84$0$84$975
CCP010000014PW5A33617475.662,540$946$721$225$2,237
CCP010000014PQ5F1,4715442635.632,540$3,772$2,899$873$5,211
CCP010000014PL1B900220.982,540$829$829$0$3,145
CCP010000014PQ5S24501525.672,540$507$507$0$3,118
CCP010000014PL5A901121990.612,540$167$72$95$3,311
CCP010000014PQ5K8312101927.362,540$4,333$3,669$664$8,103
CCP010000014PZ2G070608.802,540$564$0$564$4,562
CCP010000014PW1C16,8561,36918512.142,540$21,875$20,225$1,650$28,915
CCP010000014PL9B8052054351.762,540$3,079$2,548$531$12,860
CCP010000014PL5H851553074.002,540$592$201$391$10,413
CCP010000014PL5F1301802401.952,540$1,495$665$830$11,897
P Total48,21114,08872441.02$117,244$94,194$23,050$158,917
CCP010000014R7363003.552,540$90$0$90$14
CCP010000014R7313002.352,540$62$0$62$9
R Total05.90$152$0$152$23
CCP010000014S11401133338.062,540$15,321$15,113$208$4,022
CCP010000014S11400123120.592,540$11,236$11,130$106$1,914
CCP010000014S114414517.162,540$7,057$6,909$148$1,042
CCP010000014S1144050012.462,540$6,222$6,222$0$1,458
CCP010000014S1140288024.392,540$7,823$7,823$0$3,155
CCP010000014S114213506.682,540$4,541$4,541$0$771
CCP010000014S114203605.052,540$3,087$3,087$0$443
CCP010000014S114421013.772,540$2,277$2,094$183$624
CCP010000014S114221406.022,540$2,280$2,280$0$820
CCP010000014S11641801.312,540$1,549$1,549$0$259
CCP010000014S1130644035.192,540$3,015$3,015$0$2,244
CCP010000014S1164330.592,540$839$839$0$175
CCP010000014S1404002.592,540$1,008$0$1,008$372
CCP010000014S11308701.112,540$696$696$0$119
CCP010000014S113071206.822,540$1,106$1,106$0$587
CCP010000014S11603401.802,540$749$749$0$290
CCP010000014S11303601.312,540$549$549$0$132
CCP010000014S1164410.032,540$392$392$0$14
CCP010000014S1144610.032,540$371$371$0$13
CCP010000014S1162220.762,540$434$434$0$131
CCP010000014S1144410.102,540$307$307$0$30
CCP010000014S1402001.072,540$306$0$306$32
CCP010000014S1177001.032,540$229$0$229$8
CCP010000014S1313201.622,540$447$0$447$242
CCP010000014S11312705.712,540$766$766$0$561
CCP010000014S1711023911284.372,540$15,800$15,183$617$15,602
CCP010000014S1162310.212,540$244$244$0$47
CCP010000014S1142410.352,540$244$244$0$73
CCP010000014S1162120.382,540$188$188$0$54
CCP010000014S11730031.282,540$231$0$231$101
CCP010000014S1190035020.142,540$1,075$1,075$0$956
CCP010000014S1164010.382,540$167$167$0$62
CCP010000014S5660501.482,540$125$0$125$44
CCP010000014S1173202.242,540$68$0$68$9
CCP010000014S2055001.382,540$57$0$57$25
CCP010000014S1144310.932,540$222$222$0$199
CCP010000014S11423202.182,540$390$390$0$371
CCP010000014S1160110.862,540$91$91$0$128
CCP010000014S11602303.602,540$491$491$0$542
CCP010000014S10060329.132,540$815$396$419$933
CCP010000014S11642101.492,540$245$245$0$367
CCP010000014S11403506.782,540$755$755$0$1,115
CCP010000014S17111029.062,540$88$0$88$454
CCP010000014S1131022131.212,540$1,474$1,404$70$1,875
CCP010000014S1130522033.112,540$850$850$0$1,315
CCP010000014S1110122033.422,540$871$871$0$1,360
CCP010000014S12032105.712,540$223$223$0$1,197
CCP010000014S119014017.992,540$195$195$0$1,180
CCP010000014S113028024.572,540$683$683$0$1,978
CCP010000014S1131116033.322,540$1,328$1,328$0$2,660
CCP010000014S1130031063.182,540$1,331$1,331$0$2,783
CCP010000014S170032423688.832,540$1,018$991$27$2,706
CCP010000014S17304014.502,540$649$0$649$2,820
CCP010000014S11301800107.502,540$4,469$4,469$0$6,709
CCP010000014S11100332115.352,540$3,220$3,053$167$9,826
CCP010000014S17000443454.902,540$3,145$2,955$190$28,738
S Total1,450432136.09$113,359$108,016$5,343$105,691
CCP010000014T 042130.452,540$375$375$0$42
T Total30.45$375$375$0$42
CCP010000014 Total53,32115,06478636.83$501,838$436,061$65,777$476,702
Total CostsDifferenceepisodes this
Total Costper stratumper stratumYour costsOther costsSpec costsservice
Provider IDcategoryservicesDifferenceepisodesepisodesper svcper svcper svcoccurred
CCP010000014A88305$7,752$9$3$31$31$31414
CCP010000014ACL$641$0$0$21$339$369
CCP010000014AAS$443$0$0$0$599$3902
CCP010000014A93000$196$0$0$0$44$307
CCP010000014A82627$185$0$0$22$22$2211
CCP010000014A00300$182$0$0$0$360$3961
CCP010000014A84402$143$0$0$28$28$288
CCP010000014AS0630$127$0$0$49$0$383
CCP010000014A83550$118$0$0$7$7$721
CCP010000014A88312$117$0$0$16$16$1615
CCP010000014A95024$112$0$0$0$6$61
CCP010000014A95004$112$0$0$0$4$41
CCP010000014A86376$112$0$0$16$16$168
CCP010000014A84443$110$0$0$7$7$734
CCP010000014A86038$96$0$0$8$8$826
CCP010000014AER$95$0$0$145$204$1386
CCP010000014AA4550$95$0$0$49$49$492
CCP010000014A93017$86$0$0$0$93$1001
CCP010000014A84403$76$0$0$20$20$219
CCP010000014A80053$71$0$0$5$5$531
CCP010000014A85652$65$0$0$2$2$238
CCP010000014A87101$64$0$0$8$8$822
CCP010000014A88307$61$0$0$68$0$681
CCP010000014AA4649$60$0$0$73$0$1871
CCP010000014A86235$60$0$0$8$7$79
CCP010000014A86618$45$0$0$12$12$125
CCP010000014A83540$41$0$0$3$3$322
CCP010000014A80076$38$0$0$3$3$322
CCP010000014A86644$37$0$0$0$14$143
CCP010000014A83735$30$0$0$0$5$53
CCP010000014A80050$29$0$0$14$14$159
CCP010000014A83498$29$0$0$0$16$163
CCP010000014A86665$26$0$0$0$8$81
CCP010000014A86617$24$0$0$0$32$321
CCP010000014A86039$24$0$0$9$9$95
CCP010000014A93005$16$0$0$54$0$521
CCP010000014A82550$12$0$0$0$4$44
CCP010000014A87620$12$0$0$0$12$121
CCP010000014A86431$11$0$0$4$4$45
CCP010000014A85021$11$0$0$11$0$71
CCP010000014A86580$10$0$0$0$9$92
CCP010000014A87107$9$0$0$0$5$52
CCP010000014A93010$8$0$0$31$0$181
CCP010000014A86777$7$0$0$0$8$81
CCP010000014A85023$7$0$0$0$3$33
CCP010000014A82728$7$0$0$0$8$84
CCP010000014A82947$6$0$0$2$3$26
CCP010000014A80005$4$0$0$0$5$51
CCP010000014A84450$4$0$0$0$3$45
CCP010000014A86787$4$0$0$0$10$101
CCP010000014A85014$4$0$0$5$2$33
CCP010000014A86140$3$0$0$0$3$32
CCP010000014A83036$3$0$0$0$5$53
CCP010000014A86765$3$0$0$0$15$151
CCP010000014A85651$2$0$0$2$2$29
CCP010000014A85008$2$0$0$0$2$21
CCP010000014A80003$2$0$0$0$5$51
CCP010000014A85730$2$0$0$0$3$32
CCP010000014A82950$2$0$0$0$2$21
CCP010000014A80051$2$0$0$0$4$41
CCP010000014A87206$1$0$0$0$5$51
CCP010000014A81050$1$0$0$0$2$21
CCP010000014A83002$1$0$0$0$12$121
CCP010000014A84146$0$0$0$0$11$111
CCP010000014A85025($0)$0($0)$3$3$339
CCP010000014A86308($0)$0($0)$0$4$71
CCP010000014A81003($1)$0($0)$0$1$11
CCP010000014A84478($1)$0($0)$3$3$38
CCP010000014A81000($1)$0($0)$6$10$52
CCP010000014A81002($2)$0($0)$4$4$43
CCP010000014A83615($3)$0($0)$0$3$42
CCP010000014A87210($4)$0($0)$7$0$727
CCP010000014A84436($4)$0($0)$4$0$41
CCP010000014A82565($4)$0($0)$0$5$41
CCP010000014A81001($4)$0($0)$0$2$21
CCP010000014A83001($4)$0($0)$0$8$81
CCP010000014A87081($5)$0($0)$0$4$45
CCP010000014A86162($6)$0($0)$15$0$151
CCP010000014A82248($7)$0($0)$0$2$21
CCP010000014A82270($7)$0($0)$0$2$32
CCP010000014A85027($9)$0($0)$2$2$215
CCP010000014A82040($11)$0($0)$0$5$52
CCP010000014A80048($11)$0($0)$0$3$39
CCP010000014A87106($12)$0($0)$4$0$42
CCP010000014A87186($13)$0($0)$5$5$53
CCP010000014A80061($17)$0($0)$8$8$814
CCP010000014A84439($20)$0($0)$8$8$82
CCP010000014A86225($21)$0($0)$0$12$122
CCP010000014A84460($21)$0($0)$0$5$41
CCP010000014A86160($22)$0($0)$0$13$131
CCP010000014A87252($26)$0($0)$15$15$152
CCP010000014A87070($37)$0($0)$6$6$612
CCP010000014A88304($74)$0($0)$15$15$159
CCP010000014A95044($1,738)$1($1)$8$0$89
A Total$9,570$14$4
CCP010000014M99243$29,303$35$12$131$128$129666
CCP010000014M99213$13,468$36$5$58$64$551,303
CCP010000014M99203$8,660$4$3$144$108$10276
CCP010000014M99202$2,504$1$1$93$69$6440
CCP010000014M99214$880$1$0$88$96$8934
CCP010000014M96910$618$0$0$55$0$525
CCP010000014M99245$129$0$0$0$239$2281
CCP010000014M99385$125$0$0$0$56$563
CCP010000014M99211$73$0$0$0$35$234
CCP010000014M99215$70$0$0$0$130$1272
CCP010000014M99204$59$0$0$0$147$1442
CCP010000014M99201$50$0$0$0$61$411
CCP010000014M99386$37$0$0$0$56$561
CCP010000014M99395$9$0$0$0$56$563
CCP010000014M99396($1)$0($0)$0$56$565
CCP010000014M99394($14)$0($0)$0$56$561
CCP010000014M92012($23)$0($0)$0$10$432
CCP010000014M99241($539)$0($0)$0$63$532
CCP010000014M99242($928)$11($0)$100$101$97273
CCP010000014M99212($5,370)$3($2)$42$45$39164
M Total$49,109$93$19
CCP010000014PQ5P$10,945$13$4$3$1$2415
CCP010000014PW1D$4,882$3$2$2$2$298
CCP010000014PZ2E$668$0$0$7$0$43
CCP010000014PJ3301$495$0$0$25$0$825
CCP010000014PQ5H$396$0$0$2$5$317
CCP010000014PP4L$362$0$0$2$2$21
CCP010000014PQ5W$252$2$0$1$1$1140
CCP010000014PH3D$145$0$0$0$2$22
CCP010000014PW1Q$124$0$0$10$0$92
CCP010000014PQ8F$68$0$0$0$15$241
CCP010000014PQ4F$63$0$0$12$2$61
CCP010000014PW1W$50$0$0$0$2$133
CCP010000014PJ1030$26$0$0$8$0$123
CCP010000014PW3A$25$0$0$7$0$21
CCP010000014PL5G$20$2$0$3$3$371
CCP010000014PJ9A$17$0$0$0$0$02
CCP010000014PJ9260$13$0$0$15$0$51
CCP010000014PH2U$12$0$0$0$0$04
CCP010000014PH4B$11$0$0$0$0$15
CCP010000014PQ5R$8$0$0$8$0$45
CCP010000014PH6J($4)$0($0)$13$2$44
CCP010000014PQ8W($7)$0($0)$0$4$31
CCP010000014PS2A($13)$0($0)$0$0$01
CCP010000014PH0A($17)$0($0)$0$3$11
CCP010000014PD1A($35)$0($0)$2$0$21
CCP010000014PZ4B($40)$0($0)$2$3$32
CCP010000014PU6W($46)$0($0)$1$0$11
CCP010000014PJ5F($53)$0($0)$9$0$102
CCP010000014PS2B($59)$2($0)$2$1$260
CCP010000014PL3P($63)$0($0)$4$0$32
CCP010000014PH3A($68)$0($0)$2$1$164
CCP010000014PW4E($73)$0($0)$1$1$16
CCP010000014PP5A($74)$0($0)$0$1$128
CCP010000014P  0($138)$0($0)$3$0$31
CCP010000014PW1A($140)$1($0)$1$2$181
CCP010000014PW3B($148)$0($0)$3$2$519
CCP010000014PV1B($149)$0($0)$1$0$17
CCP010000014PL5E($231)$0($0)$0$0$12
CCP010000014PW1K($255)$0($0)$5$3$59
CCP010000014PZ2A($476)$5($0)$2$2$2121
CCP010000014PR1H($534)$0($0)$0$1$11
CCP010000014PL2A($555)$0($0)$0$2$14
CCP010000014PCL($573)$0($0)$7$0$361
CCP010000014PL9A($891)$0($0)$0$3$31
CCP010000014PW5A($1,291)$0($1)$2$13$58
CCP010000014PQ5F($1,439)$1($1)$2$2$290
CCP010000014PL1B($2,316)$0($1)$9$0$141
CCP010000014PQ5S($2,611)$0($1)$2$0$27
CCP010000014PL5A($3,144)$0($1)$1$1$27
CCP010000014PQ5K($3,770)$2($1)$4$3$435
CCP010000014PZ2G($3,998)$0($2)$0$8$73
CCP010000014PW1C($7,040)$9($3)$1$1$2272
CCP010000014PL9B($9,781)$1($4)$3$3$340
CCP010000014PL5H($9,821)$0($4)$2$3$38
CCP010000014PL5F($10,402)$1($4)$5$5$511
P Total($41,673)$46($16)
CCP010000014R73630$76$0$0$0$30$242
CCP010000014R73130$53$0$0$0$31$261
R Total$129$0$0
CCP010000014S11401$11,299$6$4$114$69$106105
CCP010000014S11400$9,322$4$4$90$106$93101
CCP010000014S11441$6,015$3$2$154$148$14542
CCP010000014S11440$4,764$2$2$124$0$11739
CCP010000014S11402$4,668$3$2$89$0$12947
CCP010000014S11421$3,770$2$1$130$0$11531
CCP010000014S11420$2,644$1$1$86$0$8829
CCP010000014S11442$1,653$1$1$209$183$16611
CCP010000014S11422$1,460$1$1$163$0$13613
CCP010000014S11641$1,290$1$1$194$0$1978
CCP010000014S11306$771$1$0$69$0$6431
CCP010000014S11643$664$0$0$280$0$2973
CCP010000014S14040$636$0$0$0$504$6331
CCP010000014S11308$577$0$0$99$0$1087
CCP010000014S11307$519$0$0$92$0$8610
CCP010000014S11603$459$0$0$187$0$1613
CCP010000014S11303$417$0$0$92$0$1004
CCP010000014S11644$378$0$0$392$0$3921
CCP010000014S11446$358$0$0$371$0$3711
CCP010000014S11622$303$0$0$217$0$1722
CCP010000014S11444$277$0$0$307$0$2891
CCP010000014S14020$274$0$0$0$306$4591
CCP010000014S11770$221$0$0$0$229$2291
CCP010000014S13132$205$0$0$0$447$3891
CCP010000014S11312$205$0$0$109$0$987
CCP010000014S17110$198$6$0$64$56$55137
CCP010000014S11623$197$0$0$244$0$2281
CCP010000014S11424$171$0$0$244$0$2121
CCP010000014S11621$134$0$0$94$0$1431
CCP010000014S11730$130$0$0$0$77$792
CCP010000014S11900$119$0$0$31$0$4732
CCP010000014S11640$105$0$0$167$0$1641
CCP010000014S56605$81$0$0$0$125$901
CCP010000014S11732$59$0$0$0$34$361
CCP010000014S20550$32$0$0$0$57$671
CCP010000014S11443$23$0$0$222$0$2131
CCP010000014S11423$19$0$0$195$0$1702
CCP010000014S11601($37)$0($0)$91$0$1481
CCP010000014S11602($51)$0($0)$164$0$1513
CCP010000014S10060($118)$0($0)$132$210$1024
CCP010000014S11642($122)$0($0)$245$0$2471
CCP010000014S11403($360)$0($0)$151$0$1645
CCP010000014S17111($366)$0($0)$0$44$501
CCP010000014S11310($401)$1($0)$64$70$6018
CCP010000014S11305($465)$0($0)$39$0$4014
CCP010000014S11101($489)$0($0)$40$0$4119
CCP010000014S12032($974)$0($0)$223$0$2101
CCP010000014S11901($985)$0($0)$49$0$664
CCP010000014S11302($1,295)$0($1)$85$0$817
CCP010000014S11311($1,332)$1($1)$83$0$8013
CCP010000014S11300($1,452)$1($1)$43$0$4419
CCP010000014S17003($1,688)$0($1)$4$9$438
CCP010000014S17304($2,171)$0($1)$0$649$6271
CCP010000014S11301($2,240)$2($1)$56$0$6250
CCP010000014S11100($6,606)$1($3)$93$84$8535
CCP010000014S17000($25,593)$1($10)$67$63$6344
S Total$7,668$45$3
CCP010000014T 0421$333$0$0$125$0$941
T Total$333$0$0
CCP010000014 Total$25,136$198$10
TABLE B1
Allergy
Dates of service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Actual physician names and IDs removed
Allergic Rhinitis etg 0332
total roleResponsibleTotal role
episodeResponsibletotal roleaverage perexpense percost
doctorid listcountexpenseexpenseepisodeepisoderankQUINTILE
1CCP010000013181$93,363$115,782$516$6401Q1
2CCP010000004127$72,348$84,166$570$6632Q1
3CCP010000011164$100,182$113,283$611$6913Q1
4CCP01000000776$36,371$52,780$479$6944Q2
5CCP010000015194$93,695$135,933$483$7015Q2
6CCP01000000580$42,292$56,626$529$7086Q2
7CCP010000009603$329,485$430,038$546$7137Q3
8CCP010000001140$88,318$100,009$631$7148Q3
9CCP010000008200$89,377$143,388$447$7179Q3
10CCP01000000365$36,455$48,193$561$74110Q4
11CCP010000002160$68,220$119,405$426$74611Q4
12CCP010000010206$128,860$155,119$626$75312Q4
13CCP010000014149$95,622$118,949$642$79813Q4
14CCP010000012109$74,708$90,000$685$82614Q5
15CCP01000000665$44,481$54,945$684$84515Q5
16CCP01000001663$43,554$55,351$691$87916Q5
Note:
physician 10 assigned to Q4 because total costs per episode were more similar to Q4 than to Q3.
TABLE B2
Total Role Allergic Rhinitis ETGno 0332 by quintile
Each doctor with greater than or equal to 50 episodes
(3 doctors per Quintile, 4 in Q4)
TotalYourOther
quintilecategoryservicesPROC_DESCSvcsSvcsSvcs
Q1A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY5,2495,2490
NUMBER
Q1A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY1,8091,8090
NUMBER
Q1A94150VITAL CAPACITY, TOTAL (SEP PROC)10010
Q1A86003ALLERGEN SPECIFIC IGE; QUANTITATIVE/SEMIQUANTITATIVE, EACH1670167
ALLERGEN
Q1A82785GAMMAGLOBULIN; IGE13013
.......
.......
.......
Q1A80053COMPREHENSIVE METABOLIC PANEL505
Q1A90782THERAPEUTIC/PROPHYLACTIC/DX INJECTION (SPECIFY MATL INJECTED);202
SUBQ/IM
Q1A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY16160
NUMBER
Q1A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY16160
Q1AEREmergency220
A Total7,3907,123267
Q1M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;49463
COMPREHENSIVE E
Q1M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED16815810
HX; DETAILED EXAM;
Q1M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN80800
IMMUNOTHERA
.......
.......
.......
Q1M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE,11011
TYPICALLY 5
Q1M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB835
FOCUS EX
Q1M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED35350
EXAM; MED
Q1M99213OFFICE/OP, VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;259125134
EXPAND PROB
Q1M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN20200
IMMUNOTHER
Q1M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION22217151
EXTRACTS; SINGLE
Q1M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN5,3425,012330
IMMUNOTHER
Q1M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION3,0592,391668
EXTRACTS; 2+ INJ
M Total9,2758,0411,234
Q1PQ7PNASAL ANTI-INFLAMMATORY STEROIDS24,70321,7122,991
Q1PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS2,0801,660420
Q1PZ2AANTIHISTAMINES22,10916,7775,332
Q1PQ7ENASAL ANTIHISTAMINE5505500
Q1PQ7ANOSE PREPARATIONS, MISCELLANEOUS (RX)30300
Q1PB3JEXPECTORANTS49049
Q1PP5AGLUCOCORTICOIDS423012
Q1PQ6REYE ANTIHISTAMINES448313135
Q1PB3KCOUGH AND/OR COLD PREPARATIONS1083078
P Total50,11941,1029,017
Q1R76375CORONAL/SAGITTAL/MULTIPLANAR/OBLIQUE/3D/HOLOGRAPHIC CT/MRI101
OTHER RECONS
Q1R70210RADIOLOGIC EXAM, SINUSES, PARANASAL, <3 VIEWS211
Q1R70486CT SCAN, MAXILLOFACIAL AREA; W/O CONTRAST MATL101
Q1R71020RADIOLOGIC EXAM, CHEST, 2 VIEWS, FRONTAL & LATERAL303
R Total716
Q1S31231NASAL ENDOSCOPY, DX, UNILAT/BILAT (SEP PROC)220
S Total220
Q1 Total66,79356,26910,524
Q2A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY3,8123,8120
NUMBER
Q2A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY90900
NUMBER
Q2A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY1,5391,5390
NUMBER
Q2A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY81810
NUMBER
Q2A87799INFECTIOUS AGENT, NUCLEIC ACID (DNA/RNA), NOS; QUANTIFICATION110
EA ORGAN
Q2A95070INHALATION BRONCHIAL CHALLENGE TESTS; W/HISTAMINE/110
METHACHOLINE
Q2A90782THERAPEUTIC/PROPHYLACTIC/DX INJECTION (SPECIFY MATL INJECTED);15015
SUBQ/IM
Q2A85025BLOOD COUNT; COMPLETE CBC, AUTOMATED (HGB, HCT, RBC, WBC,11110
& PLATELET) &
.......
.......
.......
Q2ACLClinic/Treatment/Testing101
Q2A94010SPIROMETRY W/GRAPHIC RECORD/VITAL CAPACITY/FLOW RATE W/WO541
MAXIMAL VOLUN
Q2AEREmergency101
A Total5,6515,532119
Q2M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN6,4206,300120
IMMUNOTHER
Q2M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION577231346
EXTRACTS; SINGLE
Q2M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS22220
HX;EXPAND PROB
Q2M99215OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: COMPREHENSIVE HX;541
COMPREHENSIV
Q2M99205OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: COMPREHENSIVE HX;110
COMPREHENSIV
Q2M99396PERIODIC COMPREHENSIVE PREVENTIVE MEDICINE E&M W/HX/EXAM,505
EST PT; 40-64
.......
.......
.......
Q2M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN302010
IMMUNOTHERA
Q2M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN201010
IMMUNOTHER
Q2M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED674819
EXAM;
Q2M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;17257115
EXPAND PROB
Q2M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;660
COMPREHENSIVE E
Q2M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION2,8231,0811,742
EXTRACTS; 2+ INJ
M Total10,2257,8142,411
Q2PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS1,124690434
Q2PQ6REYE ANTIHISTAMINES437191246
.......
.......
.......
Q2PB3JEXPECTORANTS853055
Q2PP5AGLUCOCORTICOIDS10010
Q2PZ2AANTIHISTAMINES13,6028,7784,824
Q2PQ7PNASAL ANTI-INFLAMMATORY STEROIDS7,7404,4723,268
P Total23,85314,7409,113
Q2R70486CT SCAN, MAXILLOFACIAL AREA; W/O CONTRAST MATL312
Q2R70250RADIOLOGIC EXAM, SKULL; <4 VIEWS110
Q2R71020RADIOLOGIC EXAM, CHEST, 2 VIEWS, FRONTAL & LATERAL312
R Total734
Q2 Total39,73628,08911,647
Q3A94010SPIROMETRY W/GRAPHIC RECORD/VITAL CAPACITY/FLOW RATE W/WO36324
MAXIMAL VOLUN
Q3AA0427Ambulance service, advanced life support, emergency transport, level 1 (110
Q3AA0429Ambulance service, basic life support, emergency transport (BLS —emerge110
Q3AA0432Paramedic intercept (PI), rural area, transport furnished by a volunteer110
.......
.......
.......
Q3A94150VITAL CAPACITY, TOTAL (SEP PROC)404
Q3A82785GAMMAGLOBULIN; IGE321
Q3AEREmergency954
Q3A86003ALLERGEN SPECIFIC IGE; QUANTITATIVE/SEMIQUANTITATIVE, EACH41329
ALLERGEN
Q3A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY660
NUMBER
Q3A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY2,9692,88089
NUMBER
Q3A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY5,6615,465196
NUMBER
A Total8,9698,458511
Q3M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION11,3617,4603,901
EXTRACTS; 2+ INJ
Q3M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN19,55419,034520
IMMUNOTHER
Q3M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION1,224487737
EXTRACTS; SINGLE
Q3M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB735716
FOCUS EX
Q3M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;572314258
EXPAND PROB
.......
.......
.......
Q3M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE,55451
TYPICALLY 5
Q3M99215OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: COMPREHENSIVE HX;220
COMPREHENSIV
Q3M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS101
HX;EXPAND PROB
Q3M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED76724
EXAM; MED
Q3M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;34304
COMPREHENSIVE E
Q3M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN322012
IMMUNOTHERA
Q3M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN29290
IMMUNOTHERA
Q3M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED915239
EXAM;
M Total33,13527,5615,574
Q3PB3JEXPECTORANTS17859119
Q3PB3KCOUGH AND/OR COLD PREPARATIONS378229149
Q3PP5AGLUCOCORTICOIDS342014
Q3PQ6REYE ANTIHISTAMINES600472128
Q3PQ7ENASAL ANTIHISTAMINE51745760
Q3PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS1,620750870
Q3PQ7PNASAL ANTI-INFLAMMATORY STEROIDS22,03915,8416,198
Q3PZ2AANTIHISTAMINES29,92219,06010,862
P Total55,28836,88818,400
Q3R70450CT SCAN, HEAD/BRAIN; W/O CONTRAST MATL202
Q3R70160RADIOLOGIC EXAM, NASAL BONES, COMPLETE, MINIMUM, 3 VIEWS101
Q3R71020RADIOLOGIC EXAM, CHEST, 2 VIEWS, FRONTAL & LATERAL413
Q3R70486CT SCAN, MAXILLOFACIAL AREA; W/O CONTRAST MATL101
R Total817
Q3 Total97,40072,90824,492
Q4A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY5,5635,47786
NUMBER
Q4ACLClinic/Treatment/Testing110
Q4A86003ALLERGEN SPECIFIC IGE; QUANTITATIVE/SEMIQUANTITATIVE, EACH12214108
ALLERGEN
Q4A94010SPIROMETRY W/GRAPHIC RECORD/VITAL CAPACITY/FLOW RATE W/WO19172
IMMUNOTHER
Q4A92557COMPREHENSIVE AUDIOMETRY THRESHOLD VAL & SPEECH101
RECOGNITION
.......
.......
.......
Q4A80053COMPREHENSIVE METABOLIC PANEL615
Q4A80050GENERAL HEALTH PANEL211
Q4A90782THERAPEUTIC/PROPHYLACTIC/DX INJECTION (SPECIFY MATL INJECTED);514
SUBQ/IM
Q4A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY20200
NUMBER
Q4A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY10100
NUMBER
Q4A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY1,9571,9498
NUMBER
A Total7,8227,505317
Q4M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED25821642
EXAM;
Q4M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN13011020
IMMUNOTHER
Q4M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN13112110
IMMUNOTHERA
Q4M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED58571
EXAM; MED
Q4M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE,61259
TYPICALLY 5
Q4M99215OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: COMPREHENSIVE HX;541
COMPREHENSIV
.......
.......
.......
Q4M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;333152181
EXPAND PROB
Q4M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS H211
EXPAND PROB
Q4M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB1037
Q4MEREmergency101
Q4M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION485215270
EXTRACTS; SINGLE
Q4M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN9,8949,014880
IMMUNOTHER
Q4M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION5,6673,2342,433
EXTRACTS; 2+ INJ
M Total17,08613,1583,928
Q4PZ2AANTIHISTAMINES31,06622,8608,206
Q4PQ7ENASAL ANTIHISTAMINE863699164
Q4PQ6REYE ANTIHISTAMINES694565129
.......
.......
.......
Q4PB3JEXPECTORANTS661056
Q4PB3KCOUGH AND/OR COLD PREPARATIONS1405288
Q4PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS930690240
Q4PQ7PNASAL ANTI-INFLAMMATORY STEROIDS16,30910,9355,374
P Total50,24135,91514,326
Q4R71020RADIOLOGIC EXAM, CHEST, 2 VIEWS, FRONTAL & LATERAL431
Q4R70220RADIOLOGIC EXAM, SINUSES, PARANASAL, COMPLETE, MINIMUM,101
3 VIEW
Q4R70486CT SCAN, MAXILLOFACIAL AREA; W/O CONTRAST MATL101
R Total633
Q4S31231NASAL ENDOSCOPY, DX, UNILAT/BILAT (SEP PROC)202
S Total202
Q4 Total75,15756,58118,576
Q5A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC, EXTRACTS, SPECIFY1,1181,1180
NUMBER
Q5A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY27270
NUMBER
Q5AEREmergency431
Q5ACLClinic/Treatment/Testing303
Q5A90782THERAPEUTIC/PROPHYLACTIC/DX INJECTION (SPECIFY MATL INJECTED10010
.......
.......
.......
Q5A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY770
NUMBER
Q5A94010SPIROMETRY W/GRAPHIC RECORD/VITAL CAPACITY/FLOW RATE W/WO110
MAXIMAL VOLUN
Q5A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY1,3151,3150
NUMBER
A Total2,6122,475137
Q5M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN4,9304,740190
IMMUNOTHER
Q5M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION2,5581,907651
EXTRACTS; 2+ INJ
Q5M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN12011010
IMMUNOTHERA
Q5M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN70700
IMMUNOTHER
Q5M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION34628561
EXTRACTS; SINGLE
Q5M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED25214
EXAM; MED
Q5M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE,33033
TYPICALLY 5
Q5M99212OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: PROB FOCUS HX; PROB18135
FOCUS EX
Q5M99204OFFICE/OP VISIT, NEW PT, 3 KEY COMPONENTS: COMPREHENSIVE101
HX;COMPREHENSIV
.......
.......
.......
Q5M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX;1407763
EXPAND PROB
Q5M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED462917
EXAM;
Q5M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;431
COMPREHENSIVE E
M Total8,2997,2581,041
Q5PQ7PNASAL ANTI-INFLAMMATORY STEROIDS9,5997,8681,731
Q5PZ2AANTIHISTAMINES10,6287,1793,449
Q5PQ6REYE ANTIHISTAMINES47444034
Q5PB3KCOUGH AND/OR COLD PREPARATIONS30423866
Q5PQ7ENASAL ANTIHISTAMINE46439668
Q5PP5AGLUCOCORTICOIDS33531916
Q5PQ7ANOSE PREPARATIONS, MISCELLANEOUS (RX)45450
Q5PB3JEXPECTORANTS49049
Q5PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS450270180
P Total22,34816,7555,593
Q5R70220RADIOLOGIC EXAM, SINUSES, PARANASAL, COMPLETE, MINIMUM, 3101
VIEWS
R Total101
Q5S30520SEPTOPLASTY/SUBMUCOUS RESECTION W/WO CARTILAGE SCORING/101
CONTOURING/GRAFT
Q5S31231NASAL ENDOSCOPY, DX, UNILAT/BILAT (SEP PROC)101
S Total202
Q5 Total33,26226,4886,774
Grand Total312,348240,33572,013
Total CostYour
Differencecosts
ExpectedquintileTotal Costper Quintileper
quintilecategoryservicesSvcsepisodesTotal CostsYour CostsOther Costsexpected costsDifferenceEpisodesvc
Q1A950044068.32472$20,676$20,676$0$15,973$4,703$10$4
Q1A950241768.96472$10,946$10,946$0$10,545$401$1$6
Q1A941502.64472$258$0$258$59$199$0$0
Q1A8600373.83472$341$0$341$153$188$0$0
Q1A827853.96472$169$0$169$51$118$0$0
............
............
............
Q1A800538.85472$25$0$25$48($23)($0)$0
Q1A907829.23472$18$0$18$74($56)($0)$0
Q1A9501023.17472$390$390$0$557($167)($0)$24
Q1A9501528.25472$356$356$0$623($267)($1)$22
Q1AER5.09472$365$365$0$855($490)($1)$183
A Total6075.92472$35,004$33,715$1,289$29,993$5,011$11
Q1M9924422.98472$9,045$8,491$554$4,228$4,817$10$185
Q1M99214118.66472$14,891$14,013$878$10,445$4,446$9$89
Q1M9514574.02472$1,730$1,730$0$1,590$140$0$22
............
............
............
Q1M9921135.03472$253$0$253$782($529)($1)$0
Q1M9921222.04472$308$120$188$883($575)($1)$40
Q1M9924342.38472$4,546$4,546$0$5,451($905)($2)$130
Q1M99213278.00472$14,137$7,000$7,137$15,176($1,039)($2)$56
Q1M9514750.67472$782$782$0$1,954($1,172)($2)$39
Q1M95115537.55472$3,408$2,736$672$8,582($5,174)($11)$16
Q1M951658690.38472$60,093$56,357$3,736$91,309($31,216)($66)$11
Q1M951174796.85472$63,856$50,048$13,808$100,110($36,254)($77)$21
M Total14680.78472$173,957$145,823$28,134$241,259($67,302)($143)
Q1PQ7P15141.29472$51,580$45,801$5,779$31,968$19,612$42$2
Q1PZ4B1168.51472$5,781$4,616$1,165$3,136$2,645$6$3
Q1PZ2A20214.82472$43,162$33,287$9,875$40,682$2,480$5$2
Q1PQ7E530.20472$1,108$1,108$0$1,059$49$0$2
Q1PQ7A56.50472$86$86$0$88($2)($0)$3
Q1PB3J80.42472$41$0$41$76($35)($0)$0
Q1PP5A85.13472$42$31$11$110($68)($0)$1
Q1PQ6R499.69472$1,479$1,076$403$1,618($139)($0)$3
Q1PB3K233.55472$181$58$123$491($310)($1)$2
P Total38010.13472$103,460$86,063$17,397$79,227$24,233$51
Q1R76375.19472$147$0$147$28$119$0$0
Q1R70210.38472$68$34$34$13$55$0$34
Q1R704861.13472$249$0$249$234$15$0$0
Q1R710202.64472$88$0$88$81$7$0$0
R Total4.33472$552$34$518$356$196$0
Q1S31231.94472$258$258$0$121$137$0$129
S Total.94$258$258$0$121
Q1 Total58772.10$313,231$265,893$47,338$350,956
Q2A950043008.14349$15,167$15,167$0$11,811$3,356$10$4
Q2A9501017.13349$2,158$2,158$0$412$1,746$5$24
Q2A950241307.98349$9,338$9,338$0$7,797$1,541$4$6
Q2A9501520.89349$1,779$1,779$0$461$1,318$4$22
Q2A87799.14349$110$110$0$15$95$0$110
Q2A95070.14349$91$91$0$13$78$0$91
Q2A907826.82349$121$0$121$55$66$0$0
Q2A850256.27349$56$26$30$22$34$0$26
............
............
............
Q2ACL.70349$10$0$10$81($71)($0)$0
Q2A9401011.00349$200$166$34$428($228)($1)$42
Q2AER3.76349$128$0$128$632($504)($1)$0
A Total4487.84349$29,690$28,939$751$22,156$7,534$22
Q2M951656425.72349$71,708$70,368$1,340$67,514$4,194$12$11
Q2M95115397.46349$8,695$3,658$5,037$6,346$2,349$7$16
Q2M992423.76349$2,146$2,146$0$367$1,779$5$98
Q2M992151.81349$649$520$129$235$414$1$130
Q2M99205.14349$187$187$0$26$161$0$187
Q2M993962.65349$280$0$280$148$132$0$0
............
............
............
Q2M9514554.73349$618$437$181$1,175($557)($2)$22
Q2M9514737.46349$723$391$332$1,444($721)($2)$39
Q2M9921487.74349$5,906$4,260$1,646$7,723($1,817)($5)$89
Q2M99213205.56349$9,260$3,176$6,084$11,221($1,961)($6)$56
Q2M9924416.99349$1,107$1,107$0$3,126($2,019)($6)$185
Q2M951173546.82349$57,343$21,437$35,906$74,022($16,679)($48)$20
M Total10864.68349$164,820$111,782$53,038$179,759($14,939)($43)
Q2PZ4B864.00349$2,943$1,738$1,205$2,318$625$2$3
Q2PQ6R369.47349$1,354$687$667$1,197$157$0$4
............
............
............
Q2PB3J59.47349$49$12$37$56($7)($0)$0
Q2PP5A62.95349$5$0$5$81($76)($0)$0
Q2PZ2A14946.98349$27,153$18,039$9,114$30,080($2,927)($8)$2
Q2PQ7P11195.57349$16,959$9,813$7,146$23,637($6,678)($19)$2
P Total28107.31349$50,034$31,259$18,775$58,583($8,549)($24)
Q2R70486.84349$673$305$368$173$500$1$305
Q2R70250.14349$36$36$0$5$31$0$36
Q2R710201.95349$86$37$49$60$26$0$37
R Total2.92$795$378$417$238
Q2 Total43462.76$245,339$172,358$72,981$260,737
Q3A9401029.73943$1,477$1,304$173$1,156$321$0$41
Q3AA0427.38943$509$509$0$192$317$0$509
Q3AA0429.38943$450$450$0$169$281$0$450
Q3AA0432.38943$320$320$0$120$200$0$320
............
............
............
Q3A941505.27943$56$0$56$118($62)($0)$0
Q3A827857.90943$39$26$13$103($64)($0)$13
Q3AER10.16943$1,605$1,081$524$1,708($103)($0)$216
Q3A86003147.51943$84$64$20$305($221)($0)$2
Q3A9501556.44943$134$134$0$1,244($1,110)($1)$22
Q3A950243534.18943$17,535$17,005$530$21,068($3,533)($4)$6
Q3A950048128.01943$21,809$21,047$762$31,912($10,103)($11)$4
A Total12131.44943$45,294$42,185$3,109$59,238($13,944)($15)
Q3M951179583.53943$238,744$155,699$83,045$200,007$38,737$41$21
Q3M9516517362.34943$189,364$183,700$5,664$182,424$6,940$7$10
Q3M951151073.95943$20,048$7,790$12,258$17,146$2,902$3$16
Q3M9921244.03943$2,948$2,280$668$1,764$1,184$1$40
Q3M99213555.41943$31,343$17,307$14,036$30,320$1,023$1$55
............
............
............
Q3M9921169.99943$1,206$92$1,114$1,563($357)($0)$23
Q3M992154.89943$259$259$0$634($375)($0)$130
Q3M9924210.16943$97$0$97$990($893)($1)$0
Q3M9924384.67943$9,639$9,120$519$10,891($1,252)($1)$127
Q3M9924445.91943$6,240$5,501$739$8,447($2,207)($2)$183
Q3M95145147.88943$712$428$284$3,176($2,464)($3)$21
Q3M95147101.22943$1,115$1,115$0$3,903($2,788)($3)$38
Q3M99214237.07943$7,871$4,463$3,408$20,868($12,997)($14)$86
M Total29354.17943$511,821$387,754$124,067$484,315$27,506$29
Q3PB3J160.68943$246$37$209$152$94$0$1
Q3PB3K466.61943$815$482$333$981($166)($0)$2
Q3PP5A170.09943$25$9$16$219($194)($0)$0
Q3PQ6R998.32943$2,220$1,830$390$3,234($1,014)($1)$4
Q3PQ7E1059.28943$961$855$106$2,115($1,154)($1)$2
Q3PZ4B2334.55943$4,271$1,984$2,287$6,265($1,994)($2)$3
Q3PQ7P30250.51943$45,664$31,993$13,671$63,868($18,204)($19)$2
Q3PZ2A40386.82943$61,825$40,014$21,811$81,277($19,452)($21)$2
P Total75826.83943$116,027$77,204$38,823$158,111($42,084)($45)
Q3R70450.75943$97$0$97$37$60$0$0
Q3R70160.38943$31$0$31$12$19$0$0
Q3R710205.27943$100$37$63$161($61)($0)$37
Q3R704862.26943$65$0$65$468($403)($0)$0
R Total8.65943$293$37$256$678($385)($0)
Q3 Total117321.09$673,435$507,180$166,255$702,341
Q4A950044964.72576$22,180$21,854$326$19,493$2,687$5$4
Q4ACL1.15576$397$397$0$134$263$0$397
Q4A8600390.10576$252$34$218$186$66$0$2
Q4A9401018.16576$751$714$37$706$45$0$42
Q4A92557.23576$50$0$50$11$39$0$0
............
............
............
Q4A8005310.80576$30$5$25$58($28)($0)$5
Q4A800505.06576$28$14$14$71($43)($0)$14
Q4A9078211.26576$40$8$32$90($50)($0)$8
Q4A9501534.48576$437$437$0$760($323)($1)$22
Q4A9501028.27576$240$240$0$680($440)($1)$24
Q4A950242158.74576$11,920$11,873$47$12,869($949)($2)$6
A Total7431.00576$37,998$36,194$1,804$36,730$1,268$2
Q4M99214144.80576$22,778$19,093$3,685$12,746$10,032$17$88
Q4M9514761.83576$5,015$4,267$748$2,384$2,631$5$39
Q4M9514590.33576$2,803$2,589$214$1,940$863$1$21
Q4M9924351.72576$7,502$7,373$129$6,653$849$1$129
Q4M9921142.75576$1,353$46$1,307$955$398$1$23
Q4M992152.99576$648$518$130$388$260$0$130
............
............
............
Q4M99213339.26576$18,313$8,455$9,858$18,520($207)($0)$56
Q4M992426.21576$194$97$97$605($411)($1)$97
Q4M9921226.89576$410$116$294$1,078($668)($1)$39
Q4MER6.21576$253$0$253$1,043($790)($1)$0
Q4M95115655.99576$7,881$3,440$4,441$10,473($2,592)($5)$16
Q4M9516510605.20576$108,460$99,200$9,260$111,428($2,968)($5)$11
Q4M951175853.78576$118,104$67,266$50,838$122,168($4,064)($7)$21
M Total17931.85576$300,507$217,833$82,674$296,672$3,835$7
Q4PZ2A24668.94576$61,796$46,892$14,904$49,646$12,150$21$2
Q4PQ7E647.02576$1,704$1,388$316$1,292$412$1$2
Q4PQ6R609.79576$2,151$1,717$434$1,975$176$0$3
............
............
............
Q4PB3J98.15576$49$8$41$93($44)($0)$1
Q4PB3K285.01576$307$141$166$599($292)($1)$3
Q4PZ4B1425.98576$2,445$1,860$585$3,827($1,382)($2)$3
Q4PQ7P18477.51576$33,632$22,787$10,845$39,011($5,379)($9)$2
P Total46390.75576$102,446$75,013$27,433$96,705$5,741$10
Q4R710203.22576$155$117$38$99$56$0$39
Q4R70220.46576$45$0$45$21$24$0$0
Q4R704861.38576$258$0$258$286($28)($0)$0
R Total5.06576$458$117$341$405$53$0
Q4S312311.15576$257$0$257$148$109$0$0
S Total1.15576$257$0$257$148$109$0
Q4 Total71759.81$441,666$329,157$112,509$430,660
Q5A95024888.23237$6,250$6,250$0$5,295$955$4$6
Q5A9501514.19237$601$601$0$313$288$1$22
Q5AER2.55237$697$569$128$429$268$1$190
Q5ACL.47237$174$0$174$55$119$1$0
Q5A907824.63237$80$0$80$37$43$0$0
............
............
............
Q5A9501011.63237$171$171$0$280($109)($0)$24
Q5A940107.47237$43$43$0$290($247)($1)$43
Q5A950042042.78237$4,974$4,974$0$8,020($3,046)($13)$4
A Total3057.36237$13,582$12,720$862$15,113($1,531)($6)
Q5M951654363.60237$55,163$53,070$2,093$45,848$9,315$39$11
Q5M951172408.59237$53,467$40,047$13,420$50,267$3,200$14$21
Q5M9514537.17237$2,577$2,363$214$798$1,779$8$21
Q5M9514725.44237$2,737$2,737$0$981$1,756$7$39
Q5M95115269.91237$5,533$4,560$973$4,309$1,224$5$16
Q5M9924321.28237$3,243$2,724$519$2,737$506$2$130
Q5M9921117.59237$759$0$759$393$366$2$0
Q5M9921211.07237$714$520$194$443$271$1$40
Q5M99204.47237$147$0$147$77$70$0$0
............
............
............
Q5M99213139.59237$7,521$4,220$3,301$7,620($99)($0)$55
Q5M9921459.58237$4,009$2,568$1,441$5,245($1,236)($5)$89
Q5M9924411.54237$738$553$185$2,123($1,385)($6)$184
M Total7373.67237$137,274$113,687$23,587$121,517$15,757$66
Q5PQ7P7602.73237$21,892$17,648$4,244$16,052$5,840$25$2
Q5PZ2A10150.24237$22,057$14,835$7,222$20,427$1,630$7$2
Q5PQ6R250.90237$1,389$1,293$96$813$576$2$3
Q5PB3K117.27237$815$609$206$246$569$2$3
Q5PQ7E266.22237$918$759$159$532$386$2$2
Q5PP5A42.75237$405$381$24$55$350$1$1
Q5PQ7A28.37237$75$75$0$44$31$0$2
Q5PB3J40.38237$20$0$20$38($18)($0)$0
Q5PZ4B586.73237$1,208$736$472$1,574($366)($2)$3
P Total19085.59237$48,779$36,336$12,443$39,781$8,998$38
Q5R70220.19237$45$0$45$9$36$0$0
R Total.19237$45$0$45$9$36$0
Q5S30520.09237$487$0$487$46$441$2$0
Q5S31231.47237$129$0$129$61$68$0$0
S Total.57237$616$0$616$107$509$2
Q5 Total29517.38$200,296$162,743$37,553$176,527
Grand Total320833.13$1,873,967$1,437,331$436,636$1,921,220
Total Costs perYour Avg Cost perother costs pertotal episodes
quintilecategoryservicesOther costs per svcSpec Costs per svcepisodeEpisodeepisodethis service occurred
Q1A95004$0$4$44$44$0147
Q1A95024$0$6$23$23$085
Q1A94150$26$22$1$0$11
Q1A86003$2$2$1$0$114
Q1A82785$13$13$0$0$013
.........
.........
.........
Q1A80053$5$5$0$0$05
Q1A90782$9$8$0$0$01
Q1A95010$0$24$1$1$02
Q1A95015$0$22$1$1$02
Q1AER$0$168$1$1$02
A Total
Q1M99244$185$184$19$18$147
Q1M99214$88$88$32$30$2124
Q1M95145$0$21$4$4$05
.........
.........
.........
Q1M99211$23$22$1$0$11
Q1M99212$38$40$1$0$07
Q1M99243$0$129$10$10$035
Q1M99213$53$55$30$15$15148
Q1M95147$0$39$2$2$02
Q1M95115$13$16$7$6$118
Q1M95165$11$11$127$119$8176
Q1M95117$21$21$135$106$29167
M Total
Q1PQ7P$2$2$109$97$12209
Q1PZ4B$3$3$12$10$213
Q1PZ2A$2$2$91$71$21194
Q1PQ7E$0$2$2$2$05
Q1PQ7A$0$2$0$0$01
Q1PB3J$1$1$0$0$03
Q1PP5A$1$1$0$0$03
Q1PQ6R$3$3$3$2$119
Q1PB3K$2$2$0$0$06
P Total
Q1R76375$147$147$0$0$01
Q1R70210$34$34$0$0$02
Q1R70486$249$208$1$0$11
Q1R71020$29$31$0$0$03
R Total
Q1S31231$0$129$1$1$02
S Total
Q1 Total
Q2A95004$0$4$43$43$063
Q2A95010$0$24$6$6$06
Q2A95024$0$6$27$27$044
Q2A95015$0$22$5$5$06
Q2A87799$0$110$0$0$01
Q2A95070$0$91$0$0$01
Q2A90782$8$8$0$0$08
Q2A85025$3$4$0$0$05
.........
.........
.........
Q2ACL$10$116$0$0$01
Q2A94010$34$39$1$0$05
Q2AER$128$168$0$0$01
A Total
Q2M95165$11$11$205$202$4249
Q2M95115$15$16$25$10$1447
Q2M99242$0$97$6$6$022
Q2M99215$129$130$2$1$05
Q2M99205$0$187$1$1$01
Q2M99396$56$56$1$0$15
.........
.........
.........
Q2M95145$18$21$2$1$12
Q2M95147$33$39$2$1$12
Q2M99214$87$88$17$12$564
Q2M99213$53$55$27$9$17128
Q2M99244$0$184$3$3$06
Q2M95117$21$21$164$61$103195
M Total
Q2PZ4B$3$3$8$5$312
Q2PQ6R$3$3$4$2$214
.........
.........
.........
Q2PB3J$1$1$0$0$07
Q2PP5A$1$1$0$0$01
Q2PZ2A$2$2$78$52$26102
Q2PQ7P$2$2$49$28$2081
P Total
Q2R70486$184$208$2$1$12
Q2R70250$0$36$0$0$01
Q2R71020$25$31$0$0$02
R Total
Q2 Total
Q3A94010$43$39$2$1$036
Q3AA0427$0$509$1$1$01
Q3AA0429$0$450$0$0$01
Q3AA0432$0$320$0$0$01
.........
.........
.........
Q3A94150$14$22$0$0$02
Q3A82785$13$13$0$0$03
Q3AER$131$168$2$1$19
Q3A86003$2$2$0$0$07
Q3A95015$0$22$0$0$01
Q3A95024$6$6$19$18$1101
Q3A95004$4$4$23$22$1110
A Total
Q3M95117$21$21$253$165$88689
Q3M95165$11$11$201$195$6768
Q3M95115$17$16$21$8$13110
Q3M99212$42$40$3$2$160
Q3M99213$54$55$33$18$15381
.........
.........
.........
Q3M99211$22$22$1$0$115
Q3M99215$0$130$0$0$02
Q3M99242$97$97$0$0$01
Q3M99243$130$129$10$10$175
Q3M99244$185$184$7$6$134
Q3M95145$24$21$1$0$03
Q3M95147$0$39$1$1$03
Q3M99214$87$88$8$5$477
M Total
Q3PB3J$2$1$0$0$020
Q3PB3K$2$2$1$1$017
Q3PP5A$1$1$0$0$05
Q3PQ6R$3$3$2$2$029
Q3PQ7E$2$2$1$1$08
Q3PZ4B$3$3$5$2$210
Q3PQ7P$2$2$48$34$14232
Q3PZ2A$2$2$66$42$23290
P Total
Q3R70450$49$49$0$0$02
Q3R70160$31$31$0$0$01
Q3R71020$21$31$0$0$04
Q3R70486$65$208$0$0$01
R Total
Q3 Total
Q4A95004$4$4$39$38$1117
Q4ACL$0$116$1$1$01
Q4A86003$2$2$0$0$012
Q4A94010$19$39$1$1$018
Q4A92557$50$50$0$0$01
.........
.........
.........
Q4A80053$5$5$0$0$05
Q4A80050$14$14$0$0$02
Q4A90782$8$8$0$0$02
Q4A95015$0$22$1$1$02
Q4A95010$0$24$0$0$02
Q4A95024$6$6$21$21$085
A Total
Q4M99214$88$88$40$33$6188
Q4M95147$37$39$9$7$16
Q4M95145$21$21$5$4$08
Q4M99243$129$129$13$13$058
Q4M99211$22$22$2$0$28
Q4M99215$130$130$1$1$05
.........
.........
.........
Q4M99213$54$55$32$15$17225
Q4M99242$97$97$0$0$02
Q4M99212$42$40$1$0$19
Q4MER$253$168$0$0$01
Q4M95115$16$16$14$6$853
Q4M95165$11$11$188$172$16360
Q4M95117$21$21$205$117$88331
M Total
Q4PZ2A$2$2$107$81$26233
Q4PQ7E$2$2$3$2$112
Q4PQ6R$3$3$4$3$122
.........
.........
.........
Q4PB3J$1$1$0$0$07
Q4PB3K$2$2$1$0$014
Q4PZ4B$2$3$4$3$111
Q4PQ7P$2$2$58$40$19189
P Total
Q4R71020$38$31$0$0$04
Q4R70220$45$45$0$0$01
Q4R70486$258$208$0$0$01
R Total
Q4S31231$129$129$0$0$02
S Total
Q4 Total
Q5A95024$0$6$26$26$042
Q5A95015$0$22$3$3$01
Q5AER$128$168$3$2$14
Q5ACL$58$116$1$0$11
Q5A90782$8$8$0$0$02
.........
.........
.........
Q5A95010$0$24$1$1$01
Q5A94010$0$39$0$0$01
Q5A95004$0$4$21$21$042
A Total
Q5M95165$11$11$233$224$9149
Q5M95117$21$21$226$169$57137
Q5M95145$21$21$11$10$17
Q5M95147$0$39$12$12$06
Q5M95115$16$16$23$19$432
Q5M99243$130$129$14$11$224
Q5M99211$23$22$3$0$33
Q5M99212$39$40$3$2$115
Q5M99204$147$163$1$0$11
.........
.........
.........
Q5M99213$52$55$32$18$1498
Q5M99214$85$88$17$11$640
Q5M99244$185$184$3$2$14
M Total
Q5PQ7P$2$2$92$74$1893
Q5PZ2A$2$2$93$63$3097
Q5PQ6R$3$3$6$5$014
Q5PB3K$3$2$3$3$110
Q5PQ7E$2$2$4$3$110
Q5PP5A$2$1$2$2$07
Q5PQ7A$0$2$0$0$02
Q5PB3J$0$1$0$0$04
Q5PZ4B$3$3$5$3$25
P Total
Q5R70220$45$45$0$0$01
R Total
Q5S30520$487$487$2$0$21
Q5S31231$129$129$1$0$11
S Total
Q5 Total
Grand Total
TABLE B3
Allergy
Dates of service Jan. 1, 2003-Dec. 31, 2004 paid Dec. 31, 2004
Total Role Allergic Rhinitis ETGno 0332 by quintile
Each doctor with greater than or equal to 50 episodes
(3 doctors per Quintile, 4 in Q4)
Total Cost
Difference
per Quintile
quintilecategoryservicesPROC_DESCEpisode
Q1A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY$10
NUMBER
A Total$10
Q1M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX;$10
COMPREHENSIVE E
Q1M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX: DETAILED $9
EXAM;
Q1M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED ($2)
EXAM; MED
Q1M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; EXPAND ($2)
PROB
Q1M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN ($2)
IMMUNOTHER
Q1M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION($11)
EXTRACTS; SINGLE
Q1M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN($66)
IMMUNOTHER
Q1M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION($77)
EXTRACTS; 2+ INJ
M Total($141) 
Q1PQ7PNASAL ANTI-INFLAMMATORY STEROIDS$42
Q1PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS $6
Q1PZ2AANTIHISTAMINES $5
P Total$52
Q1 Total
Q2A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY$10
NUMBER
Q2A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY $5
NUMBER
Q2A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY NUMBER $4
Q2A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY $4
NUMBER
A Total$23
Q2M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN$12
IMMUNOTHER
Q2M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION  $7
EXTRACTS; SINGLE
Q2M99242OFFICE CONSULTATION, 3 KEY COMPONENTS: EXPAND PROB FOCUS HX; $5
EXPAND PROB
Q2M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN ($2)
IMMUNOTHERA
Q2M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN ($2)
IMMUNOTHER
Q2M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED ($5)
EXAM;
Q2M99213OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: EXPAND PROB HX; EXPAND ($6)
PROB
Q2M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX; ($6)
COMPREHENSIVE E
Q2M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION($48)
EXTRACTS; 2+ INJ
M Total($44)
Q2PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS $2
Q2PZ2AANTIHISTAMINES ($8)
Q2PQ7PNASAL ANTI-INFLAMMATORY STEROIDS($19)
P Total($26)
Q2 Total
Q3A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY ($1)
NUMBER
Q3A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY NUMBER ($4)
Q3A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY($11)
NUMBER
A Total($16)
Q3M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION$41
EXTRACTS; 2+ INJ
Q3M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN $7
IMMUNOTHER
Q3M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION $3
EXTRACTS; SINGLE
Q3M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX; ($2)
COMPREHENSIVE E
Q3M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN ($3)
IMMUNOTHERA
Q3M95147PROFESSIONAL SVC, SUPERVISION. PROVISION. ANTIGENS, ALLERGEN ($3)
IMMUNOTHER
Q3M99214OFFICE/OP VlSIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED($14)
EXAM;
M Total$30
Q3PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS ($2)
Q3PQ7PNASAL ANTI-INFLAMMATORY STEROIDS($19)
Q3PZ2AANTIHISTAMINES($21)
P Total($42)
Q3 Total
Q4A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY $5
NUMBER
Q4A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIALINCREMENTAL, SPECIFY ($1)
NUMBER
Q4A95010ALLERGY TESTS, PERCUTANEOUS, SEQUENTIAL/INCREMENTAL, SPECIFY ($1)
NUMBER
Q4A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY NUMBER ($2)
A Total $2
Q4M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED$17
EXAM;
Q4M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN $5
IMMUNOTHER
Q4M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION. ANTIGEN, ALLERGEN $1
IMMUNOTHERA
Q4M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION ($5)
EXTRACTS; SINGLE
Q4M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS, ALLERGEN ($5)
IMMUNOTHER
Q4M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION ($7)
EXTRACTS; 2+ INJ
M Total $7
Q4PZ2AANTIHISTAMINES$21
Q4PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS ($2)
Q4PQ7PNASAL ANTI-INFLAMMATORY STEROIDS ($9)
P Total $9
Q4 Total
Q5A95024ALLERGY TESTS, INTRADERMAL, ALLERGENIC EXTRACTS, SPECIFY NUMBER $4
Q5A95015ALLERGY TESTS, INTRADERMAL, SEQUENTIAL/INCREMENTAL, SPECIFY $1
NUMBER
Q5A95004ALLERGY TESTS, PERCUTANEOUS, ALLERGENIC EXTRACTS, SPECIFY($13)
NUMBER
A Total ($8)
Q5M95165PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGENS. ALLERGEN$39
IMMUNOTHER
Q5M95117PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION$14
EXTRACTS; 2+ INJ
Q5M95145PROFES SVC, SUPERVIS, PREPARA, PROVISION, ANTIGEN, ALLERGEN $8
IMMUNOTHERA
Q5M95147PROFESSIONAL SVC, SUPERVISION, PROVISION, ANTIGENS, ALLERGEN $7
IMMUNOTHER
Q5M95115PROFESSIONAL SVC, ALLERGEN IMMUNOTHERAPY NON-PROVISION  $5
EXTRACTS; SINGLE
Q5M99243OFFICE CONSULTATION, 3 KEY COMPONENTS: DETAILED HX; DETAILED $2
EXAM; MED
Q5M99211OFFICE/OP VISIT, EST PT, NOT REQUIRING PHYSICIAN PRESENCE,  $2
TYPICALLY 5
Q5M99214OFFICE/OP VISIT, EST PT, 2 KEY COMPONENTS: DETAILED HX; DETAILED ($5)
EXAM;
Q5M99244OFFICE CONSULTATION, 3 KEY COMPONENTS: COMPREHENSIVE HX; ($6)
COMPREHENSIVE E
M Total$66
Q5PQ7PNASAL ANTI-INFLAMMATORY STEROIDS$25
Q5PZ2AANTIHISTAMINES $7
Q5PQ6REYE ANTIHISTAMINES $2
Q5PB3KCOUGH AND/OR COLD PREPARATIONS $2
Q5PQ7ENASAL ANTIHISTAMINE $2
Q5PZ4BLEUKOTRIENE RECEPTOR ANTAGONISTS ($2)
P Total$36
Q5 Total
Medical practice pattern tool (2024)

References

Top Articles
Latest Posts
Article information

Author: Stevie Stamm

Last Updated:

Views: 6327

Rating: 5 / 5 (60 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Stevie Stamm

Birthday: 1996-06-22

Address: Apt. 419 4200 Sipes Estate, East Delmerview, WY 05617

Phone: +342332224300

Job: Future Advertising Analyst

Hobby: Leather crafting, Puzzles, Leather crafting, scrapbook, Urban exploration, Cabaret, Skateboarding

Introduction: My name is Stevie Stamm, I am a colorful, sparkling, splendid, vast, open, hilarious, tender person who loves writing and wants to share my knowledge and understanding with you.